Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 67
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Germline variation at 8q24 and prostate cancer risk in men of European ancestry

  • Matejcic, Marco
  • Kogevinas, Manolis
  • Haiman, Christopher A.
Chromosome 8q24 is a susceptibility locus for multiple cancers, including prostate cancer. Here we combine genetic data across the 8q24 susceptibility region from 71,535 prostate cancer cases and 52,935 controls of European ancestry to define the overall contribution of germline variation at 8q24 to prostate cancer risk. We identify 12 independent risk signals for prostate cancer (p < 4.28 × 10-15), including three risk variants that have yet to be reported. From a polygenic risk score (PRS) model, derived to assess the cumulative effect of risk variants at 8q24, men in the top 1% of the PRS have a 4-fold (95%CI = 3.62-4.40) greater risk compared to the population average. These 12 variants account for ~25% of what can be currently explained of the familial risk of prostate cancer by known genetic risk factors. These findings highlight the overwhelming contribution of germline variation at 8q24 on prostate cancer risk which has implications for population risk stratification., Genotyping of the OncoArray was funded by the US National Institutes of Health (NIH) [U19 CA 148537 for ELucidating Loci Involved in Prostate Cancer SuscEptibility (ELLIPSE) project and X01HG007492 to the Center for Inherited Disease Research (CIDR) under contract number HHSN268201200008I]. Additional analytic support was provided by NIH NCI U01 CA188392 (PI: Schumacher). The PRACTICAL consortium (http://practical.icr.ac.uk/) was supported by Cancer Research UK Grants C5047/A7357, C1287/A10118, C1287/A16563, C5047/A3354, C5047/A10692, C16913/A6135, European Commission's Seventh Framework Programme grant agreement n° 223175 (HEALTH-F2-2009-223175), and The National Institute of Health (NIH) Cancer Post-Cancer GWAS initiative grant: No. 1 U19 CA 148537-01 (the GAME-ON initiative). We wish to thank all GWAS study groups contributing to the data set from which this study was conducted: OncoArray; iCOGS; The PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium; and The GAME-ON/ELLIPSE Consortium. Detailed acknowledgements and funding information for all GWAS study groups and from all the individual studies involved in the PRACTICAL Consortium are included in Supplementary Note 1. We would also like to thank the following for funding support: The Institute of Cancer Research and The Everyman Campaign, The Prostate Cancer Research Foundation, Prostate Research Campaign UK (now Prostate Action), The Orchid Cancer Appeal, The National Cancer Research Network UK, The National Cancer Research Institute (NCRI) UK. We are grateful for support of NIHR funding to the NIHR Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Association analyses identify 31 new risk loci for colorectal cancer susceptibility

  • Law, Philip J.
  • PRACTICAL Consortium
  • Dunlop, Malcolm G.
Colorectal cancer (CRC) is a leading cause of cancer-related death worldwide, and has a strong heritable basis. We report a genome-wide association analysis of 34,627 CRC cases and 71,379 controls of European ancestry that identifies SNPs at 31 new CRC risk loci. We also identify eight independent risk SNPs at the new and previously reported European CRC loci, and a further nine CRC SNPs at loci previously only identified in Asian populations. We use in situ promoter capture Hi-C (CHi-C), gene expression, and in silico annotation methods to identify likely target genes of CRC SNPs. Whilst these new SNP associations implicate target genes that are enriched for known CRC pathways such as Wnt and BMP, they also highlight novel pathways with no prior links to colorectal tumourigenesis. These findings provide further insight into CRC susceptibility and enhance the prospects of applying genetic risk scores to personalised screening and prevention., At the Institute of Cancer Research, this work was supported by Cancer Research UK (C1298/A25514). Additional support was provided by the National Cancer Research Network. In Edinburgh, the work was supported by Programme Grant funding from Cancer Research UK (C348/A12076) and by funding for the infrastructure and staffing of the Edinburgh CRUK Cancer Research Centre. In Birmingham, funding was provided by Cancer Research UK (C6199/A16459). We are grateful to many colleagues within UK Clinical Genetics Departments (for CORGI) and to many collaborators who participated in the VICTOR, QUASAR2 and SCOT trials. We also thank colleagues from the UK National Cancer Research Network (for NSCCG). Support from the European Union [FP7/207–2013, grant 258236] and FP7 collaborative project SYSCOL and COST Action in the UK is also acknowledged [BM1206]. The COIN and COIN-B trials were funded by Cancer Research UK and the Medical Research Council and were conducted with the support of the National Institute of Health Research Cancer Research Network. COIN and COIN-B translational studies were supported by the Bobby Moore Fund from Cancer Research UK, Tenovus, the Kidani Trust, Cancer Research Wales and the National Institute for Social Care and Health Research Cancer Genetics Biomedical Research Unit (2011–2014). We thank the High-Throughput Genomics Group at the Wellcome Trust Centre for Human Genetics (funded by Wellcome Trust grant reference 090532/Z/09/Z) and the Edinburgh Clinical Research Facility (ECRF) Genetics Core, Western General Hospital, Edinburgh, for the generation of genotyping data. We thank the Lothian Birth Cohorts’ members, investigators, research associates, and other team members. We thank the Edinburgh Clinical Research Facility (ECRF) Genetics Core, Western General Hospital, Edinburgh, for genotyping. Lothian Birth Cohorts’ data collection is supported by the Disconnected Mind project (funded by Age UK), and the Biotechnology and Biological Sciences Research Council (BBSRC, for genotyping; BB/F019394/1) and undertaken within the University of Edinburgh Centre for Cognitive Ageing and Cognitive Epidemiology (funded by the BBSRC and Medical Research Council RC as part of the LLHW [MR/K026992/1]). ET was supported by Cancer Research UK CDF (C31250/A22804). This research has been conducted using the UK Biobank Resource under Application Number 7441. Generation Scotland received core support from the Chief Scientist Office of the Scottish Government Health Directorates [CZD/16/6] and the Scottish Funding Council [HR03006]. Genotyping of the GS:SFHS samples was carried out by the Genetics Core Laboratory at the Clinical Research Facility, University of Edinburgh and was funded by the Medical Research Council UK and the Wellcome Trust (Wellcome Trust Strategic Award “STratifying Resilience and Depression Longitudinally” (STRADL) [104036/Z/14/Z]). CFR was supported by a Marie Sklodowska-Curie Intra-European Fellowship Action and received considerable help from many staff in the Department of Endoscopy at the John Radcliffe Hospital in Oxford. In Finland, this work was supported by grants from the Academy of Finland [Finnish Center of Excellence Program 2012–2017, 250345 and 2018–2025, 312041], the Jane and Aatos Erkko Foundation, the Finnish Cancer Society [personal grant to K.P.], the European Research Council [ERC; 268648], the Sigrid Juselius Foundation, SYSCOL, the Nordic Information for Action eScience Center (NIASC), the Nordic Center of Excellence financed by NordForsk [project 62721, personal grant to K.P.] and State Research Funding of Kuopio University Hospital [B1401]. We acknowledge the computational resources provided by the ELIXIR node, hosted at the CSC–IT Center for Science, Finland, and funded by the Academy of Finland [grants 271642 and 263164], the Ministry of Education and Culture, Finland. V.S. was supported by the Finnish Academy [grant number 139635] and the Finnish Foundation for Cardiovascular Research. J.-P.M. was funded by The Finnish Cancer Foundation and The Jane and Aatos Erkko Foundation. Sample collection and genotyping in the Finnish Twin Cohort has been supported by the Wellcome Trust Sanger Institute, ENGAGE—European Network for Genetic and Genomic Epidemiology, FP7-HEALTH-F4–2007; [grant agreement number 201413], the National Institute of Alcohol Abuse and Alcoholism [grants AA-12502 and AA-00145; to R.J.R. and K02AA018755 to D.M.D.] and the Academy of Finland [grants 100499, 205585, 265240 and 263278 to J.K.]. The work of the Colon Cancer Family Registry (CCFR) was supported by the National Cancer Institute (NCI) of the National Institutes of Health (NIH) under Award number U01 CA167551. The CCFR Illumina GWAS was supported by the NCI/NIH under Award Numbers U01 CA122839 and R01 CA143237 to G.C. The content of this manuscript does not necessarily reflect the views or policies of the NCI or any of the collaborating centres in the CCFR, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government or the CCFR. The CORSA study was funded by FFG BRIDGE (grant 829675, to A.G.), the “Herzfelder’sche Familienstiftung” (grant to A.G.) and was supported by COST Action BM1206. We kindly thank all individuals who agreed to participate in the CORSA study. Furthermore, we thank all cooperating physicians and students and the Biobank Graz of the Medical University of Graz. The DACHS study was supported by grants from the German Research Council (Deutsche Forschungsgemeinschaft, BR 1704/6–1, BR 1704/6–3, BR 1704/6–4, BR 1704/6–6 and CH 117/1–1), and the German Federal Ministry of Education and Research (01KH0404, 01ER0814, 01ER0815 and 01ER1505A, 01ER1505B). We thank all participants and cooperating clinicians, and Ute Handte-Daub, Ansgar Brandhorst, Muhabbet Celik and Ursula Eilber for excellent technical assistance. The Croatian study was supported through the 10,001 Dalmatians Project, and institutional support of University Hospital for Tumours, Sestre milosrdnice University Hospital Center. James East and Simon Leedham were funded by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC). The views expressed not necessarily those of the NHS, the NIHR or the Department of Health. We acknowledge use of genotype data from the British 1958 Birth Cohort DNA collection, which was funded by the Medical Research Council Grant G0000934 and the Wellcome Trust Grant 068545/Z/02. A full list of the investigators who contributed to the generation of the data is available from http://www.wtccc.org.uk. The BCAC study would not have been possible without the contributions of the following: Manjeet K. Bolla, Qin Wang, Kyriaki Michailidou and Joe Dennis. BCAC is funded by Cancer Research UK (C1287/A10118, C1287/A16563). For the BBCS study, we thank Eileen Williams, Elaine Ryder-Mills, Kara Sargus. The BBCS is funded by Cancer Research UK and Breast Cancer Now and acknowledges NHS funding to the National Institute of Health Research (NIHR) Biomedical Research Centre (BRC) and the National Cancer Research Network (NCRN). We thank the participants and the investigators of EPIC (European Prospective Investigation into Cancer and Nutrition). The coordination of EPIC is financially supported by the European Commission (DG-SANCO) and the International Agency for Research on Cancer. The national cohorts are supported by: Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Générale de l’Education Nationale, Institut National de la Santé et de la Recherche Médicale (INSERM) (France); German Cancer Aid, German Cancer Research Center (DKFZ), Federal Ministry of Education and Research (BMBF) (Germany); the Hellenic Health Foundation, the Stavros Niarchos Foundation (Greece); Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy and National Research Council (Italy); Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands); Health Research Fund (FIS), PI13/00061 to Granada, PI13/01162 to EPIC-Murcia, Regional Governments of Andalucía, Asturias, Basque Country, Murcia and Navarra, ISCIII RETIC (RD06/0020) (Spain); Cancer Research UK (14136 to EPIC-Norfolk; C570/A16491 and C8221/A19170 to EPIC-Oxford), Medical Research Council (1000143 to EPIC-Norfolk, MR/M012190/1 to EPIC-Oxford) (United Kingdom). We thank the SEARCH and EPIC teams, which were funded by a programme grant from Cancer Research UK (C490/A10124) and supported by the UK NIHR BRC at the University of Cambridge. We thank Breast Cancer Now and the Institute of Cancer Research (ICR) for support and funding of the UKBGS, and the study participants, study staff, and the doctors, nurses and other health-care providers and health information sources who have contributed to the study. Genotyping of the PRACTICAL consortium OncoArray was funded by the US National Institutes of Health (NIH) [U19 CA 148537 for ELucidating Loci Involved in Prostate cancer SuscEptibility (ELLIPSE) project and X01HG007492 to the Center for Inherited Disease Research (CIDR) under contract number HHSN268201200008I]. Additional analytic support was provided by NIH NCI U01 CA188392 (PI: Schumacher). The PRACTICAL consortium was supported by Cancer Research UK Grants C5047/A7357, C1287/A10118, C1287/A16563, C5047/A3354, C5047/A10692, C16913/A6135, European Commission’s Seventh Framework Programme grant agreement n° 223175 (HEALTH-F2–2009–223175), and The National Institute of Health (NIH) Cancer Post-Cancer GWAS initiative grant: No. 1 U19 CA 148537–01 (the GAME-ON initiative). We would also like to thank the following for funding support: The Institute of Cancer Research and The Everyman Campaign, The Prostate Cancer Research Foundation, Prostate Research Campaign UK (now Prostate Action), The Orchid Cancer Appeal, The National Cancer Research Network UK, The National Cancer Research Institute (NCRI) UK. We are grateful for support of NIHR funding to the NIHR Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, the Spanish Instituto de Salud Carlos III (ISCIII) an initiative of the Spanish Ministry of Economy and Innovation (Spain), and the Xunta de Galicia (Spain).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

The CHEK2 variant C.349A>G is associated with prostate cancer risk and carriers share a common ancestor

  • Brandão, Andreia
  • Kogevinas, Manolis
  • Teixeira, Manuel R.
The identification of recurrent founder variants in cancer predisposing genes may have important implications for implementing cost-effective targeted genetic screening strategies. In this study, we evaluated the prevalence and relative risk of the CHEK2 recurrent variant c.349A>G in a series of 462 Portuguese patients with early-onset and/or familial/hereditary prostate cancer (PrCa), as well as in the large multicentre PRACTICAL case-control study comprising 55,162 prostate cancer cases and 36,147 controls. Additionally, we investigated the potential shared ancestry of the carriers by performing identity-by-descent, haplotype and age estimation analyses using high-density SNP data from 70 variant carriers belonging to 11 different populations included in the PRACTICAL consortium. The CHEK2 missense variant c.349A>G was found significantly associated with an increased risk for PrCa (OR 1.9; 95% CI: 1.1-3.2). A shared haplotype flanking the variant in all carriers was identified, strongly suggesting a common founder of European origin. Additionally, using two independent statistical algorithms, implemented by DMLE+2.3 and ESTIAGE, we were able to estimate the age of the variant between 2300 and 3125 years. By extending the haplotype analysis to 14 additional carrier families, a shared core haplotype was revealed among all carriers matching the conserved region previously identified in the high-density SNP analysis. These findings are consistent with CHEK2 c.349A>G being a founder variant associated with increased PrCa risk, suggesting its potential usefulness for cost-effective targeted genetic screening in PrCa families., We thank the funding support from IPO-Porto Research Center (CI-IPOP-16-2012) and from Fundação para a Ciência e a Tecnologia (FCT; PEst-OE/SAU/ UI0776/2014 and PTDC/DTP-PIC/1308/2014). The following authors were awarded with grants from FCT: PPa (UID/DTP/00776/2013/POCI-01-0145-FEDER-006868), SM (SFRH/BD/71397/2010) and PPi (SFRH/BD/73719/2010). The PRACTICAL consortium (http://practical.icr.ac.uk/) was supported by the Canadian Institutes of Health Research, European Commission’s Seventh Framework Programme grant agreement n° 223175 (HEALTH-F2-2009-223175), Cancer Research UK Grants C5047/A7357, C1287/A10118, C1287/A16563, C5047/A3354, C5047/A10692, C16913/A6135, and The National Institute of Health (NIH) Cancer Post-Cancer GWAS initiative grant: No. 1 U19 CA 148537-01 (the GAME-ON initiative). Genotyping of the OncoArray was funded by the US National Institutes of Health (NIH) [U19 CA 148537 for ELucidating Loci Involved in Prostate cancer SuscEptibility (ELLIPSE) project and X01HG007492 to the Center for Inherited Disease Research (CIDR) under contract number HHSN268201200008I] and by Cancer Research UK grant A8197/A16565. Additional analytic support was provided by NIH NCI U01 CA188392 (PI: Schumacher). We would also like to thank the following for funding support: The Institute of Cancer Research and The Everyman Campaign, The Prostate Cancer Research Foundation, Prostate Research Campaign UK (now PCUK), The Orchid Cancer Appeal, Rosetrees Trust, The National Cancer Research Network UK, The National Cancer Research Institute (NCRI) UK. We are grateful for support of NIHR funding to the NIHR Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, NIHR funding to the Manchester Biomedical Research Centre and the Manchester Academic Health Sciences Centre.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Genomic analysis of male puberty timing highlights shared genetic basis with hair colour and lifespan

  • Hollis, Ben
  • Day, Felix R.
  • Busch, Alexander S.
  • Thompson, Deborah J.
  • Soares, Ana Luiza G.
  • Timmers, Paul R.H.J.
  • Kwong, Alex
  • Easton, Doug F.
  • Joshi, Peter K.
  • Timpson, Nicholas J.
  • PRACTICAL Consortium
  • 23andMe Research Team
  • Ong, Ken K.
  • Perry, John R. B.
The timing of puberty is highly variable and is associated with long-term health outcomes. To date, understanding of the genetic control of puberty timing is based largely on studies in women. Here, we report a multi-trait genome-wide association study for male puberty timing with an effective sample size of 205,354 men. We find moderately strong genomic correlation in puberty timing between sexes (rg = 0.68) and identify 76 independent signals for male puberty timing. Implicated mechanisms include an unexpected link between puberty timing and natural hair colour, possibly reflecting common effects of pituitary hormones on puberty and pigmentation. Earlier male puberty timing is genetically correlated with several adverse health outcomes and Mendelian randomization analyses show a genetic association between male puberty timing and shorter lifespan. These findings highlight the relationships between puberty timing and health outcomes, and demonstrate the value of genetic studies of puberty timing in both sexes., This work was funded by the UK Medical Research Council (MRC; Unit programme MC_UU_12015/2) and used UK Biobank data under application 9905. The MRC, Wellcome Trust (Grant ref: 102215/2/13/2) and the University of Bristol provide core support for ALSPAC. This publication is the work of the authors and <John Perry and Ken Ong> will serve as guarantors for the contents of this paper. GWAS data for ALSPAC was generated by Sample Logistics and Genotyping Facilities at Wellcome Sanger Institute and LabCorp (Laboratory Corporation of America) using support from 23andMe. We are extremely grateful to all the families who took part in the ALSPAC study, the midwives for their help in recruiting them, and the whole ALSPAC team, which includes interviewers, computer and laboratory technicians, clerical workers, research assistants, volunteers, managers, receptionists and nurses. We thank the research participants and employees of 23andMe for making this work possible. Genotyping of the OncoArray was funded by the US National Institutes of Health (NIH) [U19 CA154 148537 for ELucidating Loci Involved in Prostate cancer SuscEptibility (ELLIPSE) project and X01HG007492 to the Center for Inherited Disease Research (CIDR) under contract number 156 HHSN268201200008I]. Additional analytic support was provided by NIH NCI U01 CA188392 157 (PI: Schumacher). The PRACTICAL consortium was supported by Cancer Research UK Grants C5047/A7357, C1287/A10118, C1287/A16563, C5047/A3354, C5047/A10692, C16913/A6135, European 160 Commission’s Seventh Framework Programme grant agreement no° 223175 (HEALTH-F2-2009-223175), and The National Institute of Health (NIH) Cancer Post-Cancer GWAS initiative grant: No. 1 U19 CA 148537-01 (the GAME-ON initiative). We would also like to thank the following for funding support: The Institute of Cancer Research and The Everyman Campaign, The Prostate Cancer Research Foundation, Prostate Research Campaign UK (now Prostate Action), The Orchid Cancer Appeal, The National Cancer Research Network UK, The National Cancer Research Institute (NCRI) UK. We are grateful for support of NIHR funding to the NIHR Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust. In memoriam: Brian E. Henderson.
Repisalud
Publication Artículo científico (JournalArticle)

Large-scale genotyping identifies a new locus at 22q13.2 associated with female breast size

  • Li, Jingmei
  • Foo, Jia Nee
  • Schoof, Nils
  • Varghese, Jajini S
  • Fernandez-Navarro, Pablo L
  • Gierach, Gretchen L
  • Quek, Swee Tian
  • Hartman, Mikael
  • Nord, Silje
  • Kristensen, Vessela N
  • Pollan-Santamaria, Marina
  • Figueroa, Jonine D
  • Thompson, Deborah J
  • Li, Yi
  • Khor, Chiea-Chuen
  • Humphreys, Keith
  • Liu, Jianjun
  • Czene, Kamila
  • Hall, Per
BACKGROUND: Individual differences in breast size are a conspicuous feature of variation in human females and have been associated with fecundity and advantage in selection of mates. To identify common variants that are associated with breast size, we conducted a large-scale genotyping association meta-analysis in 7169 women of European descent across three independent sample collections with digital or screen film mammograms. METHODS: The samples consisted of the Swedish KARMA, LIBRO-1 and SASBAC studies genotyped on iCOGS, a custom illumina iSelect genotyping array comprising of 211 155 single nucleotide polymorphisms (SNPs) designed for replication and fine mapping of common and rare variants with relevance to breast, ovary and prostate cancer. Breast size of each subject was ascertained by measuring total breast area (mm(2)) on a mammogram. RESULTS: We confirm genome-wide significant associations at 8p11.23 (rs10086016, p=1.3×10(-14)) and report a new locus at 22q13 (rs5995871, p=3.2×10(-8)). The latter region contains the MKL1 gene, which has been shown to impact endogenous oestrogen receptor α transcriptional activity and is recruited on oestradiol sensitive genes. We also replicated previous genome-wide association study findings for breast size at four other loci. CONCLUSIONS: A new locus at 22q13 may be associated with female breast size.
Repisalud
Publication Artículo científico (JournalArticle)

Reproductive profiles and risk of breast cancer subtypes: a multi-center case-only study

  • Brouckaert, Olivier
  • Rudolph, Anja
  • Laenen, Annouschka
  • Keeman, Renske
  • Bolla, Manjeet K
  • Wang, Qin
  • Soubry, Adelheid
  • Wildiers, Hans
  • Andrulis, Irene L
  • Arndt, Volker
  • Beckmann, Matthias W
  • Benitez, Javier
  • Blomqvist, Carl
  • Bojesen, Stig E
  • Brauch, Hiltrud
  • Brennan, Paul
  • Brenner, Hermann
  • Chenevix-Trench, Georgia
  • Choi, Ji-Yeob
  • Cornelissen, Sten
  • Couch, Fergus J
  • Cox, Angela
  • Cross, Simon S
  • Czene, Kamila
  • Eriksson, Mikael
  • Fasching, Peter A
  • Figueroa, Jonine
  • Flyger, Henrik
  • Giles, Graham G
  • González-Neira A, Anna
  • Guénel, Pascal
  • Hall, Per
  • Hollestelle, Antoinette
  • Hopper, John L
  • Ito, Hidemi
  • Jones, Michael
  • Kang, Daehee
  • Knight, Julia A
  • Kosma, Veli-Matti
  • Li, Jingmei
  • Lindblom, Annika
  • Lilyquist, Jenna
  • Lophatananon, Artitaya
  • Mannermaa, Arto
  • Manoukian, Siranoush
  • Margolin, Sara
  • Matsuo, Keitaro
  • Muir, Kenneth
  • Nevanlinna, Heli
  • Peterlongo, Paolo
  • Pylkäs, Katri
  • Saajrang, Suleeporn
  • Seynaeve, Caroline
  • Shen, Chen-Yang
  • Shu, Xiao-Ou
  • Southey, Melissa C
  • Swerdlow, Anthony
  • Teo, Soo-Hwang
  • Tollenaar, Rob A E M
  • Truong, Thérèse
  • Tseng, Chiu-Chen
  • van den Broek, Alexandra J
  • van Deurzen, Carolien H M
  • Winqvist, Robert
  • Wu, Anna H
  • Yip, Cheng Har
  • Yu, Jyh-Cherng
  • Zheng, Wei
  • Milne, Roger L
  • Pharoah, Paul D P
  • Easton, Douglas F
  • Schmidt, Marjanka K
  • Garcia-Closas, Montserrat
  • Chang-Claude, Jenny
  • Lambrechts, Diether
  • Neven, Patrick
BACKGROUND: Previous studies have shown that reproductive factors are differentially associated with breast cancer (BC) risk by subtypes. The aim of this study was to investigate associations between reproductive factors and BC subtypes, and whether these vary by age at diagnosis. METHODS: We used pooled data on tumor markers (estrogen and progesterone receptor, human epidermal growth factor receptor-2 (HER2)) and reproductive risk factors (parity, age at first full-time pregnancy (FFTP) and age at menarche) from 28,095 patients with invasive BC from 34 studies participating in the Breast Cancer Association Consortium (BCAC). In a case-only analysis, we used logistic regression to assess associations between reproductive factors and BC subtype compared to luminal A tumors as a reference. The interaction between age and parity in BC subtype risk was also tested, across all ages and, because age was modeled non-linearly, specifically at ages 35, 55 and 75 years. RESULTS: Parous women were more likely to be diagnosed with triple negative BC (TNBC) than with luminal A BC, irrespective of age (OR for parity = 1.38, 95% CI 1.16-1.65, p = 0.0004; p for interaction with age = 0.076). Parous women were also more likely to be diagnosed with luminal and non-luminal HER2-like BCs and this effect was slightly more pronounced at an early age (p for interaction with age = 0.037 and 0.030, respectively). For instance, women diagnosed at age 35 were 1.48 (CI 1.01-2.16) more likely to have luminal HER2-like BC than luminal A BC, while this association was not significant at age 75 (OR = 0.72, CI 0.45-1.14). While age at menarche was not significantly associated with BC subtype, increasing age at FFTP was non-linearly associated with TNBC relative to luminal A BC. An age at FFTP of 25 versus 20 years lowered the risk for TNBC (OR = 0.78, CI 0.70-0.88, p < 0.0001), but this effect was not apparent at a later FFTP. CONCLUSIONS: Our main findings suggest that parity is associated with TNBC across all ages at BC diagnosis, whereas the association with luminal HER2-like BC was present only for early onset BC.
Repisalud
Publication Artículo científico (JournalArticle)

Genome-wide and transcriptome-wide association studies of mammographic density phenotypes reveal novel loci

  • Chen, Hongjie
  • Fan, Shaoqi
  • Stone, Jennifer
  • Thompson, Deborah J
  • Douglas, Julie
  • Li, Shuai
  • Scott, Christopher
  • Bolla, Manjeet K
  • Wang, Qin
  • Dennis, Joe
  • Michailidou, Kyriaki
  • Li, Christopher
  • Peters, Ulrike
  • Hopper, John L
  • Southey, Melissa C
  • Nguyen-Dumont, Tu
  • Nguyen, Tuong L
  • Fasching, Peter A
  • Behrens, Annika
  • Cadby, Gemma
  • Murphy, Rachel A
  • Aronson, Kristan
  • Howell, Anthony
  • Astley, Susan
  • Couch, Fergus
  • Olson, Janet
  • Milne, Roger L
  • Giles, Graham G
  • Haiman, Christopher A
  • Maskarinec, Gertraud
  • Winham, Stacey
  • John, Esther M
  • Kurian, Allison
  • Eliassen, Heather
  • Andrulis, Irene
  • Evans, D Gareth
  • Newman, William G
  • Hall, Per
  • Czene, Kamila
  • Swerdlow, Anthony
  • Jones, Michael
  • Pollan-Santamaria, Marina
  • Fernandez-Navarro, Pablo L
  • McConnell, Daniel S
  • Kristensen, Vessela N
  • Rothstein, Joseph H
  • Wang, Pei
  • Habel, Laurel A
  • Sieh, Weiva
  • Dunning, Alison M
  • Pharoah, Paul D P
  • Easton, Douglas F
  • Gierach, Gretchen L
  • Tamimi, Rulla M
  • Vachon, Celine M
  • Lindström, Sara
Background: Mammographic density (MD) phenotypes, including percent density (PMD), area of dense tissue (DA), and area of non-dense tissue (NDA), are associated with breast cancer risk. Twin studies suggest that MD phenotypes are highly heritable. However, only a small proportion of their variance is explained by identified genetic variants. Methods: We conducted a genome-wide association study, as well as a transcriptome-wide association study (TWAS), of age- and BMI-adjusted DA, NDA, and PMD in up to 27,900 European-ancestry women from the MODE/BCAC consortia. Results: We identified 28 genome-wide significant loci for MD phenotypes, including nine novel signals (5q11.2, 5q14.1, 5q31.1, 5q33.3, 5q35.1, 7p11.2, 8q24.13, 12p11.2, 16q12.2). Further, 45% of all known breast cancer SNPs were associated with at least one MD phenotype at p < 0.05. TWAS further identified two novel genes (SHOX2 and CRISPLD2) whose genetically predicted expression was significantly associated with MD phenotypes. Conclusions: Our findings provided novel insight into the genetic background of MD phenotypes, and further demonstrated their shared genetic basis with breast cancer.
Repisalud
Publication Artículo científico (JournalArticle)

Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer

  • Couch, Fergus J
  • Kuchenbaecker, Karoline B
  • Michailidou, Kyriaki
  • Mendoza-Fandino, Gustavo A
  • Nord, Silje
  • Lilyquist, Janna
  • Olswold, Curtis
  • Hallberg, Emily
  • Agata, Simona
  • Ahsan, Habibul
  • Aittomäki, Kristiina
  • Ambrosone, Christine
  • Andrulis, Irene L
  • Anton-Culver, Hoda
  • Arndt, Volker
  • Arun, Banu K
  • Arver, Brita
  • Barile, Monica
  • Barkardottir, Rosa B
  • Barrowdale, Daniel
  • Beckmann, Lars
  • Beckmann, Matthias W
  • Benitez, Javier
  • Blank, Stephanie V
  • Blomqvist, Carl
  • Bogdanova, Natalia V
  • Bojesen, Stig E
  • Bolla, Manjeet K
  • Bonanni, Bernardo
  • Brauch, Hiltrud
  • Brenner, Hermann
  • Burwinkel, Barbara
  • Buys, Saundra S
  • Caldes, Trinidad
  • Caligo, Maria A
  • Canzian, Federico
  • Carpenter, Jane
  • Chang-Claude, Jenny
  • Chanock, Stephen J
  • Chung, Wendy K
  • Claes, Kathleen B M
  • Cox, Angela
  • Cross, Simon S
  • Cunningham, Julie M
  • Czene, Kamila
  • Daly, Mary B
  • Damiola, Francesca
  • Darabi, Hatef
  • de la Hoya, Miguel
  • Devilee, Peter
  • Diez, Orland
  • Ding, Yuan C
  • Dolcetti, Riccardo
  • Domchek, Susan M
  • Dorfling, Cecilia M
  • Dos-Santos-Silva, Isabel
  • Dumont, Martine
  • Dunning, Alison M
  • Eccles, Diana M
  • Ehrencrona, Hans
  • Ekici, Arif B
  • Eliassen, Heather
  • Ellis, Steve
  • Fasching, Peter A
  • Figueroa, Jonine
  • Flesch-Janys, Dieter
  • Försti, Asta
  • Fostira, Florentia
  • Foulkes, William D
  • Friebel, Tara
  • Friedman, Eitan
  • Frost, Debra
  • Gabrielson, Marike
  • Gammon, Marilie D
  • Ganz, Patricia A
  • Gapstur, Susan M
  • Garber, Judy
  • Gaudet, Mia M
  • Gayther, Simon A
  • Gerdes, Anne-Marie
  • Ghoussaini, Maya
  • Giles, Graham G
  • Glendon, Gord
  • Godwin, Andrew K
  • Goldberg, Mark S
  • Goldgar, David E
  • González-Neira A, Anna
  • Greene, Mark H
  • Gronwald, Jacek
  • Guénel, Pascal
  • Gunter, Marc
  • Haeberle, Lothar
  • Haiman, Christopher A
  • Hamann, Ute
  • Hansen, Thomas V O
  • Hart, Steven
  • Healey, Sue
  • Heikkinen, Tuomas
  • Henderson, Brian E
  • Herzog, Josef
  • Hogervorst, Frans B L
  • Hollestelle, Antoinette
  • Hooning, Maartje J
  • Hoover, Robert N
  • Hopper, John L
  • Humphreys, Keith
  • Hunter, David J
  • Huzarski, Tomasz
  • Imyanitov, Evgeny N
  • Isaacs, Claudine
  • Jakubowska, Anna
  • James, Paul
  • Janavicius, Ramunas
  • Jensen, Uffe Birk
  • John, Esther M
  • Jones, Michael
  • Kabisch, Maria
  • Kar, Siddhartha
  • Karlan, Beth Y
  • Khan, Sofia
  • Khaw, Kay-Tee
  • Kibriya, Muhammad G
  • Knight, Julia A
  • Ko, Yon-Dschun
  • Konstantopoulou, Irene
  • Kosma, Veli-Matti
  • Kristensen, Vessela
  • Kwong, Ava
  • Laitman, Yael
  • Lambrechts, Diether
  • Lazaro, Conxi
  • Lee, Eunjung
  • Le Marchand, Loic
  • Lester, Jenny
  • Lindblom, Annika
  • Lindor, Noralane
  • Lindstrom, Sara
  • Liu, Jianjun
  • Long, Jirong
  • Lubinski, Jan
  • Mai, Phuong L
  • Makalic, Enes
  • Malone, Kathleen E
  • Mannermaa, Arto
  • Manoukian, Siranoush
  • Margolin, Sara
  • Marme, Frederik
  • Martens, John W M
  • McGuffog, Lesley
  • Meindl, Alfons
  • Miller, Austin
  • Milne, Roger L
  • Miron, Penelope
  • Montagna, Marco
  • Mazoyer, Sylvie
  • Mulligan, Anna M
  • Muranen, Taru A
  • Nathanson, Katherine L
  • Neuhausen, Susan L
  • Nevanlinna, Heli
  • Nordestgaard, Børge G
  • Nussbaum, Robert L
  • Offit, Kenneth
  • Olah, Edith
  • Olopade, Olufunmilayo I
  • Olson, Janet E
  • Osorio, Ana
  • Park, Sue K
  • Peeters, Petra H
  • Peissel, Bernard
  • Peterlongo, Paolo
  • Peto, Julian
  • Phelan, Catherine M
  • Pilarski, Robert
  • Poppe, Bruce
  • Pylkäs, Katri
  • Radice, Paolo
  • Rahman, Nazneen
  • Rantala, Johanna
  • Rappaport, Christine
  • Rennert, Gad
  • Richardson, Andrea
  • Robson, Mark
  • Romieu, Isabelle
  • Rudolph, Anja
  • Rutgers, Emiel J
  • Sanchez, Maria-Jose
  • Santella, Regina M
  • Sawyer, Elinor J
  • Schmidt, Daniel F
  • Schmidt, Marjanka K
  • Schmutzler, Rita K
  • Schumacher, Fredrick
  • Scott, Rodney
  • Senter, Leigha
  • Sharma, Priyanka
  • Simard, Jacques
  • Singer, Christian F
  • Sinilnikova, Olga M
  • Soucy, Penny
  • Southey, Melissa
  • Steinemann, Doris
  • Stenmark-Askmalm, Marie
  • Stoppa-Lyonnet, Dominique
  • Swerdlow, Anthony
  • Szabo, Csilla I
  • Tamimi, Rulla
  • Tapper, William
  • Teixeira, Manuel R
  • Teo, Soo-Hwang
  • Terry, Mary B
  • Thomassen, Mads
  • Thompson, Deborah
  • Tihomirova, Laima
  • Toland, Amanda E
  • Tollenaar, Robert A E M
  • Tomlinson, Ian
  • Truong, Thérèse
  • Tsimiklis, Helen
  • Teulé, Alex
  • Tumino, Rosario
  • Tung, Nadine
  • Turnbull, Clare
  • Ursin, Giski
  • van Deurzen, Carolien H M
  • van Rensburg, Elizabeth J
  • Varon-Mateeva, Raymonda
  • Wang, Zhaoming
  • Wang-Gohrke, Shan
  • Weiderpass, Elisabete
  • Weitzel, Jeffrey N
  • Whittemore, Alice
  • Wildiers, Hans
  • Winqvist, Robert
  • Yang, Xiaohong R
  • Yannoukakos, Drakoulis
  • Yao, Song
  • Zamora, M Pilar
  • Zheng, Wei
  • Hall, Per
  • Kraft, Peter
  • Vachon, Celine
  • Slager, Susan
  • Chenevix-Trench, Georgia
  • Pharoah, Paul D P
  • Monteiro, Alvaro A N
  • García-Closas, Montserrat
  • Easton, Douglas F
  • Antoniou, Antonis C
Common variants in 94 loci have been associated with breast cancer including 15 loci with genome-wide significant associations (P<5 × 10(-8)) with oestrogen receptor (ER)-negative breast cancer and BRCA1-associated breast cancer risk. In this study, to identify new ER-negative susceptibility loci, we performed a meta-analysis of 11 genome-wide association studies (GWAS) consisting of 4,939 ER-negative cases and 14,352 controls, combined with 7,333 ER-negative cases and 42,468 controls and 15,252 BRCA1 mutation carriers genotyped on the iCOGS array. We identify four previously unidentified loci including two loci at 13q22 near KLF5, a 2p23.2 locus near WDR43 and a 2q33 locus near PPIL3 that display genome-wide significant associations with ER-negative breast cancer. In addition, 19 known breast cancer risk loci have genome-wide significant associations and 40 had moderate associations (P<0.05) with ER-negative disease. Using functional and eQTL studies we implicate TRMT61B and WDR43 at 2p23.2 and PPIL3 at 2q33 in ER-negative breast cancer aetiology. All ER-negative loci combined account for ∼11% of familial relative risk for ER-negative disease and may contribute to improved ER-negative and BRCA1 breast cancer risk prediction.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations

  • Feliubadaló i Elorza, Maria Lídia
  • Teulé-Vega, Àlex
  • CIMBA Consortium
The prevalence and spectrum of germline mutations in BRCA1 and BRCA2 have been reported in single populations, with the majority of reports focused on White in Europe and North America. The Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) has assembled data on 18,435 families with BRCA1 mutations and 11,351 families with BRCA2 mutations ascertained from 69 centers in 49 countries on six continents. This study comprehensively describes the characteristics of the 1,650 unique BRCA1 and 1,731 unique BRCA2 deleterious (disease-associated) mutations identified in the CIMBA database. We observed substantial variation in mutation type and frequency by geographical region and race/ethnicity. In addition to known founder mutations, mutations of relatively high frequency were identified in specific racial/ethnic or geographic groups that may reflect founder mutations and which could be used in targeted (panel) first pass genotyping for specific populations. Knowledge of the population-specific mutational spectrum in BRCA1 and BRCA2 could inform efficient strategies for genetic testing and may justify a more broad-based oncogenetic testing in some populations.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer

  • Blanco Guillermo, Ignacio
  • Australian Cancer Study
  • Australian Ovarian Cancer Study Group
  • GENICA (Gene Environment Interaction and Breast Cancer)
  • SWE-BRCA Group
  • HEBON Investigators
  • EMBRACE Collaborators
  • GEMO Study Collaborators
TERT-locus SNPs and leukocyte telomere measures are reportedly associated with risks of multiple cancers. Using the Illumina custom genotyping array iCOGs, we analyzed ~480 SNPs at the TERT locus in breast (n = 103,991), ovarian (n = 39,774) and BRCA1 mutation carrier (n = 11,705) cancer cases and controls. Leukocyte telomere measurements were also available for 53,724 participants. Most associations cluster into three independent peaks. The minor allele at the peak 1 SNP rs2736108 associates with longer telomeres (P = 5.8 × 10−7), lower risks for estrogen receptor (ER)-negative (P = 1.0 × 10−8) and BRCA1 mutation carrier (P = 1.1 × 10−5) breast cancers and altered promoter assay signal. The minor allele at the peak 2 SNP rs7705526 associates with longer telomeres (P = 2.3 × 10−14), higher risk of low-malignant-potential ovarian cancer (P = 1.3 × 10−15) and greater promoter activity. The minor alleles at the peak 3 SNPs rs10069690 and rs2242652 increase ER-negative (P = 1.2 × 10−12) and BRCA1 mutation carrier (P = 1.6 × 10−14) breast and invasive ovarian (P = 1.3 × 10−11) cancer risks but not via altered telomere length. The cancer risk alleles of rs2242652 and rs10069690, respectively, increase silencing and generate a truncated TERT splice variant.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers

  • Teulé-Vega, Àlex
  • Lázaro García, Conxi
  • Blanco Guillermo, Ignacio
  • Valle Domínguez, Jesús del
  • COGS (Collaborative Oncological Gene-environment Study)
  • CIMBA Consortium
  • EMBRACE Collaborators
  • HEBON Investigators
  • GEMO Study Collaborators
  • CONSIT Team (CONsorzio Studi ITaliani sui Tumori Ereditari Alla Mammella, Italy)
Introduction: Individuals carrying pathogenic mutations in the BRCA1 and BRCA2 genes have a high lifetime risk of breast cancer. BRCA1 and BRCA2 are involved in DNA double-strand break repair, DNA alterations that can be caused by exposure to reactive oxygen species, a main source of which are mitochondria. Mitochondrial genome variations affect electron transport chain efficiency and reactive oxygen species production. Individuals with different mitochondrial haplogroups differ in their metabolism and sensitivity to oxidative stress. Variability in mitochondrial genetic background can alter reactive oxygen species production, leading to cancer risk. In the present study, we tested the hypothesis that mitochondrial haplogroups modify breast cancer risk in BRCA1/2 mutation carriers. Methods: We genotyped 22,214 (11,421 affected, 10,793 unaffected) mutation carriers belonging to the Consortium of Investigators of Modifiers of BRCA1/2 for 129 mitochondrial polymorphisms using the iCOGS array. Haplogroup inference and association detection were performed using a phylogenetic approach. ALTree was applied to explore the reference mitochondrial evolutionary tree and detect subclades enriched in affected or unaffected individuals. Results: We discovered that subclade T1a1 was depleted in affected BRCA2 mutation carriers compared with the rest of clade T (hazard ratio (HR) = 0.55; 95% confidence interval (CI), 0.34 to 0.88; P = 0.01). Compared with the most frequent haplogroup in the general population (that is, H and T clades), the T1a1 haplogroup has a HR of 0.62 (95% CI, 0.40 to 0.95; P = 0.03). We also identified three potential susceptibility loci, including G13708A/rs28359178, which has demonstrated an inverse association with familial breast cancer risk. Conclusions: This study illustrates how original approaches such as the phylogeny-based method we used can empower classical molecular epidemiological studies aimed at identifying association or risk modification effects.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer

  • Couch, Fergus J.
  • Kuchenbaecker, Karoline B.
  • Michailidou, Kyriaki
  • Mendoza-Fandino, Gustavo A.
  • Nord, Silje
  • Lilyquist, Jenna
  • Olswold, Curtis
  • Hallberg, Emily
  • Agata, Simona
  • Ahsan, Habibul
  • Aittomäki, Kristiina
  • Flesch-Janys, Dieter
  • Carpenter, Jane
  • Tomlinson, Ian P.
  • James, Paul
  • Tollenaar, Raem
  • Swerdlow, Anthony J.
  • Bojesen, Stig E.
  • McGuffog, Lesley
  • Miron, Penelope
  • Truong, Thérèse
  • Toland, Amanda E.
  • Henderson, Brian E.
  • Hollestelle, Antoinette
  • Knight, Julia A.
  • Cox, Angela
  • Burwinkel, Barbara
  • Yang, Xiaohong R
  • Yannoukakos, Drakoulis
  • Varon-Mateeva, Raymonda
  • Lázaro García, Conxi
  • Hooning, Maartje J.
  • Rutgers, Emiel J.
  • Domchek, Susan M.
  • Wang-Gohrke, Shan
  • Lambrechts, Diether
  • Wang, Zhaoming
  • Tsimiklis, Helen
  • Daly, Mary B.
  • Arver, Brita
  • Olah, Edith
  • Sawyer, Elinor J.
  • Khaw, Kay-Tee
  • Long, Jirong
  • Eccles, Diana
  • Díez Gibert, Orland
  • Chenevix-Trench, Georgia
  • Pharoah, Paul D. P.
  • Yao, Song
  • Margolin, Sara
  • Kibriya, Muhammad G.
  • Zheng, Wei
  • Manoukian, Siranoush
  • Zamora, M. Pilar
  • Blank, Stephanie V.
  • Ambrosone, Christine
  • Chang-Claude, Jenny
  • Phelan, Catherine M.
  • Szabo, Csilla I.
  • Barrowdale, Daniel
  • Frost, Debra
  • Bolla, Manjeet K.
  • Bonanni, Bernardo
  • Hunter, David J.
  • Nathanson, Katherine L.
  • Liu, Jianjun
  • García Closas, Montserrat
  • Muranen, Taru A.
  • Monteiro, Alvaro N.
  • Buys, Saundra S.
  • Dorfling, Cecilia M.
  • Teulé-Vega, Àlex
  • Claes, Kathleen B. M.
  • Glendon, Gord
  • Damiola, Francesca
  • Darabi, Hatef
  • Kosma, Veli-Matti
  • Park, Sue K.
  • Brenner, Hermann
  • Osorio, Ana
  • Brauch, Hiltrud
  • Rudolph, Anja
  • Weitzel, Jeffrey N.
  • Dunning, Alison M.
  • Haeberle, Lothar
  • Eliassen, Heather
  • Ellis, Steve
  • Pylkäs, Katri
  • Devilee, Peter
  • Poppe, Bruce
  • Hoya, Miguel de la
  • Blomqvist, Carl
  • Jakubowska, Anna
  • Herzog, Josef
  • Ganz, Patricia A.
  • Gapstur, Susan M.
  • Figueroa, Jonine D.
  • Scott, Rodney J.
  • Fasching, Peter A.
  • Cunningham, Julie M.
  • Arun, Banu K.
  • Ko, Yon-Dschun
  • Fostira, Florentia
  • Schmutzler, Rita Katharina
  • Försti, Asta
  • Santos-Silva, Isabel dos
  • John, Esther M.
  • van Rensburg, Elizabeth J.
  • Weiderpass, Elisabete
  • Foulkes, William D.
  • Barkardottir, Rosa B.
  • Robson, Mark
  • Steinemann, Doris
  • Laitman, Yael
  • Khan, Sofia
  • Goldgar, David E.
  • González Neira, Anna
  • Gaudet, Mia M.
  • Teo, Soo-Hwang
  • Romieu, Isabelle
  • Lubinski, Jan
  • Gerdes, Anne-Marie
  • Teixeira, Manuel R.
  • Gayther, Simon A.
  • Friebel, Tara M.
  • Lee, Eunjung
  • Humphreys, Keith
  • Hall, Peter
  • Chung, Wendy K.
  • Beckmann, Matthias W.
  • Mannermaa, Arto
  • Lindström, Sara
  • Hansen, Thomas V. O.
  • Hart, Steven
  • Greene, Mark H.
  • Turnbull, Clare
  • Southey, Melissa C.
  • Guénel, Pascal
  • Tung, Nadine
  • Gronwald, Jacek
  • Hogervorst, Frans B. L.
  • Konstantopoulou, Irene
  • Easton, Douglas F.
  • Dumont, Martine
  • Imyanitov, Evgeny N.
  • Mulligan, Anna Marie
  • Jones, Michael
  • Kabisch, Maria
  • Santella, Regina M.
  • Winqvist, Robert
  • Heikkinen, Tuomas
  • Wildiers, Hans
  • Healey, Sue
  • Andrulis, Irene L.
  • Arndt, Volker
  • Friedman, Eitan
  • Kwong, Ava
  • Olson, Janet E.
  • Marchand, Loïc Le
  • Lester, Jenny
  • Slager, Susan L.
  • Karlan, Beth Y.
  • Vachon, Celine M.
  • Kar, Siddhartha P.
  • Canzian, Federico
  • Giles, Graham G.
  • Malone, Kathleen E.
  • Pilarski, Robert
  • Marmé, Frederik
  • Martens, John W. M.
  • Lindor, Noralane
  • Bogdanova, Natalia V.
  • Lindblom, Annika
  • Janavicius, Ramunas
  • Schmidt, Marjanka K.
  • Rennert, Gad
  • Neuhausen, Susan L.
  • Nevanlinna, Heli
  • Meindl, Alfons
  • Czene, Kamila
  • Anton-Culver, Hoda
  • Hopper, John L.
  • Stenmark-Askmalm, Marie
  • Milne, Roger L.
  • Cross, Simon S.
  • Miller, Austin
  • Mai, Phuong L.
  • Senter, Leigha
  • Garber, Judy
  • Ghoussaini, Maya
  • Huzarski, Tomasz
  • Caldes, Trinidad
  • Dolcetti, Riccardo
  • Tapper, William
  • Soucy, Penny
  • Peeters, Petra H. M.
  • Peissel, Bernard
  • Nordestgaard, Børge G.
  • Ekici, Arif B.
  • Caligo, Maria A.
  • Offit, Kenneth
  • Ehrencrona, Hans
  • Nussbaum, Robert L.
  • Montagna, Marco
  • Beckmann, Lars
  • Sánchez, María José
  • Gunter, Marc J.
  • Kristensen, Vessela N.
  • Isaacs, Claudine
  • Tumino, Rosario
  • Radice, Paolo
  • Rahman, Nazneen
  • Barile, Monica
  • Gammon, Marilie D.
  • Ding, Yuan C.
  • Peto, Julian
  • Gabrielson, Marike
  • Peterlongo, Paolo
  • Richardson, Andrea
  • Stoppa-Lyonnet, Dominique
  • Makalic, Enes
  • Schmidt, Daniel F.
  • Whittemore, Alice
  • Sharma, Priyanka
  • Simard, Jacques
  • Chanock, Stephen J.
  • Goldberg, Mark S.
  • Rappaport-Fuerhauser, Christine
  • Godwin, Andrew K.
  • Rantala, Johanna
  • Hoover, Robert N.
  • Mazoyer, Sylvie
  • Tamimi, Rulla
  • Kraft, Peter
  • Terry, Mary Beth
  • Thomassen, Mads
  • Hamann, Ute
  • Sinilnikova, Olga M.
  • Haiman, Christopher A.
  • Singer, Christian F.
  • Olopade, Olufunmilayo I.
  • Benitez, Javier
  • Antoniou, Antonis C.
  • Ursin, Giski
  • Van Deurzen, Carolien H. M.
  • Tihomirova, Laima
  • Jensen, Uffe Birk
  • Thompson, Deborah J.
  • Schumacher, Fredrick
Common variants in 94 loci have been associated with breast cancer including 15 loci with genome-wide significant associations (P<5 x 10(-8)) with oestrogen receptor (ER)-negative breast cancer and BRCA1-associated breast cancer risk. In this study, to identify new ER-negative susceptibility loci, we performed a meta-analysis of 11 genome-wide association studies (GWAS) consisting of 4,939 ER-negative cases and 14,352 controls, combined with 7,333 ER-negative cases and 42,468 controls and 15,252 BRCA1 mutation carriers genotyped on the iCOGS array. We identify four previously unidentified loci including two loci at 13q22 near KLF5, a 2p23.2 locus near WDR43 and a 2q33 locus near PPIL3 that display genome-wide significant associations with ER-negative breast cancer. In addition, 19 known breast cancer risk loci have genome-wide significant associations and 40 had moderate associations (P<0.05) with ER-negative disease. Using functional and eQTL studies we implicate TRMT61B and WDR43 at 2p23.2 and PPIL3 at 2q33 in ER-negative breast cancer aetiology. All ER-negative loci combined account for similar to 11% of familial relative risk for ER-negative disease and may contribute to improved ER-negative and BRCA1 breast cancer risk prediction.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast–ovarian cancer susceptibility locus

  • Feliubadaló i Elorza, Maria Lídia
  • Genetic Modifiers of Cancer Risk in BRCA1/2 Mutation Carriers (GEMO)
  • Epidemiological study of BRCA1 &amp; BRCA2 Mutation Carriers (EMBRACE)
  • Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON)
  • KConFab Investigators
  • Australian Ovarian Cancer Study Group
A locus at 19p13 is associated with breast cancer (BC) and ovarian cancer (OC) risk. Here we analyse 438 SNPs in this region in 46,451 BC and 15,438 OC cases, 15,252 BRCA1 mutation carriers and 73,444 controls and identify 13 candidate causal SNPs associated with serous OC (P = 9.2 x 10(-20)), ER-negative BC (P = 1.1 x 10(-13)), BRCA1-associated BC (P = 7.7 x 10(-16)) and triple negative BC (P-diff = 2 x 10(-5)). Genotype-gene expression associations are identified for candidate target genes ANKLE1 (P = 2 x 10(-3)) and ABHD8 (P<2 x 10(-3)). Chromosome conformation capture identifies interactions between four candidate SNPs and ABHD8, and luciferase assays indicate six risk alleles increased transactivation of the ADHD8 promoter. Targeted deletion of a region containing risk SNP rs56069439 in a putative enhancer induces ANKLE1 downregulation; and mRNA stability assays indicate functional effects for an ANKLE1 30-UTR SNP. Altogether, these data suggest that multiple SNPs at 19p13 regulate ABHD8 and perhaps ANKLE1 expression, and indicate common mechanisms underlying breast and ovarian cancer risk.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Germline variation at 8q24 and prostate cancer risk in men of European ancestry

  • Matejcic, Marco
  • Sanders, Edward J.
  • Mengual Brichs, Lourdes
  • PRACTICAL Consortium
Chromosome 8q24 is a susceptibility locus for multiple cancers, including prostate cancer. Here we combine genetic data across the 8q24 susceptibility region from 71,535 prostate cancer cases and 52,935 controls of European ancestry to define the overall contribution of germline variation at 8q24 to prostate cancer risk. We identify 12 independent risk signals for prostate cancer (p < 4.28 × 10-15), including three risk variants that have yet to be reported. From a polygenic risk score (PRS) model, derived to assess the cumulative effect of risk variants at 8q24, men in the top 1% of the PRS have a 4-fold (95%CI = 3.62-4.40) greater risk compared to the population average. These 12 variants account for ~25% of what can be currently explained of the familial risk of prostate cancer by known genetic risk factors. These findings highlight the overwhelming contribution of germline variation at 8q24 on prostate cancer risk which has implications for population risk stratification.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Identification of a BRCA2-Specific modifier locus at 6p24 related to breast cancer risk

  • Gaudet, Mia M.
  • Kuchenbaecker, Karoline B.
  • Vijai, Joseph
  • Klein, Robert J.
  • Kirchhoff, Tomas
  • McGuffog, Lesley
  • Barrowdale, Daniel
  • Dunning, Alison M.
  • Lee, Andrew
  • Dennis, Joe
  • Healey, Sue
  • Dicks, Ed
  • Soucy, Penny
  • Sinilnikova, Olga M.
  • Pankratz, Vernon S.
  • Wang, Xianshu
  • Eldridge, Ronald C.
  • Tessier, Daniel C.
  • Vincent, Daniel
  • Bacot, François
  • Hogervorst, Frans B. L.
  • Peock, Susan
  • Stoppa-Lyonnet, Dominique
  • Peterlongo, Paolo
  • Schmutzler, Rita Katharina
  • Nathanson, Katherine L.
  • Piedmonte, Marion
  • Singer, Christian F.
  • Thomassen, Mads
  • Hansen, Thomas V. O.
  • Neuhausen, Susan L.
  • Blanco Guillermo, Ignacio
  • Lázaro García, Conxi
Common genetic variants contribute to the observed variation in breast cancer risk for BRCA2 mutation carriers; those known to date have all been found through population-based genome-wide association studies (GWAS). To comprehensively identify breast cancer risk modifying loci for BRCA2 mutation carriers, we conducted a deep replication of an ongoing GWAS discovery study. Using the ranked P-values of the breast cancer associations with the imputed genotype of 1.4 M SNPs, 19,029 SNPs were selected and designed for inclusion on a custom Illumina array that included a total of 211,155 SNPs as part of a multi-consortial project. DNA samples from 3,881 breast cancer affected and 4,330 unaffected BRCA2 mutation carriers from 47 studies belonging to the Consortium of Investigators of Modifiers of BRCA1/2 were genotyped and available for analysis. We replicated previously reported breast cancer susceptibility alleles in these BRCA2 mutation carriers and for several regions (including FGFR2, MAP3K1, CDKN2A/B, and PTHLH) identified SNPs that have stronger evidence of association than those previously published. We also identified a novel susceptibility allele at 6p24 that was inversely associated with risk in BRCA2 mutation carriers (rs9348512; per allele HR = 0.85, 95% CI 0.80-0.90, P = 3.9×10−8). This SNP was not associated with breast cancer risk either in the general population or in BRCA1 mutation carriers. The locus lies within a region containing TFAP2A, which encodes a transcriptional activation protein that interacts with several tumor suppressor genes. This report identifies the first breast cancer risk locus specific to a BRCA2 mutation background. This comprehensive update of novel and previously reported breast cancer susceptibility loci contributes to the establishment of a panel of SNPs that modify breast cancer risk in BRCA2 mutation carriers. This panel may have clinical utility for women with BRCA2 mutations weighing options for medical prevention of breast cancer.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers

  • Lázaro García, Conxi
  • Blanco Guillermo, Ignacio
  • Tornero, Eva
  • Navarro, Matilde
  • CIMBA Consortium
Germline mutations in BRCA1 and BRCA2 are associated with increased risks of breast and ovarian cancer. A genome-wide association study (GWAS) identified six alleles associated with risk of ovarian cancer for women in the general population. We evaluated four of these loci as potential modifiers of ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. Four single-nucleotide polymorphisms (SNPs), rs10088218 (at 8q24), rs2665390 (at 3q25), rs717852 (at 2q31), and rs9303542 (at 17q21), were genotyped in 12,599 BRCA1 and 7,132 BRCA2 carriers, including 2,678 ovarian cancer cases. Associations were evaluated within a retrospective cohort approach. All four loci were associated with ovarian cancer risk in BRCA2 carriers; rs10088218 per-allele hazard ratio (HR) = 0.81 (95% CI: 0.67-0.98) P-trend = 0.033, rs2665390 HR = 1.48 (95% CI: 1.21-1.83) P-trend = 1.8 x 10(-4), rs717852 HR = 1.25 (95% CI: 1.10-1.42) P-trend = 6.6 x 10(-4), rs9303542 HR = 1.16 (95% CI: 1.02-1.33) P-trend = 0.026. Two loci were associated with ovarian cancer risk in BRCA1 carriers; rs10088218 per-allele HR = 0.89 (95% CI: 0.81-0.99) P-trend = 0.029, rs2665390 HR = 1.25 (95% CI: 1.10-1.42) P-trend = 6.1 x 10(-4). The HR estimates for the remaining loci were consistent with odds ratio estimates for the general population. The identification of multiple loci modifying ovarian cancer risk may be useful for counseling women with BRCA1 and BRCA2 mutations regarding their risk of ovarian cancer.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women

  • Rebbeck, Timothy R.
  • Friebel, Tara M.
  • Mitra, Nandita
  • Wan, Fei
  • Chen, Stephanie
  • Andrulis, Irene L.
  • Apostolou, Paraskevi
  • Arnold, Norbert
  • Arun, Banu K.
  • Barrowdale, Daniel
  • Benitez, Javier
  • Ramus, Susan J.
  • Berger, Raanan
  • Berthet, Pascaline
  • Borg, Åke
  • Buys, Saundra S.
  • Caldes, Trinidad
  • Carter, Jonathan
  • Chiquette, Jocelyne
  • Claes, Kathleen B. M.
  • Couch, Fergus J.
  • Cybulski, Cezary
  • Daly, Mary B.
  • Hoya, Miguel de la
  • Díez Gibert, Orland
  • Domchek, Susan M.
  • Nathanson, Katherine L.
  • Durda, Katarzyna
  • Ellis, Steve
  • Evans, D. Gareth
  • EMBRACE Collaborators
  • Foretova, Lenka
  • Friedman, Eitan
  • Frost, Debra
  • Ganz, Patricia A.
  • HEBON Investigators
  • Garber, Judy
  • Glendon, Gord
  • Godwin, Andrew K.
  • Greene, Mark H.
  • KConFab Investigators
  • Gronwald, Jacek
  • Hahnen, Eric
  • Hallberg, Emily
  • Hamann, Ute
  • Hansen, Thomas V. O.
  • Imyanitov, Evgeny N.
  • Isaacs, Claudine
  • Jakubowska, Anna
  • Janavicius, Ramunas
  • Jaworska-Bieniek, Katarzyna
  • John, Esther M.
  • Karlan, Beth Y.
  • Kaufman, Bella
  • Kwong, Ava
  • Laitman, Yael
  • Lasset, Christine
  • Lázaro García, Conxi
  • Lester, Jenny
  • Loman, Niklas
  • Lubinski, Jan
  • Manoukian, Siranoush
  • Mitchell, Gillian
  • Montagna, Marco
  • Neuhausen, Susan L.
  • Nevanlinna, Heli
  • Niederacher, Dieter
  • Nussbaum, Robert L.
  • Offit, Kenneth
  • Olah, Edith
  • Olopade, Olufunmilayo I.
  • Kyung Park, Sue
  • Piedmonte, Marion
  • Radice, Paolo
  • Rappaport-Fuerhauser, Christine
  • Rookus, Matti A.
  • Seynaeve, Caroline
  • Simard, Jacques
  • Singer, Christian F.
  • Soucy, Penny
  • Southey, Melissa C.
  • Stoppa-Lyonnet, Dominique
  • Sukiennicki, Grzegorz
  • Szabo, Csilla I.
  • Tancredi, Mariella
  • Teixeira, Manuel R.
  • Teo, Soo-Hwang
  • Terry, Mary Beth
  • Thomassen, Mads
  • Tihomirova, Laima
  • Tischkowitz, Marc
  • Ewart Toland, Amanda
  • Toloczko-Grabarek, Aleksandra
  • Tung, Nadine
  • Rensburg, Elizabeth J. van
  • Villano, Danylo J.
  • Wang-Gohrke, Shan
  • Wappenschmidt, Barbara
  • Weitzel, Jeffrey N.
  • Zidan, Jamal
  • Zorn, Kristin K.
  • McGuffog, Lesley
  • Easton, Douglas F.
  • Chenevix-Trench, Georgia
  • Antoniou, Antonis C.
Background: Most BRCA1 or BRCA2 mutation carriers have inherited a single (heterozygous) mutation. Transheterozygotes (TH) who have inherited deleterious mutations in both BRCA1 and BRCA2 are rare, and the consequences of transheterozygosity are poorly understood. Methods: From 32,295 female BRCA1/2 mutation carriers, we identified 93 TH (0.3 %). "Cases" were defined as TH, and "controls" were single mutations at BRCA1 (SH1) or BRCA2 (SH2). Matched SH1 "controls" carried a BRCA1 mutation found in the TH "case". Matched SH2 "controls" carried a BRCA2 mutation found in the TH "case". After matching the TH carriers with SH1 or SH2, 91 TH were matched to 9316 SH1, and 89 TH were matched to 3370 SH2. Results: The majority of TH (45.2 %) involved the three common Jewish mutations. TH were more likely than SH1 and SH2 women to have been ever diagnosed with breast cancer (BC; p = 0.002). TH were more likely to be diagnosed with ovarian cancer (OC) than SH2 (p = 0.017), but not SH1. Age at BC diagnosis was the same in TH vs. SH1 (p = 0.231), but was on average 4.5 years younger in TH than in SH2 (p < 0.001). BC in TH was more likely to be estrogen receptor (ER) positive (p = 0.010) or progesterone receptor (PR) positive (p = 0.013) than in SH1, but less likely to be ER positive (p < 0.001) or PR positive (p = 0.012) than SH2. Among 15 tumors from TH patients, there was no clear pattern of loss of heterozygosity (LOH) for BRCA1 or BRCA2 in either BC or OC. Conclusions: Our observations suggest that clinical TH phenotypes resemble SH1. However, TH breast tumor marker characteristics are phenotypically intermediate to SH1 and SH2.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Shared heritability and functional enrichment across six solid cancers

  • Jiang, Xia
  • Finucane, Hilary K.
  • Schumacher, Fredrick R.
  • Schmit, Stephanie L.
  • Tyrer, Jonathan P.
  • Han, Younghun
  • Michailidou, Kyriaki
  • Lesseur, Corina
  • Kuchenbaecker, Karoline B.
  • Dennis, Joe
  • Conti, David V.
  • Cunningham, Julie M.
  • John, Esther M.
  • Couch, Fergus J.
  • Bolla, Manjeet K.
  • Casey, Graham
  • Margolin, Sara
  • Goodman, Gary
  • Evans, D. Gareth
  • Riggan, Marjorie J.
  • Gago-Dominguez, Manuela
  • Jenkins, Mattias
  • Fostira, Florentia
  • Kaneva, Radka
  • Arnold, Susanne M.
  • Offit, Kenneth
  • Ruyck, Kim De
  • Olsson, Håkan
  • Arun, Banu K.
  • Schleutker, Johanna
  • Aronson, Kristan J.
  • Caligo, Maria A.
  • Tardón, Adonina
  • Edlund, Christopher K.
  • Ingles, Sue Ann
  • Hsu, Li
  • Rosenstein, Barry S.
  • Chenevix-Trench, Georgia
  • McKay, James D.
  • Claes, Kathleen B. M.
  • Chanock, Stephen J.
  • Nordestgaard, Børge G.
  • Park, Jong Y.
  • Kupryjanczyk, Jolanta
  • Cadoni, Gabriella
  • Neal, David E.
  • Diez, Orland
  • Ferris, Robert L.
  • Stefansson, Kari
  • Cannon-Albright, Lisa A.
  • Weinberg, Clarice R.
  • McGuffog, Lesley
  • Raskin, Leon
  • Mannermaa, Arto
  • Kibel, Adam S.
  • Neuhausen, Susan L.
  • Hulick, Peter J.
  • Shen, Hongbing
  • Wichmann, H-Erich
  • Goldberg, Mark S.
  • Greene, Mark H.
  • Maehle, Lovise
  • Yannoukakos, Drakoulis
  • Garber, Judy
  • Webb, Penelope M.
  • Weissler, Mark C.
  • Pejovic, Tanja
  • Bojesen, Stig E.
  • Toland, Amanda E.
  • Blomqvist, Carl
  • Knight, Julia A.
  • Huntsman, David G.
  • Dörk, Thilo
  • Gaudet, Mia M.
  • Hong, Yun-Chul
  • Whittemore, Alice S.
  • Torres, Diana
  • Hung, Rayjean J.
  • García-Closas, Montserrat
  • Li, Li
  • Friedman, Eitan
  • Hillemanns, Peter
  • Haugen, Aage
  • Cruz Correa, Marcia
  • Wolk, Alicja
  • Olopade, Olufunmilayo I.
  • Risch, Harvey A.
  • Terry, Kathryn L.
  • Hamdy, Freddie C.
  • Burwinkel, Barbara
  • Brauch, Hiltrud
  • Parsons, Michael T.
  • Tangen, Catherine M.
  • Travis, Ruth C.
  • Middha, Pooja
  • Terry, Mary Beth
  • Newcomb, Lisa F.
  • Nielsen, Finn C.
  • Ness, Andrew R.
  • Stanford, Janet L.
  • Kraft, Peter
  • Montagna, Marco
  • Brenton, James D.
  • Roobol, Monique J.
  • Thibodeau, Stephen N.
  • Sundfeldt, Karin
  • Hampe, Jochen
  • Lubiński, Jan
  • Tung, Nadine
  • Nevanlinna, Heli
  • Chang-Claude, Jenny
  • Stone, Jennifer
  • Swerdlow, Anthony J.
  • Brenner, Hermann
  • Wiklund, Fredrik
  • Bandera, Elisa V.
  • Siegel, Erin M.
  • Lester, Jenny
  • Le, Nhu D.
  • Taylor, Jack A.
  • Chan, Andrew T.
  • Donovan, Jenny L.
  • Landi, Maria Teresa
  • Aldrich, Melinda C.
  • White, Emily
  • Stevens, Victoria L.
  • Velez Edwards, Digna R.
  • Goodman, Marc T.
  • Easton, Douglas F.
  • Dwek, Miriam
  • Berchuck, Andrew
  • deFazio, Anna
  • Devilee, Peter
  • Heitz, Florian
  • Hopper, John L.
  • Hunter, David J.
  • Peters, Ulrike
  • Albanes, Jeroen R.
  • Singer, Christian F.
  • Woll, Penella
  • Tajara, Eloiza H.
  • Brunet, Joan
  • Christiani, David C.
  • Weitzel, Jeffrey N.
  • García-Sáenz, José A.
  • Liloglou, Triantafillos
  • Phipps, Amanda I.
  • Cybulski, Cezary
  • Li, Christopher I.
  • Lazarus, Philip
  • Sawyer, Elinor J.
  • Lane, Jacqueline M.
  • Meindl, Alfons
  • Liu, Geoffrey
  • Grankvist, Kjell
  • Peters, Wilbert H. M.
  • Goode, Ellen L.
  • Godwin, Andrew K.
  • Butzow, Ralf
  • Barkardottir, Rosa B.
  • Bien, Stephanie A.
  • Ulrich, Cornelia M.
  • Brunnström, Hans
  • Goldgar, David E.
  • Lee, Eunjung
  • Koutros, Stella
  • Setiawan, V. Wendy
  • Fletcher, Olivia
  • Moysich, Kirsten B.
  • Høgdall, Estrid
  • Gallinger, Steven
  • Lacko, Martin
  • Chen, Chu
  • Beckmann, Matthias W.
  • Elías Aguado-Barrera, Miguel
  • Barnes, Daniel R.
  • Imyanitov, Evgeny N.
  • Clements, Judith
  • Pandha, Hardev
  • Lenz, Heinz-Josef
  • MacInnis, Robert J.
  • Idos, Gregory
  • Daly, Mary B.
  • Anton-Culver, Hoda
  • Winqvist, Robert
  • Khusnutdinova, Elza
  • Muir, Kenneth
  • Diergaarde, Brenda
  • Collée, J. Margriet
  • Rossing, Mary Anne
  • Radice, Paolo
  • Bjørge, Line
  • Phelan, Catherine M.
  • Usmani, Nawaid
  • Brook, Mark N.
  • Rennert, Hedy S.
  • Lindo, Noralane M.
  • West, Catharine M. L.
  • Lam, Stephan
  • Teare, M. Dawn
  • Sandler, Dale P.
  • van Rensburg, Elizabeth J.
  • Levine, Douglas A.
  • Milne, Roger L.
  • Sorensen, Karina Dalsgaard
  • Sutphen, Rebecca
  • Miller, Austin
  • Isaacs, Claudine
  • Lesse, Davor
  • Zheng, Wei
  • Campbell, Peter T.
  • Olshan, Andrew F.
  • Modugno, Francesmary
  • Ramus, Susan J.
  • James, Paul
  • Cox, Angela
  • Caldés, Trinidad
  • Wang, Qin
  • Simard, Jacques
  • Schabath, Matthew B.
  • Pasaniuc, Bogdan
  • Carvalho, André L.
  • Lambrechts, Diether
  • Antonenkova, Natalia N.
  • Andrew, Angeline S.
  • Johansson, Mikael
  • Johansson, Mattias
  • Herrero, Rolando
  • Boccia, Stefania
  • Håkansson, Niclas
  • Kjaer, Susanne K.
  • Berndt, Sonja I.
  • Lejbkowicz, Flavio
  • Pharoah, Paul D. P.
  • Hamilton, Robert J.
  • Moreno Aguado, Víctor
  • Gruber, Stephen B.
  • Gronberg, Henrik
  • Kristensen, Vessela N.
  • Sieh, Weiva
  • Saxena, Richa
  • Bickeböller, Heike
  • Joshi, Amit D.
  • Olah, Edith
  • Zienolddiny, Shanbeh
  • Vega, Ana
  • Gayther, Simon A.
  • Campbell, Ian
  • Kühl, Tabea
  • Hall, Per
  • Rennert, Gad
  • Dunning, Alison M.
  • Czene, Kamila
  • Stintzing, Sebastian
  • Osorio, Ana
  • Hoffmeister, Michael
  • Spurdle, Amanda B.
  • Marchand, Loïc Le
  • Buchanan, Daniel D.
  • Slattery, Martha L.
  • Hamann, Ute
  • Caporaso, Neil E.
  • Kelemen, Linda E.
  • Mulligan, Anna Marie
  • Fortner, Renée T.
  • Weinstein, Stephanie
  • Penney, Kathryn L.
  • Mucci, Lorelei
  • Jakubowska, Anna
  • Nikitina-Zake, Liene
  • Loupakis, Fotios
  • Van Nieuwenhuysen, Els
  • Wu, Anna H.
  • Pashayan, Nora
  • Risch, Angela
  • Andrulis, Irene L.
  • Ganz, Patricia A.
  • Maier, Christiane
  • Wu, Xifeng
  • Khaw, Kay-Tee
  • Southey, Melissa C.
  • Townsend, Paul A.
  • Thomas, Duncan C.
  • Vachon, Celine M.
  • Eccles, Diana
  • Schmidt, Marjanka K.
  • Kote-Jarai, Zsofia
  • Campa, Daniele
  • Huyghe, Jeroen R.
  • Duell, Eric J.
  • Claessens, Frank
  • May, Taymaa
  • Houlston, Richard
  • Fasching, Peter A.
  • Kim, Jeri
  • Prokofyeva, Darya
  • Giles, Graham G.
  • Karlan, Beth Y.
  • Lindström, Sara
  • Antoniou, Antonis C.
  • Figueiredo, Jane C.
  • Kiemeney, Lambertus A. L. M.
  • Eeles, Rosalind A.
  • Kogevinas, Manolis
  • Bogdanova, Natalia V.
  • Guénel, Pascal
  • Gronwald, Jacek
  • Brennan, Paul
  • Batra, Jyotsna
  • Franceschi, Silvia
  • Lindblom, Annika
  • Amos, Christopher I.
  • Leslie, Goska
  • Thomassen, Mads
  • Haiman, Christopher A.
  • Nussbaum, Robert L.
  • Benlloch, Sara
  • Al Olama, Ali Amin
  • Pring, Miranda
  • Benitez, Javier
  • Ziogas, Argyrios
  • Cancel-Tassin, Géraldine
  • Price, Alkes L.
  • Woods, Michael
  • Tworoger, Shelley S.
  • Nathanson, Katherine L.
  • Ellberg, Carolina
  • Teixeira, Manuel R.
  • Saloustros, Emmanouil
  • Tischkowitz, Marc
  • Zorn, Kristin K.
  • Plaseska-Karanfilska, Dijana
  • Newcomb, Polly A.
Quantifying the genetic correlation between cancers can provide important insights into the mechanisms driving cancer etiology. Using genome-wide association study summary statistics across six cancer types based on a total of 296,215 cases and 301,319 controls of European ancestry, here we estimate the pair-wise genetic correlations between breast, colorectal, head/neck, lung, ovary and prostate cancer, and between cancers and 38 other diseases. We observed statistically significant genetic correlations between lung and head/neck cancer (rg = 0.57, p = 4.6 × 10-8), breast and ovarian cancer (rg = 0.24, p = 7 × 10-5), breast and lung cancer (rg = 0.18, p =1.5 × 10-6) and breast and colorectal cancer (rg = 0.15, p = 1.1 × 10-4). We also found that multiple cancers are genetically correlated with non-cancer traits including smoking, psychiatric diseases and metabolic characteristics. Functional enrichment analysis revealed a significant excess contribution of conserved and regulatory regions to cancer heritability. Our comprehensive analysis of cross-cancer heritability suggests that solid tumors arising across tissues share in part a common germline genetic basis.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2

  • Pujana Genestar, M. Ángel
  • KConFab Investigators
  • Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON)
  • Epidemiological study of BRCA1 &amp; BRCA2 Mutation Carriers (EMBRACE)
Background: BRCA1 and, more commonly, BRCA2 mutations are associated with increased risk of male breast cancer (MBC). However, only a paucity of data exists on the pathology of breast cancers (BCs) in men with BRCA1/2 mutations. Using the largest available dataset, we determined whether MBCs arising in BRCA1/2 mutation carriers display specific pathologic features and whether these features differ from those of BRCA1/2 female BCs (FBCs). Methods: We characterised the pathologic features of 419 BRCA1/2 MBCs and, using logistic regression analysis, contrasted those with data from 9675 BRCA1/2 FBCs and with population-based data from 6351 MBCs in the Surveillance, Epidemiology, and End Results (SEER) database. Results: Among BRCA2 MBCs, grade significantly decreased with increasing age at diagnosis (P = 0.005). Compared with BRCA2 FBCs, BRCA2 MBCs were of significantly higher stage (P for trend = 2 x 10(-5)) and higher grade (P for trend = 0.005) and were more likely to be oestrogen receptor-positive [odds ratio (OR) 10.59; 95 % confidence interval (CI) 5.15-21.80] and progesterone receptor-positive (OR 5.04; 95 % CI 3.17-8.04). With the exception of grade, similar patterns of associations emerged when we compared BRCA1 MBCs and FBCs. BRCA2 MBCs also presented with higher grade than MBCs from the SEER database (P for trend = 4 x 10(-12)). Conclusions: On the basis of the largest series analysed to date, our results show that BRCA1/2 MBCs display distinct pathologic characteristics compared with BRCA1/2 FBCs, and we identified a specific BRCA2-associated MBC phenotype characterised by a variable suggesting greater biological aggressiveness (i.e., high histologic grade). These findings could lead to the development of gender-specific risk prediction models and guide clinical strategies appropriate for MBC management.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Transcriptome‐wide association study of breast cancer risk by estrogen‐receptor status

  • Feng, Helian
  • Gusev, Alexander
  • Pasaniuc, Bogdan
  • Lázaro García, Conxi
  • Teulé-Vega, Àlex
  • GEMO Study Collaborators
  • EMBRACE Collaborators
  • GC‐HBOC Study Collaborators
  • ABCTB Investigators
  • HEBON Investigators
  • BCFR Investigators
  • OCGN Investigators
Previous transcriptome-wide association studies (TWAS) have identified breast cancer risk genes by integrating data from expression quantitative loci and genome-wide association studies (GWAS), but analyses of breast cancer subtype-specific associations have been limited. In this study, we conducted a TWAS using gene expression data from GTEx and summary statistics from the hitherto largest GWAS meta-analysis conducted for breast cancer overall, and by estrogen receptor subtypes (ER+ and ER-). We further compared associations with ER+ and ER- subtypes, using a case-only TWAS approach. We also conducted multigene conditional analyses in regions with multiple TWAS associations. Two genes, STXBP4 and HIST2H2BA, were specifically associated with ER+ but not with ER- breast cancer. We further identified 30 TWAS-significant genes associated with overall breast cancer risk, including four that were not identified in previous studies. Conditional analyses identified single independent breast-cancer gene in three of six regions harboring multiple TWAS-significant genes. Our study provides new information on breast cancer genetics and biology, particularly about genomic differences between ER+ and ER- breast cancer.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers

  • Menéndez Vilà, Mireia
  • Lázaro García, Conxi
  • Blanco Guillermo, Ignacio
Single Nucleotide Polymorphisms (SNPs) in genes involved in the DNA Base Excision Repair (BER) pathway could be associated with cancer risk in carriers of mutations in the high-penetrance susceptibility genes BRCA1 and BRCA2, given the relation of synthetic lethality that exists between one of the components of the BER pathway, PARP1 (poly ADP ribose polymerase), and both BRCA1 and BRCA2. In the present study, we have performed a comprehensive analysis of 18 genes involved in BER using a tagging SNP approach in a large series of BRCA1 and BRCA2 mutation carriers. 144 SNPs were analyzed in a two stage study involving 23,463 carriers from the CIMBA consortium (the Consortium of Investigators of Modifiers of BRCA1 and BRCA2). Eleven SNPs showed evidence of association with breast and/or ovarian cancer at p<0.05 in the combined analysis. Four of the five genes for which strongest evidence of association was observed were DNA glycosylases. The strongest evidence was for rs1466785 in the NEIL2 (endonuclease VIII-like 2) gene (HR: 1.09, 95% CI (1.03-1.16), p = 2.7x10(-3)) for association with breast cancer risk in BRCA2 mutation carriers, and rs2304277 in the OGG1 (8-guanine DNA glycosylase) gene, with ovarian cancer risk in BRCA1 mutation carriers (HR: 1.12 95% CI: 1.03-1.21, p = 4.8x10(-3)). DNA glycosylases involved in the first steps of the BER pathway may be associated with cancer risk in BRCA1/2 mutation carriers and should be more comprehensively studied.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer

  • Figlioli, Gisella
  • Lázaro García, Conxi
  • Pujana Genestar, M. Ángel
  • ABCTB Investigators
  • GEMO Study Collaborators
  • KConFab Investigators
Breast cancer is a common disease partially caused by genetic risk factors. Germline pathogenic variants in DNA repair genes BRCA1, BRCA2, PAM, ATM, and CHEK2 are associated with breast cancer risk. FANCM, which encodes for a DNA translocase, has been proposed as a breast cancer predisposition gene, with greater effects for the ER-negative and triple-negative breast cancer (TNBC) subtypes. We tested the three recurrent protein-truncating variants FANCM:p.Arg658*, p.Gln1701*, and pArg1931* for association with breast cancer risk in 67,112 cases, 53,766 controls, and 26,662 carriers of pathogenic variants of BRCA1 or BRCA2. These three variants were also studied functionally by measuring survival and chromosome fragility in FANCM(-/-) patient-derived immortalized fibroblasts treated with diepoxybutane or olaparib. We observed that FANCM:p.Arg658* was associated with increased risk of ER-negative disease and TNBC (OR = 2.44, P = 0.034 and OR = 3.79; P = 0.009, respectively). In a country-restricted analysis, we confirmed the associations detected for FANCM:p.Arg658* and found that also FANCM:p.Arg1931* was associated with ER-negative breast cancer risk (OR = 1.96; P = 0.006). The functional results indicated that all three variants were deleterious affecting cell survival and chromosome stability with FANCM:p.Arg658* causing more severe phenotypes. In conclusion, we confirmed that the two rare FANCM deleterious variants p.Arg658* and p.Arg1931* are risk factors for ER-negative and TNBC subtypes. Overall our data suggest that the effect of truncating variants on breast cancer risk may depend on their position in the gene. Cell sensitivity to olaparib exposure, identifies a possible therapeutic option to treat FANCM-associated tumors.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170

  • Pujana Genestar, M. Ángel
  • EMBRACE Collaborators
  • GEMO Study Collaborators
  • Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON)
We analyzed 3,872 common genetic variants across the ESR1 locus (encoding estrogen receptor a) in 118,816 subjects from three international consortia. We found evidence for at least five independent causal variants, each associated with different phenotype sets, including estrogen receptor (ER+ or ER-) and human ERBB2 (HER2(+) or HER2(-)) tumor subtypes, mammographic density and tumor grade. The best candidate causal variants for ER-tumors lie in four separate enhancer elements, and their risk alleles reduce expression of ESR1, RMND1 and CCDC170, whereas the risk alleles of the strongest candidates for the remaining independent causal variant disrupt a silencer element and putatively increase ESR1 and RMND1 expression.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers

  • Pujana Genestar, M. Ángel
  • Teulé-Vega, Àlex
  • GEMO Study Collaborators
  • EMBRACE Collaborators
  • KConFab Investigators
  • HEBON Investigators
  • ABCTB Investigators
Breast cancer (BC) risk for BRCA1 and BRCA2 mutation carriers varies by genetic and familial factors. About 50 common variants have been shown to modify BC risk for mutation carriers. All but three, were identified in general population studies. Other mutation carrier-specific susceptibility variants may exist but studies of mutation carriers have so far been underpowered. We conduct a novel case-only genome-wide association study comparing genotype frequencies between 60,212 general population BC cases and 13,007 cases with BRCA1 or BRCA2 mutations. We identify robust novel associations for 2 variants with BC for BRCA1 and 3 for BRCA2 mutation carriers, P < 10-8, at 5 loci, which are not associated with risk in the general population. They include rs60882887 at 11p11.2 where MADD, SP11 and EIF1, genes previously implicated in BC biology, are predicted as potential targets. These findings will contribute towards customising BC polygenic risk scores for BRCA1 and BRCA2 mutation carriers.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Identification of six new susceptibility loci for invasive epithelial ovarian cancer

  • Kuchenbaecker, Karoline B.
  • Ramus, Susan J.
  • Tyrer, Jonathan P.
  • Lee, Andrew
  • Shen, Howard C.
  • Beesley, Jonathan
  • Lawrenson, Kate
  • McGuffog, Lesley
  • Healey, Sue
  • Lee, Janet M.
  • Spindler, Tassja J.
  • Lin, Yvonne G.
  • Pejovic, Tanja
  • Bean, Yukie
  • Li, Qiyuan
  • Coetzee, Simon
  • Hazelett, Dennis
  • Miron, Alexander
  • Southey, Melissa C.
  • Terry, Mary Beth
  • Goldgar, David E.
  • Buys, Saundra S.
  • Janavicius, Ramunas
  • Dorfling, Cecilia M.
  • van Rensburg, Elizabeth J.
  • Neuhausen, Susan L.
  • Ding, Yuan Chun
  • Hansen, Thomas V. O.
  • Jønson, Lars
  • Gerdes, Anne Marie
  • Ejlertsen, Bent
  • Barrowdale, Daniel
  • Dennis, Joe
  • Benitez, Javier
  • Osorio, Ana
  • Garcia, Maria Jose
  • Komenaka, Ian
  • Blanco Guillermo, Ignacio
  • Lázaro García, Conxi
  • Pujana Genestar, M. Ángel
Genome-wide association studies (GWAS) have identified 12 epithelial ovarian cancer (EOC) susceptibility alleles. The pattern of association at these loci is consistent in BRCA1 and BRCA2 mutation carriers who are at high risk of EOC. After imputation to 1000 Genomes Project data, we assessed associations of 11 million genetic variants with EOC risk from 15,437 cases unselected for family history and 30,845 controls and from 15,252 BRCA1 mutation carriers and 8,211 BRCA2 mutation carriers (3,096 with ovarian cancer), and we combined the results in a meta-analysis. This new study design yielded increased statistical power, leading to the discovery of six new EOC susceptibility loci. Variants at 1p36 (nearest gene, WNT4), 4q26 (SYNPO2), 9q34.2 (ABO) and 17q11.2 (ATAD5) were associated with EOC risk, and at 1p34.3 (RSPO1) and 6p22.1 (GPX6) variants were specifically associated with the serous EOC subtype, all with P < 5 × 10(-8). Incorporating these variants into risk assessment tools will improve clinical risk predictions for BRCA1 and BRCA2 mutation carriers.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Telomere length shows no association with BRCA1 and BRCA2 mutation status

  • Killick, Emma
  • Tymrakiewicz, Malgorzata
  • Cieza-Borrella, Clara
  • Smith, Paula
  • Thompson, Deborah J.
  • Pooley, Karen A.
  • Easton, Douglas F.
  • Bancroft, Elizabeth K.
  • Page, Elizabeth
  • Leongamornlert, Daniel
  • IMPACT Study Collaborators
  • Kote-Jarai, Zsofia
  • Eeles, Rosalind A.
  • Blanco Guillermo, Ignacio
  • Salinas Masdeu, Mònica
This study aimed to determine whether telomere length (TL) is a marker of cancer risk or genetic status amongst two cohorts of BRCA1 and BRCA2 mutation carriers and controls. The first group was a prospective set of 665 male BRCA1/2 mutation carriers and controls (mean age 53 years), all healthy at time of enrolment and blood donation, 21 of whom have developed prostate cancer whilst on study. The second group consisted of 283 female BRCA1/2 mutation carriers and controls (mean age 48 years), half of whom had been diagnosed with breast cancer prior to enrolment. TL was quantified by qPCR from DNA extracted from peripheral blood lymphocytes. Weighted and unweighted Cox regressions and linear regression analyses were used to assess whether TL was associated with BRCA1/2 mutation status or cancer risk. We found no evidence for association between developing cancer or being a BRCA1 or BRCA2 mutation carrier and telomere length. It is the first study investigating TL in a cohort of genetically predisposed males and although TL and BRCA status was previously studied in females our results don't support the previous finding of association between hereditary breast cancer and shorter TL.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Interplay between BRCA1 and RHAMM Regulates Epithelial Apicobasal Polarization and May Influence Risk of Breast Cancer.

  • Maxwell, Christopher A.
  • Gomez-Baldó, Laia
  • Bonifaci Cano, Núria
  • Guinó, Elisabet
  • Català, Isabel
  • Petit, Anna
  • Aguilar, Helena
  • Villanueva Garatachea, Alberto
  • Aytés Meneses, Álvaro
  • Serra-Musach, Jordi
  • Aiza, Gemma
  • Brunet, Joan
  • Castellsagué, Joan
  • Martrat Sànchez, Griselda
  • Urruticoechea Ribate, Ander
  • Blanco Guillermo, Ignacio
  • Lázaro García, Conxi
  • Capellá, G. (Gabriel)
  • Genestar, Miquel Àngel
  • Moreno Aguado, Víctor
Differentiated mammary epithelium shows apicobasal polarity, and loss of tissue organization is an early hallmark of breast carcinogenesis. In BRCA1 mutation carriers, accumulation of stem and progenitor cells in normal breast tissue and increased risk of developing tumors of basal-like type suggest that BRCA1 regulates stem/progenitor cell proliferation and differentiation. However, the function of BRCA1 in this process and its link to carcinogenesis remain unknown. Here we depict a molecular mechanism involving BRCA1 and RHAMM that regulates apicobasal polarity and, when perturbed, may increase risk of breast cancer. Starting from complementary genetic analyses across families and populations, we identified common genetic variation at the low-penetrance susceptibility HMMR locus (encoding for RHAMM) that modifies breast cancer risk among BRCA1, but probably not BRCA2, mutation carriers: n = 7,584, weighted hazard ratio (wHR) = 1.09 (95% CI 1.02-1.16), ptrend = 0.017; and n = 3,965, wHR = 1.04 (95% CI 0.94-1.16), ptrend = 0.43; respectively. Subsequently, studies of MCF10A apicobasal polarization revealed a central role for BRCA1 and RHAMM, together with AURKA and TPX2, in essential reorganization of microtubules. Mechanistically, reorganization is facilitated by BRCA1 and impaired by AURKA, which is regulated by negative feedback involving RHAMM and TPX2. Taken together, our data provide fundamental insight into apicobasal polarization through BRCA1 function, which may explain the expanded cell subsets and characteristic tumor type accompanying BRCA1 mutation, while also linking this process to sporadic breast cancer through perturbation of HMMR/RHAMM.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk

  • Couch, Fergus J.
  • Wang, Xianshu
  • McGuffog, Lesley
  • Lee, Andrew
  • Olswold, Curtis
  • Kuchenbaecker, Karoline B.
  • Soucy, Penny
  • Fredericksen, Zachary
  • Barrowdale, Daniel
  • Dennis, Joe
  • Gaudet, Mia M.
  • Dicks, Ed
  • Kosel, Matthew
  • Healey, Sue
  • Sinilnikova, Olga M.
  • Bacot, François
  • Vincent, Daniel
  • Hogervorst, Frans B. L.
  • Peock, Susan
  • Stoppa-Lyonnet, Dominique
  • Jakubowska, Anna
  • Radice, Paolo
  • Schmutzler, Rita Katharina
  • Domchek, Susan M.
  • Piedmonte, Marion
  • Singer, Christian F.
  • Friedman, Eitan
  • Thomassen, Mads
  • Hansen, Thomas V. O.
  • Neuhausen, Susan L.
  • Szabo, Csilla I.
  • Blanco Guillermo, Ignacio
  • Greene, Mark H.
  • Karlan, Beth Y.
  • Garber, Judy
  • Phelan, Catherine M.
  • Weitzel, Jeffrey N.
  • Montagna, Marco
  • Olah, Edith
BRCA1-associated breast and ovarian cancer risks can be modified by common genetic variants. To identify further cancer risk-modifying loci, we performed a multi-stage GWAS of 11,705 BRCA1 carriers (of whom 5,920 were diagnosed with breast and 1,839 were diagnosed with ovarian cancer), with a further replication in an additional sample of 2,646 BRCA1 carriers. We identified a novel breast cancer risk modifier locus at 1q32 for BRCA1 carriers (rs2290854, P = 2.7×10−8, HR = 1.14, 95% CI: 1.09-1.20). In addition, we identified two novel ovarian cancer risk modifier loci: 17q21.31 (rs17631303, P = 1.4×10−8, HR = 1.27, 95% CI: 1.17-1.38) and 4q32.3 (rs4691139, P = 3.4×10−8, HR = 1.20, 95% CI: 1.17-1.38). The 4q32.3 locus was not associated with ovarian cancer risk in the general population or BRCA2 carriers, suggesting a BRCA1-specific association. The 17q21.31 locus was also associated with ovarian cancer risk in 8,211 BRCA2 carriers (P = 2×10−4). These loci may lead to an improved understanding of the etiology of breast and ovarian tumors in BRCA1 carriers. Based on the joint distribution of the known BRCA1 breast cancer risk-modifying loci, we estimated that the breast cancer lifetime risks for the 5% of BRCA1 carriers at lowest risk are 28%-50% compared to 81%-100% for the 5% at highest risk. Similarly, based on the known ovarian cancer risk-modifying loci, the 5% of BRCA1 carriers at lowest risk have an estimated lifetime risk of developing ovarian cancer of 28% or lower, whereas the 5% at highest risk will have a risk of 63% or higher. Such differences in risk may have important implications for risk prediction and clinical management for BRCA1 carriers.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus

  • Lázaro García, Conxi
  • Teulé-Vega, Àlex
  • Epidemiological study of BRCA1 &amp; BRCA2 Mutation Carriers (EMBRACE)
  • Genetic Modifiers of Cancer Risk in BRCA1/2 Mutation Carriers (GEMO)
  • Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON)
  • KConFab Investigators
  • AOCS Investigators
Background: Multiple recent genome-wide association studies (GWAS) have identified a single nucleotide polymorphism (SNP), rs10771399, at 12p11 that is associated with breast cancer risk. Method: We performed a fine-scale mapping study of a 700 kb region including 441 genotyped and more than 1300 imputed genetic variants in 48,155 cases and 43,612 controls of European descent, 6269 cases and 6624 controls of East Asian descent and 1116 cases and 932 controls of African descent in the Breast Cancer Association Consortium (BCAC; http://bcac.ccge.medschl.cam.ac.uk/), and in 15,252 BRCA1 mutation carriers in the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Stepwise regression analyses were performed to identify independent association signals. Data from the Encyclopedia of DNA Elements project (ENCODE) and the Cancer Genome Atlas (TCGA) were used for functional annotation. Results: Analysis of data from European descendants found evidence for four independent association signals at 12p11, represented by rs7297051 (odds ratio (OR) = 1.09, 95 % confidence interval (CI) = 1.06-1.12; P = 3 x 10(-9)), rs805510 (OR = 1.08, 95 % CI = 1.04-1.12, P = 2 x 10(-5)), and rs1871152 (OR = 1.04, 95 % CI = 1.02-1.06; P = 2 x 10(-4)) identified in the general populations, and rs113824616 (P = 7 x 10(-5)) identified in the meta-analysis of BCAC ER-negative cases and BRCA1 mutation carriers. SNPs rs7297051, rs805510 and rs113824616 were also associated with breast cancer risk at P < 0.05 in East Asians, but none of the associations were statistically significant in African descendants. Multiple candidate functional variants are located in putative enhancer sequences. Chromatin interaction data suggested that PTHLH was the likely target gene of these enhancers. Of the six variants with the strongest evidence of potential functionality, rs11049453 was statistically significantly associated with the expression of PTHLH and its nearby gene CCDC91 at P < 0.05. Conclusion: This study identified four independent association signals at 12p11 and revealed potentially functional variants, providing additional insights into the underlying biological mechanism(s) for the association observed between variants at 12p11 and breast cancer risk.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification

  • Parsons, Michael T.
  • Tudini, Emma
  • Li, Hongyan
  • Hahnen, Eric
  • Wappenschmidt, Barbara
  • Feliubadaló i Elorza, Maria Lídia
  • Aalfs, Cora M.
  • Agata, Simona
  • Aittomäki, Kristiina
  • Alducci, Elisa
  • Alonso Cerezo, María Concepción
  • Hauke, Jan
  • Heinrich, Tilman
  • Törngren, Therese
  • Hellebrand, Heide
  • Arnold, Norbert
  • Seggewiß, Jochen
  • Caldés, Trinidad
  • Herold, Karen N.
  • Honisch, Ellen
  • Naldi, Nadia
  • Witzel, Isabell
  • Walters, Rhiannon J.
  • Rump, Andreas
  • Horvath, Judit
  • Poplawski, Nicola K.
  • Velasco, Àngela
  • Houdayer, Claude
  • Brunet, Joan
  • Cini, Giulia
  • Hübbel, Verena
  • Iglesias, Silvia
  • Wöckel, Achim
  • Steinemann, Doris
  • Izquierdo, Angel
  • Barbieri, Elena
  • Wang Gohrke, Shan
  • James, Paul A.
  • Carnevali, Ileana
  • Torres Esquius, Sara
  • Janssen, Linda A.M.
  • Jeschke, Udo
  • Kruse, Torben A.
  • Kölbl, Alexandra
  • Ledig, Susanne
  • Cops, Elisa J.
  • Vesper, Anne Sophie
  • Kaulfuß, Silke
  • Porfirio, Berardino
  • Auber, Bernd
  • Weber, Bernhard H. F.
  • Leinert, Elena
  • Rofes, Paula
  • Bruzzone, Carla
  • Woodward, Emma R.
  • Matricardi, Laura
  • Solanes, Ares
  • Carrasco, Estela
  • Mackelenbergh, Marion T.
  • Waha, Anke
  • Nathanson, Katherine L.
  • Tucker, Katherine M.
  • Bucksch, Karolin
  • Navarro, Matilde
  • Faust, Ulrike
  • Bonanni, Bernardo
  • González, Sara
  • Nevanlinna, Heli
  • Nichols, Cassandra B.
  • Cortesi, Laura
  • Wiesmüller, Lisa
  • Niederacher, Dieter
  • Vreeswijk, Maaike P. G.
  • Caux Moncoutier, Virginie
  • Nielsen, Henriette R.
  • Giesecke, Jutta
  • Hackmann, Karl
  • Azzollini, Jacopo
  • Ong, Kai Ren
  • Pachter, Nicholas
  • Galvao, Henrique C.R.
  • Couch, Fergus J.
  • Palmero, Edenir I.
  • Guerrieri Gonzaga, Aliana
  • Cagnoli, Giulia
  • Papi, Laura
  • Asperen, Christi J.
  • Pohl Rescigno, Esther
  • Ramser, Juliane
  • Cavalli, Pietro
  • Pedersen, Inge Søkilde
  • Wagner, Sebastian A.
  • Felbor, Ute
  • Darder, Esther
  • Reis, Rui M.
  • Wieland, Kerstin
  • Gismondi, Viviana
  • Blümcke, Britta
  • Zachariae, Silke
  • Calvello, Mariarosaria
  • Stiller, Mathias
  • Bartram, Claus R.
  • Feroce, Irene
  • Stoppa-Lyonnet, Dominique
  • Keupp, Katharina
  • Hoya, Miguel
  • Lucci Cordisco, Emanuela
  • Sullivan, Kelly J.
  • Susman, Rachel
  • Zampiga, Valentina
  • Guillaud Bataille, Marine
  • Concolino, Paola
  • Sutter, Christian
  • Caliebe, Almuth
  • Gómez, Carolina
  • Tavtigian, Sean V.
  • Lewis, Alexandra L.
  • Montagna, Marco
  • Teo, Soo-Hwang
  • Teulé-Vega, Àlex
  • Debatin, Irmgard
  • Thomassen, Mads
  • Kvist, Anders
  • Gutiérrez Enríquez, Sara
  • Tibiletti, Maria Grazia
  • Meindl, Alfons
  • Fine, Miriam
  • Tischkowitz, Marc
  • Blanco, Ana
  • Toss, Angela
  • Varesco, Liliana
  • Montes, Eva
  • Garcia, Encarna B.
  • Tognazzo, Silvia
  • Caligo, Maria A.
  • Kiechle, Marion
  • Haaf, Thomas
  • Vargas Parra, Gardenía María
  • Clarke, Edward M.
  • Lim, Joanna
  • Bonache, Sandra
  • Dean, Michael
  • Michelli, Rodrigo D.
  • Gensini, Francesca
  • Gross, Eva
  • Zeder Göß, Christine
  • Gambino, Gaetana
  • Loeffler, Markus
  • Investigators, Kconfab
  • Peissel, Bernard
  • Rivera, Daniela
  • Lázaro García, Conxi
  • Nicolo, Arcangela
  • Mori, Luigi
  • Harris, Marion
  • Radice, Paolo
  • Grau Garcés, Èlia
  • Moghadasi, Setareh
  • Engel, Christoph
  • Revillion, Françoise
  • Krieger, Sophie
  • Schmutzler, Rita Katharina
  • Goldgar, David E.
  • Balmaña, Judith
  • Austin, Rachel
  • Borg, Åke
  • Salinas, Monica
  • López Fernández, Adrià
  • Spurdle, Amanda B.
  • Gehrig, Andrea
  • Capone, Gabriele L.
  • Moles Fernández, Alejandro
  • Bortesi, Beatrice
  • Grill, Sabine
  • Pérez Segura, Pedro
  • Moserle, Lidia
  • Caputo, Sandrine M.
  • Hansen, Thomas V.O.
  • Rhiem, Kerstin
  • Lattimore, Vanessa L.
  • Marabelli, Monica
  • Del Valle, Jesús
  • Lalloo, Fiona
  • Pfeifer, Katharina
  • Delnatte, Capucine
  • Toland, Amanda E.
  • Müller, Clemens R.
  • Viel, Alessandra
  • Derive, Nicolas
  • Diez, Orland
  • Sánchez de Abajo, Ana María
  • Monteiro, Alvaro N.
  • Ditsch, Nina
  • Maass, Nicolai
  • Riboli, Barbara
  • Domchek, Susan M.
  • Varon-Mateeva, Raymonda
  • Weichert, Wilko
  • Dutrannoy, Véronique
  • Eccles, Diana
  • Ehrencrona, Hans
  • Trainer, Alison H.
  • Schmidt, Gunnar
  • Enders, Ute
  • Walker, Logan C.
  • Pineda Riu, Marta
  • Evans, D. Gareth
  • Larsen, Mirjam
  • Foulkes, William D.
  • Gerdes, Anne Marie
  • Ritter, Julia
  • Farra, Chantal
  • Manoukian, Siranoush
  • Tornero, Eva
  • Schoenwiese, Ulrike
  • Germani, Aldo
  • Montalban, Gemma
  • Vega, Ana
  • Lautrup, Charlotte
  • Mundhenke, Christoph
  • Quante, Anne S.
The multifactorial likelihood analysis method has demonstrated utility for quantitative assessment of variant pathogenicity for multiple cancer syndrome genes. Independent data types currently incorporated in the model for assessing BRCA1 and BRCA2 variants include clinically calibrated prior probability of pathogenicity based on variant location and bioinformatic prediction of variant effect, co-segregation, family cancer history profile, co-occurrence with a pathogenic variant in the same gene, breast tumor pathology, and case-control information. Research and clinical data for multifactorial likelihood analysis were collated for 1,395 BRCA1/2 predominantly intronic and missense variants, enabling classification based on posterior probability of pathogenicity for 734 variants: 447 variants were classified as (likely) benign, and 94 as (likely) pathogenic; and 248 classifications were new or considerably altered relative to ClinVar submissions. Classifications were compared with information not yet included in the likelihood model, and evidence strengths aligned to those recommended for ACMG/AMP classification codes. Altered mRNA splicing or function relative to known nonpathogenic variant controls were moderately to strongly predictive of variant pathogenicity. Variant absence in population datasets provided supporting evidence for variant pathogenicity. These findings have direct relevance for BRCA1 and BRCA2 variant evaluation, and justify the need for gene-specific calibration of evidence types used for variant classification.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers.

  • Couch, Fergus J.
  • Gaudet, Mia M.
  • Durán, Mercedes
  • Tejada, María Isabel
  • Offit, Kenneth
  • Simard, Jacques
PMCID: PMC3319317.-- et al., [Background]: Genome-wide association studies (GWAS) identified variants at 19p13.1 and ZNF365 (10q21.2) as risk factors for breast cancer among BRCA1 and BRCA2 mutation carriers, respectively. We explored associations with ovarian cancer and with breast cancer by tumor histopathology for these variants in mutation carriers from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). [Methods]: Genotyping data for 12,599 BRCA1 and 7,132 BRCA2 mutation carriers from 40 studies were combined. [Results]: We confirmed associations between rs8170 at 19p13.1 and breast cancer risk for BRCA1 mutation carriers [HR, 1.17; 95% confidence interval (CI), 1.07-1.27; P = 7.42 × 10(-4)] and between rs16917302 at ZNF365 (HR, 0.84; 95% CI, 0.73-0.97; P = 0.017) but not rs311499 at 20q13.3 (HR, 1.11; 95% CI, 0.94-1.31; P = 0.22) and breast cancer risk for BRCA2 mutation carriers. Analyses based on tumor histopathology showed that 19p13 variants were predominantly associated with estrogen receptor (ER)-negative breast cancer for both BRCA1 and BRCA2 mutation carriers, whereas rs16917302 at ZNF365 was mainly associated with ER-positive breast cancer for both BRCA1 and BRCA2 mutation carriers. We also found for the first time that rs67397200 at 19p13.1 was associated with an increased risk of ovarian cancer for BRCA1 (HR, 1.16; 95% CI, 1.05-1.29; P = 3.8 × 10(-4)) and BRCA2 mutation carriers (HR, 1.30; 95% CI, 1.10-1.52; P = 1.8 × 10(-3)). [Conclusions]: 19p13.1 and ZNF365 are susceptibility loci for ovarian cancer and ER subtypes of breast cancer among BRCA1 and BRCA2 mutation carriers. [Impact]: These findings can lead to an improved understanding of tumor development and may prove useful for breast and ovarian cancer risk prediction for BRCA1 and BRCA2 mutation carriers., This research was supported by NIH grant CA128978, an NCI Specialized Program of Research Excellence (SPORE) in Breast Cancer (CA116201), a U.S. Department of Defence Ovarian Cancer Idea award (W81XWH-10-1-0341), and grants from the Breast Cancer Research Foundation and the Komen Foundation for the Cure. This work was also supported by Cancer Research UK (CR-UK) grants C12292/A11174 and C1287/A10118. The research leading to these results has received funding from the European Community's Seventh Framework Programme under grant agreement no. 223175 (HEALTH-F2-2009-223175). Support was also provided by the Canadian Institutes of Health Research for the “CIHR Team in Familial Risks of Breast Cancer” program and by the Canadian Breast Cancer Research Alliance-grant #019511., A.C. Antoniou is a CR-UK Senior Cancer Research Fellow. D.F. Easton is CR-UK Principal Research Fellow. G. Chenevix-Trench6 is a NHMRC Senior Principal Research Fellow. BFBOCC was supported by the Research Council of Lithuania grant LIG-19/2010 to R. Janavicius. BMBSA was supported by grants from the Cancer Association of South Africa (CANSA) to E.J. van Rensburg. BCFR was supported by the National Cancer Institute, NIH under RFA-CA-06-503 and through cooperative agreements with members of the Breast Cancer Family Registry (BCFR) and Principal Investigators, including Cancer Care Ontario (U01 CA69467), Columbia University (U01 CA69398), Fox Chase Cancer Center (U01 CA69631), Huntsman Cancer Institute (U01 CA69446), Cancer Prevention Institute of California (formerly the Northern California Cancer Center; U01 CA69417), University of Melbourne (U01 CA69638), and Research Triangle Institute Informatics Support Center (RFP No. N02PC45022-46). CBCS was supported by The Neye Foundation. CNIO was partially supported by Fundación Mutua Madrileña, Asociación Española Contra el Cáncer, the Spanish Ministry of Science and Innovation (FIS PI08 1120), and the Basque Foundation for Health Innovation and Research (BIOEF): BIO07/CA/006. CONSIT TEAM was supported by grants from Ministero della Salute (Extraordinary National Cancer Program 2006 “Alleanza contro il Cancro” to L. Varesco and P. Radice, and “Progetto Tumori Femminili” to P. Radice), Ministero dell'Universita' e Ricerca (RBLAO3-BETH to P. Radice), Fondazione Italiana per la Ricerca sul Cancro (Special Project “Hereditary tumors” to P. Radice), Associazione Italiana per la Ricerca sul Cancro (4017 to P. Pujol), and by funds from Italian citizens who allocated the 5 × 1,000 share of their tax payment in support of the Fondazione IRCCS Istituto Nazionale Tumori, according to Italian laws (INT-Institutional strategic projects “5 × 1000”)., The DKFZ study was supported by funds from the DKFZ. EMBRACE was supported by CR-UK Grants C1287/A10118 and C1287/A11990. D.G. Evans and Fiona Lalloo were supported by an NIHR grant to the Biomedical Research Centre, Manchester, UK. The Investigators at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust were supported by an NIHR grant to the Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust. R.A. Eeles, Elizabeth Bancroft, and Lucia D'Mello were supported by CR-UK Grant C5047/A8385. GC-HBOC was supported by a grant of the German Cancer Aid (grant 109076) and by the Centre of Molecular Medicine Cologne (CMMC). The GEMO study was supported by the Ligue National Contre le Cancer; Association for International Cancer Research Grant (AICR-07-0454); and the Association “Le cancer du sein, parlons-en!” Award. The Georgetown study was supported by the Familial Cancer Registry at Georgetown University (NIH/NCI grant P30-CA051008), the Cancer Genetics Network (HHSN261200744000C), and Swing Fore the Cure. GOG was supported through funding provided by both intramural (Clinical Genetics Branch, DCEG) and extramural (Community Oncology and Prevention Trials Program—COPTRG) NCI programs. K. Phillips is the Cancer Council Victoria, Colebatch Clinical Research Fellow. HEBCS was supported by the Helsinki University Central Hospital Research Fund, Academy of Finland (132473), the Finnish Cancer Society, and the Sigrid Juselius Foundation. The HEBON study was supported by the Dutch Cancer Society grants NKI1998-1854, NKI2004-3088, NKI2007-3756, and the ZonMW grant 91109024. HUNBOCS was supported by the Hungarian Research Grant KTIA-OTKA CK-80745. ICO was supported by Asociación Española Contra el Cáncer, Spanish Health Research Fund; Carlos III Health Institute; Catalan Health Institute and Autonomous Government of Catalonia; contract grant numbers ISCIIIRETIC RD06/0020/1051, PI10/01422, PI10/31488, and 2009SGR290. IHCC was supported by a Polish Foundation of Science award to K. Jaworska, a fellow of International PhD program, Postgraduate School of Molecular Medicine, Warsaw Medical University. ILUH was supported by the Icelandic Association “Walking for Breast Cancer Research” and by the Landspitali University Hospital Research Fund., INHERIT was supported with J. Simard, Chairholder of the Canada Research Chair in Oncogenetics. IOVHBOCS was supported by Ministero dell'Istruzione, dell'Università e della Ricerca (MIUR), and “Ministero della Salute” (“Progetto Tumori Femminili and grant numbers RFPS 2006-5-341353, ACC2/R6.9”). kConFab was supported by grants from the National Breast Cancer Foundation, the National Health and Medical Research Council (NHMRC), and by the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania, and South Australia, and the Cancer Foundation of Western Australia. The kConFab Clinical Follow-Up Study was funded by the NHMRC [145684, 288704, 454508]. A.-B. Skytte is supported by a NHMRC Senior Research Fellowship. A.K. Godwin was funded by U01CA69631, 5U01CA113916, and the Eileen Stein Jacoby Fund while at FCCC. The author acknowledges support from The University of Kansas Cancer Center and the Kansas Bioscience Authority Eminent Scholar Program. A.K. Godwin is the Chancellors Distinguished Chair in Biomedical Sciences endowed Professor. The McGill study was supported by the Jewish General Hospital Weekend to End Breast Cancer. M. Thomassen holds a Fonds de la Recherche en Santé du Québec clinician-scientist award. The MSKCC study was supported by the Starr Cancer Consortium, the Breast Cancer Research Foundation, the Norman and Carol Stone Cancer Research Initiative, the Kate and Robert Niehaus Clinical Cancer Research Initiative, the Lymphoma Foundation, and the Sabin Family Research Initiative. The NCI study was supported by the Intramural Research Program of the U.S. National Cancer Institute and by support services contracts NO2-CP-11019-50 and N02-CP-65504 with Westat, Inc. NNPIO was supported by the Russian Federation for Basic Research (grants 10-04-92601, 10-04-92110, 11-04-00227) and the Federal Agency for Science and Innovations (contract 16.512.11.2237)., OCGN was supported by Cancer Care Ontario and the U.S. National Cancer Institute, NIH under RFA # CA-06-503 and through cooperative agreements with members of the Breast Cancer Family Registry (BCFR) and Principal Investigators. OSU-CCG was supported by the Ohio State University Comprehensive Cancer Center. PBCS was supported by an Instituto Toscano Tumori grant to M.A. Caligo. SEABASS was supported by CARIF and University Malaya. The UCSF study was supported by the Helen Diller Family Comprehensive Cancer Center at UCSF, the Avon Foundation, and the Center for Translational and Policy Research in Personalized Medicine (TRANSPERS), NIH/NCI P01 CA130818-02A1. UKFOCR was supported by a project grant from CRUK to P.P.D. Pharoah. The UPENN study was supported Komen Foundation for the Cure to S.M. Domchek, the Breast Cancer Research Foundation to K.L. Nathanson, and NIH grants R01-CA083855 and R01-CA102776 to T.R. Rebbeck. WCRI was supported by the American Cancer Society Clinical Research Professorship #SIOP-06-258-06-COUN., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Identification of six new susceptibility loci for invasive epithelial ovarian cancer

  • Kuchenbaecker, Karoline B.
  • Ramus, Susan J.
  • Tyrer, Jonathan
  • Hoya, Miguel de la
  • Díez, Orland
  • Blanco, Ignacio
  • Durán, Mercedes
  • Tejada, María Isabel
Consortium of Investigators of Modifiers of BRCA1 and BRCA2.-- et al., PMCID: PMC4445140, Genome-wide association studies (GWAS) have identified 12 epithelial ovarian cancer (EOC) susceptibility alleles. The pattern of association at these loci is consistent in BRCA1 and BRCA2 mutation carriers who are at high EOC risk. After imputation to the 1000 Genomes Project data, we assessed associations of 11 million genetic variants with EOC risk from 15,397 cases unselected for family history and 30,816 controls, 15,252 BRCA1 mutation carriers and 8,211 BRCA2 mutation carriers (3,096 with ovarian cancer), and combined the results in a meta-analysis. This new study design yielded increased statistical power, leading to the discovery of six new EOC susceptibility loci. Variants at 1p36 (nearest gene WNT4), 4q26 (SYNPO2), 9q34.2 (ABO) and 17q11.2 (ATAD5) were associated with EOC risk, and at 1p34.3 (RSPO1) and 6p22.1 (GPX6) specifically with the serous EOC subtype, at p<5×10−8. Incorporating these variants into risk assessment tools will improve clinical risk predictions for BRCA1/2 mutation carriers., The COGS project is funded through a European Commission's Seventh Framework Programme grant (agreement number 223175 - HEALTHF2-2009-223175). The CIMBA data management and data analysis were supported by Cancer Research–UK grants C12292/A11174 and C1287/A10118. The Ovarian Cancer Association Consortium is supported by a grant from the Ovarian Cancer Research Fund thanks to donations by the family and friends of Kathryn Sladek Smith (PPD/RPCI. 07). The scientific development and funding for this project were in part supported by the US National Cancer Institute GAME-ON Post-GWAS Initiative (U19-CA148112). This study made use of data generated by the Wellcome Trust Case Control consortium. Funding for the project was provided by the Wellcome Trust under award 076113., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer

  • Hollestelle, Antoinette
  • Berchuck, Andrew
  • Durán, Mercedes
Ovarian Cancer Association Consortium, Breast Cancer Association Consortium, and Consortium of Modifiers of BRCA1 and BRCA2: et al., [Objective]: Clinical genetic testing is commercially available for rs61764370, an inherited variant residing in a KRAS 3' UTR microRNA binding site, based on suggested associations with increased ovarian and breast cancer risk as well as with survival time. However, prior studies, emphasizing particular subgroups, were relatively small. Therefore, we comprehensively evaluated ovarian and breast cancer risks as well as clinical outcome associated with rs61764370. [Methods]: Centralized genotyping and analysis were performed for 140,012 women enrolled in the Ovarian Cancer Association Consortium (15,357 ovarian cancer patients; 30,816 controls), the Breast Cancer Association Consortium (33,530 breast cancer patients; 37,640 controls), and the Consortium of Modifiers of BRCA1 and BRCA2 (14,765 BRCA1 and 7904 BRCA2 mutation carriers). [Results]: We found no association with risk of ovarian cancer (OR = 0.99, 95% CI 0.94-1.04, p = 0.74) or breast cancer (OR = 0.98, 95% CI 0.94-1.01, p = 0.19) and results were consistent among mutation carriers (BRCA1, ovarian cancer HR = 1.09, 95% CI 0.97-1.23, p = 0.14, breast cancer HR = 1.04, 95% CI 0.97-1.12, p = 0.27; BRCA2, ovarian cancer HR = 0.89, 95% CI 0.71-1.13, p = 0.34, breast cancer HR = 1.06, 95% CI 0.94-1.19, p = 0.35). Null results were also obtained for associations with overall survival following ovarian cancer (HR = 0.94, 95% CI 0.83-1.07, p = 0.38), breast cancer (HR = 0.96, 95% CI 0.87-1.06, p = 0.38), and all other previously-reported associations. [Conclusions]: rs61764370 is not associated with risk of ovarian or breast cancer nor with clinical outcome for patients with these cancers. Therefore, genotyping this variant has no clinical utility related to the prediction or management of these cancers., The COGS project is funded through a European Commission's Seventh Framework Programme grant (agreement number 223175 — HEALTH-F2-2009-223175). The scientific development and funding for this project were in part supported by the US National Cancer Institute GAME-ON Post-GWAS Initiative (U19-CA148112). Funding for the project was provided by the Wellcome Trust under award 076113. This work was partially supported by Spanish Association against Cancer (AECC08), RTICC 06/0020/1060, FISPI08/1120, Mutua Madrileña Foundation (FMMA) and SAF2010-20493. Was supported by a grant RD12/00369/0006 and 12/00539 from ISCIII (Spain), partially supported by European Regional Development FEDER funds. Contract grant sponsor: Asociación Española Contra el Cáncer, Spanish Health Research Fund; Carlos III Health Institute; Catalan Health Institute and Autonomous Government of Catalonia. Contract grant numbers: ISCIIIRETIC RD06/0020/1051, RD12/0036/008, PI10/01422, PI10/00748, PI13/00285 and 2009SGR290., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations

  • Rebbeck, Timothy R.
  • Friebel, Tara M.
  • Friedman, Eitan
  • Hamann, Ute
  • Huo, Dezheng
  • Kwong, Ava
  • Olah, Edith
  • Olopade, Olufunmilayo I.
  • Solano, Angela R.
  • Teo, Soo-Hwamg
  • Thomassen, Mads
  • Mebirouk, Noura
  • Meijers-Heijboer, Hanne
  • Meindl, Alfons
  • Mensenkamp, Arjen R.
  • Kruse, Torben A.
  • Benitez, Javier
  • Mickys, Ugnius
  • Greene, Mark H.
  • Miller, Austin
  • thomas, Abigail
  • Cook, Jackie
  • Montagna, Marco
  • Moysich, Kirsten B.
  • Mulligan, Anna Marie
  • Musinsky, Jacob
  • Neuhausen, Susan L.
  • Nevanlinna, Heli
  • Ngeow, Joanne
  • Berger, Andreas
  • Nguyen, Huu Phuc
  • Palmero, Edenir Inêz
  • Davidson, Rosemarie
  • Bonadona, Valérie
  • Schmutzler, Rita Katharina
  • Niederacher, Dieter
  • Nielsen, Henriette Roed
  • Nielsen, Finn Cilius
  • Nussbaum, Robert L.
  • Offit, Kenneth
  • Öfverholm, Anna
  • Ong, Kai-ren
  • Berger, Raanan
  • Hoya, Miguel de la
  • Osorio, Ana
  • Konstantopoulou, Irene
  • Papi, Laura
  • Papp, Janos
  • Senter, Leigha
  • Kyung Park, Sue
  • Pasini, Barbara
  • Pedersen, Inge Sokilde
  • Peixoto, Ana
  • Peruga, Nina
  • Leeneer, Kim de
  • Peterlongo, Paolo
  • Blanco, Amie M.
  • Thull, Darcy L.
  • Pohl, Esther
  • Pradhan, Nisha
  • Prajzendanc, Karolina
  • Prieur, Fabienne
  • Shah, Payal D.
  • Pujol, Pascal
  • Torres, Diana
  • Pauw, Antoine de
  • Radice, Paolo
  • Sharma, Priyanka
  • Side, Lucy E.
  • Tischkowitz, Marc
  • Blazer, Kathleen R.
  • Simard, Jacques
  • Singer, Christian F.
  • Skytte, Anne-Bine
  • Slavin, Thomas P.
  • Snape, Katie
  • Rashid, Muhammad Usman
  • Gronwald, Jacek
  • McGuffog, Lesley
  • Sobol, Hagay
  • Southey, Melissa
  • Tognazzo, Silvia
  • Steele, Linda
  • Blok, Marinus J.
  • Steinemann, Doris
  • Toland, Amanda Ewart
  • Topka, Sabine
  • Delnatte, Capucine
  • Trainer, Alison H.
  • Tung, Nadine
  • Hahnen, Eric
  • Asperen, Christi J. van
  • Hout, Annemieke H. van der
  • Korach, Jacob
  • Hogervorst, Frans B. L.
  • Leslie, Goska
  • Kolk, Lizet E. van der
  • Luijt, Rob B. van der
  • Weitzel, Jeffrey N.
  • Heetvelde, Mattias van
  • Varesco, Liliana
  • Varon-Mateeva, Raymonda
  • Vega, Ana I.
  • Villarreal-Garza, Cynthia
  • Hauke, Jan
  • Laitman, Yael
  • Wachenfeldt, Anna von
  • Ramus, Susan J.
  • Walker, Lisa
  • Díez, Orland
  • Wang-Gohrke, Shan
  • Aalfs, Cora M.
  • Wappenschmidt, Barbara
  • Weber, Bernhard H. F.
  • Yannoukakos, Drakoulis
  • Yoon, Sook-Yee
  • Zanzottera, Cristina
  • Lasa, Adrian
  • Zidan, Jamal
  • HEBON
  • Lee, Min Hyuk
  • Bonanni, Bernardo
  • Zorn, Kristin K.
  • Selkirk, Christina G. Hutten
  • Hulick, Peter J.
  • Chenevix-Trench, Georgia
  • Abugattas, Julio
  • Spurdle, Amanda B.
  • Antoniou, Antonis C.
  • Lasset, Christine
  • Nathanson, Katherine L.
  • Sukiennicki, Grzegorz
  • Adlard, Julian
  • Agata, Simona
  • Bradbury, Angela R.
  • Henderson, Alex
  • Aittomäki, Kristiina
  • Andrews, Lesley
  • Andrulis, Irene L.
  • Arason, Adalgeir
  • Arnold, Norbert
  • Couch, Fergus J.
  • Ding, Yuan Chun
  • Arun, Branu K.
  • Asseryanis, Ella
  • Auerbach, Leo
  • Azzollini, Jacopo
  • Brewer, Carole
  • Balmaña, Judith
  • Hentschel, Julia
  • Barile, Monica
  • Buecher, Bruno
  • Buys, Saundra S.
  • Ditsch, Nina
  • Lázaro, Conxi
  • Caldés, Trinidad
  • Caliebe, Almuth
  • Caligo, Maria A.
  • Campbell, Ian
  • Caputo, Sandrine M.
  • Rantala, Johanna
  • Honisch, Ellen
  • Chiquette, Jocelyne
  • Chung, Wendy K.
  • Domchek, Susan M.
  • Claes, Kathleen B.
  • Lee, Annette T.
  • Collée, J. Margriet
  • Evans, D. Gareth
  • Dorfling, Cecilia M.
  • Velázquez Pérez, Carolina
  • Dworniczak, Bernd
  • Eason, Jacqueline
  • Rhiem, Kerstin
  • Easton, Douglas F.
  • Eeles, Ros
  • Sutter, Christian
  • Schmidt, Ane Y.
  • Imyanitov, Evgeny N.
  • Ehrencrona, Hans
  • Ejlertsen, Bent
  • EMBRACE
  • Engel, Christoph
  • Engert, Stefanie
  • Faivre, Laurence
  • Feliubadaló, Lidia
  • Robson, Mark
  • szabo, Csilla I., Tan, Yen Y.
  • Fert Ferrer, Sandra
  • Barkardottir, Rosa B.
  • Foretova, Lenka
  • Fowler, Jeffrey
  • Isaacs, Claudine
  • Frost, Debra
  • Galvão, Henrique C. R.
  • Ganz, Patricia A.
  • Garber, Judy
  • Gauthier-Villars, Marion
  • Teixeira, Manuel R.
  • Gehrig, Andrea
  • Rodriguez, Gustavo C.
  • Lester, Jenny
  • GEMO Study Collaborators
  • Gerdes, Anne-Marie
  • Gesta, Paul
  • Giannini, Giuseppe
  • Izat, Louise
  • Giraud, Sophie
  • Glendon, Gord
  • Terry, Mary Beth
  • Godwin, Andrew K.
  • Izquierdo, Angel
  • Jakubowska, Anna
  • Lesueur, Fabienne
  • Rogers, Mark T.
  • James, Paul
  • Janavicius, Ramunas
  • Jensen, Uffe Birk
  • John, Esther M.
  • Vijai, Joseph
  • Gutierrez-Barrera, Angelica
  • Chan, T. L.
  • Kaczmarek, Katarzyna
  • Karlan, Beth Y.
  • Kast, Karin
  • Liljegren, Annelie
  • KConFab Investigators
  • Rudaitis, Vilius
  • Kim, Sung-Won
  • Lindor, Noralane M.
  • Longy, Michel
  • Teulé, Alex
  • Loud, Jennifer T.
  • Lu, Karen H.
  • Goldgar, David E.
  • Lubinski, Jan
  • Machackova, Eva
  • Barrowdale, Daniel
  • Rensburg, Elizabeth J. van
  • Manoukian, Siranoush
  • Mari, Véronique
  • Martínez-Bouzaz, Cristina
  • Parsons, Michael T.
  • Matrai, Zoltan
The prevalence and spectrum of germline mutations in BRCA1 and BRCA2 have been reported in single populations, with the majority of reports focused on White in Europe and North America. The Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) has assembled data on 18,435 families with BRCA1 mutations and 11,351 families with BRCA2 mutations ascertained from 69 centers in 49 countries on six continents. This study comprehensively describes the characteristics of the 1,650 unique BRCA1 and 1,731 unique BRCA2 deleterious (disease-associated) mutations identified in the CIMBA database. We observed substantial variation in mutation type and frequency by geographical region and race/ethnicity. In addition to known founder mutations, mutations of relatively high frequency were identified in specific racial/ethnic or geographic groups that may reflect founder mutations and which could be used in targeted (panel) first pass genotyping for specific populations. Knowledge of the population-specific mutational spectrum in BRCA1 and BRCA2 could inform efficient strategies for genetic testing and may justify a more broad-based oncogenetic testing in some populations., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes

  • Fachal, Laura
  • Aschard, Hugues
  • Beesley, Jonathan
  • Barnes, Daniel R.
  • Allen, Jamie
  • Kar, Siddhartha
  • Pooley, Karen A.
  • Dennis, Joe
  • Michailidou, Kyriaki
  • Turman, Constance
  • Soucy, Penny
  • Lemaçon, Audrey
  • Lush, Michael
  • Tyrer, Jonathan P.
  • Ghoussaini, Maya
  • Moradi Marjaneh, Mahdi
  • Jiang, Xia
  • Agata, Simona
  • Aittomäki, Kristiina
  • Alonso, M. Rosario
  • Andrulis, Irene L.
  • Anton-Culver, Hoda
  • Antonenkova, Natalia N.
  • Arason, Adalgeir
  • Arndt, Volker
  • Aronson, Kristan J.
  • Arun, Banu K.
  • Auber, Bernd
  • Auer, Paul L.
  • Azzollini, Jacopo
  • Balmaña, Judith
  • Barkardottir, Rosa B.
  • Barrowdale, Daniel
  • Beeghly-Fadiel, Alicia
  • Benitez, Javier
  • Bermisheva, Marina
  • Białkowska, Katarzyna
  • Blanco, Amie M.
  • Blomqvist, Carl
  • Blot, William
  • Bogdanova, Natalia V.
  • Bojesen, Stig E.
  • Bolla, Manjeet K.
  • Bonanni, Bernardo
  • Borg, Ake
  • Bosse, Kristin
  • Brauch, Hiltrud
  • Brenner, H.
  • Briceno, I.
  • Caldés, T.
  • Castelao, J. E.
  • Hoya, Miguel de la
  • Diez, Orland
  • Durán, Mercedes
  • Gago-Dominguez, Manuela
  • García-Saenz, José Ángel
  • González-Neira, Anna
  • Moreno, Fernando
  • Muñoz-Garzón, Víctor M.
  • Osorio, Ana
  • Pujana, Miguel Ángel
  • Romero, Atocha
  • Sánchez-Herrero, Estela
  • Santamariña, Marta
  • Teulé, Alex
  • Vega, Ana I.
Genome-wide association studies have identified breast cancer risk variants in over 150 genomic regions, but the mechanisms underlying risk remain largely unknown. These regions were explored by combining association analysis with in silico genomic feature annotations. We defined 205 independent risk-associated signals with the set of credible causal variants in each one. In parallel, we used a Bayesian approach (PAINTOR) that combines genetic association, linkage disequilibrium and enriched genomic features to determine variants with high posterior probabilities of being causal. Potentially causal variants were significantly over-represented in active gene regulatory regions and transcription factor binding sites. We applied our INQUSIT pipeline for prioritizing genes as targets of those potentially causal variants, using gene expression (expression quantitative trait loci), chromatin interaction and functional annotations. Known cancer drivers, transcription factors and genes in the developmental, apoptosis, immune system and DNA integrity checkpoint gene ontology pathways were over-represented among the highest-confidence target genes., This work was supported by the European Union’s Horizon 2020 Research and Innovation Programme under Marie Sklodowska-Curie grant agreement number 656144. Genotyping of the OncoArray was principally funded from three sources: the PERSPECTIVE project (funded by the Government of Canada through Genome Canada and the Canadian Institutes of Health Research, the ‘Ministère de l’Économie de la Science et de l’Innovation du Québec’ (through Genome Québec) and the Quebec Breast Cancer Foundation); the NCI Genetic Associations and Mechanisms in Oncology (GAME-ON) initiative and the Discovery, Biology and Risk of Inherited Variants in Breast Cancer (DRIVE) project (NIH grants U19 CA148065 and X01HG007492); and Cancer Research UK (C1287/A10118, C8197/A16565 and C1287/A16563). BCAC is funded by Cancer Research UK (C1287/A16563), by the European Community’s Seventh Framework Programme under grant agreement 223175 (HEALTH-F2-2009-223175) (COGS) and by the European Union’s Horizon 2020 Research and Innovation Programme under grant agreements 633784 (B-CAST) and 634935 (BRIDGES). Genotyping of the iCOGS array was funded by the European Union (HEALTH-F2-2009-223175), Cancer Research UK (C1287/A10710), the Canadian Institutes of Health Research for the ‘CIHR Team in Familial Risks of Breast Cancer’ program, and the Ministry of Economic Development, Innovation and Export Trade of Quebec (grant PSR-SIIRI-701). Combining of the GWAS data was supported in part by NIH Cancer Post-Cancer GWAS initiative grant U19 CA 148065 (DRIVE; part of the GAME-ON initiative).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Genome-wide association analyses of ovarian cancer patients undergoing primary debulking surgery identify candidate genes for residual disease

  • Ramachandran, Dhanya
  • Tyrer, Jonathan P.
  • Kommoss, Stefan
  • DeFazio, Anna
  • Riggan, Marjorie J.
  • Webb, Penelope M.
  • Fasching, Peter A.
  • Lambrechts, Diether
  • García, María J.
  • Rodríguez-Antona, Cristina
  • Goodman, Marc T.
  • Modugno, Francesmary
  • Moysich, Kirsten B.
  • Karlan, Beth Y.
  • Lester, Jenny
  • Kjaer, Susanne K.
  • Jensen, Allan
  • Høgdall, Estrid
  • Goode, Ellen L.
  • Cliby, William A.
  • Kumar, Amanika
  • Wang, Chen
  • Cunningham, Julie M.
  • Winham, Stacey J.
  • Monteiro, Álvaro N.
  • Schildkraut, Joellen M.
  • Cramer, Daniel W.
  • Terry, Kathryn L.
  • Titus, Linda
  • Bjorge, Line
  • Thomsen, Liv Cecilie Vestrheim
  • Pejovic, Tanja
  • Høgdall, Claus K.
  • McNeish, Iain A.
  • May, Taymaa
  • Huntsman, David G.
  • Pfisterer, Jacobus
  • Canzler, Ulrich
  • Park-Simon, Tjoung-Won
  • Schröder, Willibald
  • Belau, Antje
  • Hanker, Lars
  • Harter, Philipp
  • Sehouli, Jalid
  • Kimmig, Rainer
  • de Gregorio, Nikolaus
  • Schmalfeldt, Barbara
  • Baumann, Klaus
  • Hilpert, Felix
  • Burges, Alexander
  • Winterhoff, Boris
  • Schürmann, Peter
  • Speith, Lisa-Marie
  • Hillemanns, Peter
  • Berchuck, Andrew
  • Johnatty, Sharon E.
  • Ramus, Susan J.
  • Chenevix-Trench, Georgia
  • Pharoah, Paul D. P.
  • Dörk, Thilo
  • Heitz, Florian
Survival from ovarian cancer depends on the resection status after primary surgery. We performed genome-wide association analyses for resection status of 7705 ovarian cancer patients, including 4954 with high-grade serous carcinoma (HGSOC), to identify variants associated with residual disease. The most significant association with resection status was observed for rs72845444, upstream of MGMT, in HGSOC (p = 3.9 × 10-8). In gene-based analyses, PPP2R5C was the most strongly associated gene in HGSOC after stage adjustment. In an independent set of 378 ovarian tumours from the AGO-OVAR 11 study, variants near MGMT and PPP2R5C correlated with methylation and transcript levels, and PPP2R5C mRNA levels predicted progression-free survival in patients with residual disease. MGMT encodes a DNA repair enzyme, and PPP2R5C encodes the B56γ subunit of the PP2A tumour suppressor. Our results link heritable variation at these two loci with resection status in HGSOC., The Ovarian Cancer Association Consortium is funded by generous contributions from its research investigators and through anonymous donations. OCAC was funded by a grant from the Ovarian Cancer Research Fund (OCRF). The OCAC OncoArray genotyping project was funded through grants from the U.S. National Institutes of Health (CA1X01HG007491-01 (C.I.A.), U19-CA148112 (T.A.S.), R01-CA149429 (C.M.P.) and R01-CA058598 (M.T.G.); Canadian Institutes of Health Research (MOP-86727 (L.E.K.) and the Ovarian Cancer Research Fund (A.B.). The COGS project was funded through a European Commission’s Seventh Framework Programme grant (agreement number 223175 - HEALTH-F2-2009-223175) and in part by the US National Cancer Institute GAME-ON Post-GWAS Initiative (U19-CA148112). This study made use of data generated by the Wellcome Trust Case Control consortium that was funded by the Wellcome Trust under award 076113. The results published are in part based upon data generated by The Cancer Genome Atlas Pilot Project established by the National Cancer Institute and National Human Genome Research Institute (dbGap accession number phs000178.v8.p7). Funding for individual studies: AUS: The Australian Ovarian Cancer Study (AOCS) was supported by the U.S. Army Medical Research and Materiel Command (DAMD17-01-1-0729), National Health & Medical Research Council of Australia (199600, 400413 and 400281), Cancer Councils of New South Wales, Victoria, Queensland, South Australia and Tasmania and Cancer Foundation of Western Australia (Multi-State Applications 191, 211 and 182). AOCS gratefully acknowledges additional support from Ovarian Cancer Australia and the Peter MacCallum Foundation; BAV: ELAN Funds of the University of Erlangen-Nuremberg; BEL: National Kankerplan; CNI: Instituto de Salud Carlos III (PI 19/01730); Ministerio de Economía y Competitividad (SAF2012); HAW: U.S. National Institutes of Health (R01-CA58598, N01-CN-55424 and N01-PC-67001); HOP: University of Pittsburgh School of Medicine Dean’s Faculty Advancement Award (F. Modugno), Department of Defense (DAMD17-02-1-0669, OC20085) and United States National Cancer Institute (R21-CA267050, K07-CA080668, R01-CA95023, MO1-RR000056); LAX: American Cancer Society Early Detection Professorship (SIOP-06-258-01-COUN) and the National Center for Advancing Translational Sciences (NCATS), Grant UL1TR000124; MAC: National Institutes of Health (R01-CA2482288, P30-CA15083, P50-CA136393); Mayo Foundation; Minnesota Ovarian Cancer Alliance; Fred C. and Katherine B. Andersen Foundation; Fraternal Order of Eagles; MAL: Funding for this study was provided by research grant R01- CA61107 from the National Cancer Institute, Bethesda, MD, research grant 94 222 52 from the Danish Cancer Society, Copenhagen, Denmark, the Mermaid I project; and the Mermaid III project; MAY: National Institutes of Health (R01-CA248288, P30-CA15083, P50-CA136393); Mayo Foundation; Minnesota Ovarian Cancer Alliance; Fred C. and Katherine B. Andersen Foundation; MOF: Moffitt Cancer Center, Merck Pharmaceuticals, the state of Florida, Hillsborough County, and the city of Tampa; NCO: National Institutes of Health (R01-CA76016) and the Department of Defense (DAMD17-02-1-0666); NEC: National Institutes of Health R01-CA54419 and P50-CA105009 and Department of Defense W81XWH-10-1-02802; NOR: Helse Vest, The Norwegian Cancer Society, The Research Council of Norway; OPL: National Health and Medical Research Council (NHMRC) of Australia (APP1025142, APP1120431) and Brisbane Women’s Club; ORE: Sherie Hildreth Ovarian Cancer (SHOC) Foundation; PVD: Canadian Cancer Society and Cancer Research Society GRePEC Program; SRO: Cancer Research UK (C536/A13086, C536/A6689) and Imperial Experimental Cancer Research Centre (C1312/A15589); UHN: Princess Margaret Cancer Centre Foundation-Bridge for the Cure; VAN: BC Cancer Foundation, VGH & UBC Hospital Foundation; VTL: NIH K05-CA154337; WMH: National Health and Medical Research Council of Australia, Enabling Grants ID 310670 & ID 628903. Cancer Institute NSW Grants 12/RIG/1-17 & 15/RIG/1-16. The AGO-OVAR 11 study was funded by Roche Pharma AG. Open Access funding enabled and organized by Projekt DEAL., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer

  • Figlioli, Gisella
  • Lázaro García, Conxi
  • Pujana Genestar, M. Ángel
  • ABCTB Investigators
  • GEMO Study Collaborators
  • KConFab Investigators
Breast cancer is a common disease partially caused by genetic risk factors. Germline pathogenic variants in DNA repair genes BRCA1, BRCA2, PAM, ATM, and CHEK2 are associated with breast cancer risk. FANCM, which encodes for a DNA translocase, has been proposed as a breast cancer predisposition gene, with greater effects for the ER-negative and triple-negative breast cancer (TNBC) subtypes. We tested the three recurrent protein-truncating variants FANCM:p.Arg658*, p.Gln1701*, and pArg1931* for association with breast cancer risk in 67,112 cases, 53,766 controls, and 26,662 carriers of pathogenic variants of BRCA1 or BRCA2. These three variants were also studied functionally by measuring survival and chromosome fragility in FANCM(-/-) patient-derived immortalized fibroblasts treated with diepoxybutane or olaparib. We observed that FANCM:p.Arg658* was associated with increased risk of ER-negative disease and TNBC (OR = 2.44, P = 0.034 and OR = 3.79; P = 0.009, respectively). In a country-restricted analysis, we confirmed the associations detected for FANCM:p.Arg658* and found that also FANCM:p.Arg1931* was associated with ER-negative breast cancer risk (OR = 1.96; P = 0.006). The functional results indicated that all three variants were deleterious affecting cell survival and chromosome stability with FANCM:p.Arg658* causing more severe phenotypes. In conclusion, we confirmed that the two rare FANCM deleterious variants p.Arg658* and p.Arg1931* are risk factors for ER-negative and TNBC subtypes. Overall our data suggest that the effect of truncating variants on breast cancer risk may depend on their position in the gene. Cell sensitivity to olaparib exposure, identifies a possible therapeutic option to treat FANCM-associated tumors.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Genomic analysis of male puberty timing highlights shared genetic basis with hair colour and lifespan

  • Hollis, Ben
  • Day, Felix R.
  • Busch, Alexander S.
  • Thompson, Deborah J.
  • Soares, Ana Luiza G.
  • Timmers, Paul R.H.J.
  • Kwong, Alex
  • Easton, Doug F.
  • Joshi, Peter K.
  • Timpson, Nicholas J.
  • PRACTICAL Consortium
  • 23andMe Research Team
  • Ong, Ken K.
  • Perry, John R. B.
The timing of puberty is highly variable and is associated with long-term health outcomes. To date, understanding of the genetic control of puberty timing is based largely on studies in women. Here, we report a multi-trait genome-wide association study for male puberty timing with an effective sample size of 205,354 men. We find moderately strong genomic correlation in puberty timing between sexes (rg = 0.68) and identify 76 independent signals for male puberty timing. Implicated mechanisms include an unexpected link between puberty timing and natural hair colour, possibly reflecting common effects of pituitary hormones on puberty and pigmentation. Earlier male puberty timing is genetically correlated with several adverse health outcomes and Mendelian randomization analyses show a genetic association between male puberty timing and shorter lifespan. These findings highlight the relationships between puberty timing and health outcomes, and demonstrate the value of genetic studies of puberty timing in both sexes., This work was funded by the UK Medical Research Council (MRC; Unit programme MC_UU_12015/2) and used UK Biobank data under application 9905. The MRC, Wellcome Trust (Grant ref: 102215/2/13/2) and the University of Bristol provide core support for ALSPAC. This publication is the work of the authors and <John Perry and Ken Ong> will serve as guarantors for the contents of this paper. GWAS data for ALSPAC was generated by Sample Logistics and Genotyping Facilities at Wellcome Sanger Institute and LabCorp (Laboratory Corporation of America) using support from 23andMe. We are extremely grateful to all the families who took part in the ALSPAC study, the midwives for their help in recruiting them, and the whole ALSPAC team, which includes interviewers, computer and laboratory technicians, clerical workers, research assistants, volunteers, managers, receptionists and nurses. We thank the research participants and employees of 23andMe for making this work possible. Genotyping of the OncoArray was funded by the US National Institutes of Health (NIH) [U19 CA154 148537 for ELucidating Loci Involved in Prostate cancer SuscEptibility (ELLIPSE) project and X01HG007492 to the Center for Inherited Disease Research (CIDR) under contract number 156 HHSN268201200008I]. Additional analytic support was provided by NIH NCI U01 CA188392 157 (PI: Schumacher). The PRACTICAL consortium was supported by Cancer Research UK Grants C5047/A7357, C1287/A10118, C1287/A16563, C5047/A3354, C5047/A10692, C16913/A6135, European 160 Commission’s Seventh Framework Programme grant agreement no° 223175 (HEALTH-F2-2009-223175), and The National Institute of Health (NIH) Cancer Post-Cancer GWAS initiative grant: No. 1 U19 CA 148537-01 (the GAME-ON initiative). We would also like to thank the following for funding support: The Institute of Cancer Research and The Everyman Campaign, The Prostate Cancer Research Foundation, Prostate Research Campaign UK (now Prostate Action), The Orchid Cancer Appeal, The National Cancer Research Network UK, The National Cancer Research Institute (NCRI) UK. We are grateful for support of NIHR funding to the NIHR Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust. In memoriam: Brian E. Henderson.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The CHEK2 variant C.349A>G is associated with prostate cancer risk and carriers share a common ancestor

  • Brandão, Andreia
  • Kogevinas, Manolis
  • Teixeira, Manuel R.
The identification of recurrent founder variants in cancer predisposing genes may have important implications for implementing cost-effective targeted genetic screening strategies. In this study, we evaluated the prevalence and relative risk of the CHEK2 recurrent variant c.349A>G in a series of 462 Portuguese patients with early-onset and/or familial/hereditary prostate cancer (PrCa), as well as in the large multicentre PRACTICAL case-control study comprising 55,162 prostate cancer cases and 36,147 controls. Additionally, we investigated the potential shared ancestry of the carriers by performing identity-by-descent, haplotype and age estimation analyses using high-density SNP data from 70 variant carriers belonging to 11 different populations included in the PRACTICAL consortium. The CHEK2 missense variant c.349A>G was found significantly associated with an increased risk for PrCa (OR 1.9; 95% CI: 1.1-3.2). A shared haplotype flanking the variant in all carriers was identified, strongly suggesting a common founder of European origin. Additionally, using two independent statistical algorithms, implemented by DMLE+2.3 and ESTIAGE, we were able to estimate the age of the variant between 2300 and 3125 years. By extending the haplotype analysis to 14 additional carrier families, a shared core haplotype was revealed among all carriers matching the conserved region previously identified in the high-density SNP analysis. These findings are consistent with CHEK2 c.349A>G being a founder variant associated with increased PrCa risk, suggesting its potential usefulness for cost-effective targeted genetic screening in PrCa families., We thank the funding support from IPO-Porto Research Center (CI-IPOP-16-2012) and from Fundação para a Ciência e a Tecnologia (FCT; PEst-OE/SAU/ UI0776/2014 and PTDC/DTP-PIC/1308/2014). The following authors were awarded with grants from FCT: PPa (UID/DTP/00776/2013/POCI-01-0145-FEDER-006868), SM (SFRH/BD/71397/2010) and PPi (SFRH/BD/73719/2010). The PRACTICAL consortium (http://practical.icr.ac.uk/) was supported by the Canadian Institutes of Health Research, European Commission’s Seventh Framework Programme grant agreement n° 223175 (HEALTH-F2-2009-223175), Cancer Research UK Grants C5047/A7357, C1287/A10118, C1287/A16563, C5047/A3354, C5047/A10692, C16913/A6135, and The National Institute of Health (NIH) Cancer Post-Cancer GWAS initiative grant: No. 1 U19 CA 148537-01 (the GAME-ON initiative). Genotyping of the OncoArray was funded by the US National Institutes of Health (NIH) [U19 CA 148537 for ELucidating Loci Involved in Prostate cancer SuscEptibility (ELLIPSE) project and X01HG007492 to the Center for Inherited Disease Research (CIDR) under contract number HHSN268201200008I] and by Cancer Research UK grant A8197/A16565. Additional analytic support was provided by NIH NCI U01 CA188392 (PI: Schumacher). We would also like to thank the following for funding support: The Institute of Cancer Research and The Everyman Campaign, The Prostate Cancer Research Foundation, Prostate Research Campaign UK (now PCUK), The Orchid Cancer Appeal, Rosetrees Trust, The National Cancer Research Network UK, The National Cancer Research Institute (NCRI) UK. We are grateful for support of NIHR funding to the NIHR Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, NIHR funding to the Manchester Biomedical Research Centre and the Manchester Academic Health Sciences Centre.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Transcriptome‐wide association study of breast cancer risk by estrogen‐receptor status

  • Feng, Helian
  • Gusev, Alexander
  • Pasaniuc, Bogdan
  • Lázaro García, Conxi
  • Teulé-Vega, Àlex
  • GEMO Study Collaborators
  • EMBRACE Collaborators
  • GC‐HBOC Study Collaborators
  • ABCTB Investigators
  • HEBON Investigators
  • BCFR Investigators
  • OCGN Investigators
Previous transcriptome-wide association studies (TWAS) have identified breast cancer risk genes by integrating data from expression quantitative loci and genome-wide association studies (GWAS), but analyses of breast cancer subtype-specific associations have been limited. In this study, we conducted a TWAS using gene expression data from GTEx and summary statistics from the hitherto largest GWAS meta-analysis conducted for breast cancer overall, and by estrogen receptor subtypes (ER+ and ER-). We further compared associations with ER+ and ER- subtypes, using a case-only TWAS approach. We also conducted multigene conditional analyses in regions with multiple TWAS associations. Two genes, STXBP4 and HIST2H2BA, were specifically associated with ER+ but not with ER- breast cancer. We further identified 30 TWAS-significant genes associated with overall breast cancer risk, including four that were not identified in previous studies. Conditional analyses identified single independent breast-cancer gene in three of six regions harboring multiple TWAS-significant genes. Our study provides new information on breast cancer genetics and biology, particularly about genomic differences between ER+ and ER- breast cancer.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Association analyses identify 31 new risk loci for colorectal cancer susceptibility

  • Law, Philip J.
  • PRACTICAL Consortium
  • Dunlop, Malcolm G.
Colorectal cancer (CRC) is a leading cause of cancer-related death worldwide, and has a strong heritable basis. We report a genome-wide association analysis of 34,627 CRC cases and 71,379 controls of European ancestry that identifies SNPs at 31 new CRC risk loci. We also identify eight independent risk SNPs at the new and previously reported European CRC loci, and a further nine CRC SNPs at loci previously only identified in Asian populations. We use in situ promoter capture Hi-C (CHi-C), gene expression, and in silico annotation methods to identify likely target genes of CRC SNPs. Whilst these new SNP associations implicate target genes that are enriched for known CRC pathways such as Wnt and BMP, they also highlight novel pathways with no prior links to colorectal tumourigenesis. These findings provide further insight into CRC susceptibility and enhance the prospects of applying genetic risk scores to personalised screening and prevention., At the Institute of Cancer Research, this work was supported by Cancer Research UK (C1298/A25514). Additional support was provided by the National Cancer Research Network. In Edinburgh, the work was supported by Programme Grant funding from Cancer Research UK (C348/A12076) and by funding for the infrastructure and staffing of the Edinburgh CRUK Cancer Research Centre. In Birmingham, funding was provided by Cancer Research UK (C6199/A16459). We are grateful to many colleagues within UK Clinical Genetics Departments (for CORGI) and to many collaborators who participated in the VICTOR, QUASAR2 and SCOT trials. We also thank colleagues from the UK National Cancer Research Network (for NSCCG). Support from the European Union [FP7/207–2013, grant 258236] and FP7 collaborative project SYSCOL and COST Action in the UK is also acknowledged [BM1206]. The COIN and COIN-B trials were funded by Cancer Research UK and the Medical Research Council and were conducted with the support of the National Institute of Health Research Cancer Research Network. COIN and COIN-B translational studies were supported by the Bobby Moore Fund from Cancer Research UK, Tenovus, the Kidani Trust, Cancer Research Wales and the National Institute for Social Care and Health Research Cancer Genetics Biomedical Research Unit (2011–2014). We thank the High-Throughput Genomics Group at the Wellcome Trust Centre for Human Genetics (funded by Wellcome Trust grant reference 090532/Z/09/Z) and the Edinburgh Clinical Research Facility (ECRF) Genetics Core, Western General Hospital, Edinburgh, for the generation of genotyping data. We thank the Lothian Birth Cohorts’ members, investigators, research associates, and other team members. We thank the Edinburgh Clinical Research Facility (ECRF) Genetics Core, Western General Hospital, Edinburgh, for genotyping. Lothian Birth Cohorts’ data collection is supported by the Disconnected Mind project (funded by Age UK), and the Biotechnology and Biological Sciences Research Council (BBSRC, for genotyping; BB/F019394/1) and undertaken within the University of Edinburgh Centre for Cognitive Ageing and Cognitive Epidemiology (funded by the BBSRC and Medical Research Council RC as part of the LLHW [MR/K026992/1]). ET was supported by Cancer Research UK CDF (C31250/A22804). This research has been conducted using the UK Biobank Resource under Application Number 7441. Generation Scotland received core support from the Chief Scientist Office of the Scottish Government Health Directorates [CZD/16/6] and the Scottish Funding Council [HR03006]. Genotyping of the GS:SFHS samples was carried out by the Genetics Core Laboratory at the Clinical Research Facility, University of Edinburgh and was funded by the Medical Research Council UK and the Wellcome Trust (Wellcome Trust Strategic Award “STratifying Resilience and Depression Longitudinally” (STRADL) [104036/Z/14/Z]). CFR was supported by a Marie Sklodowska-Curie Intra-European Fellowship Action and received considerable help from many staff in the Department of Endoscopy at the John Radcliffe Hospital in Oxford. In Finland, this work was supported by grants from the Academy of Finland [Finnish Center of Excellence Program 2012–2017, 250345 and 2018–2025, 312041], the Jane and Aatos Erkko Foundation, the Finnish Cancer Society [personal grant to K.P.], the European Research Council [ERC; 268648], the Sigrid Juselius Foundation, SYSCOL, the Nordic Information for Action eScience Center (NIASC), the Nordic Center of Excellence financed by NordForsk [project 62721, personal grant to K.P.] and State Research Funding of Kuopio University Hospital [B1401]. We acknowledge the computational resources provided by the ELIXIR node, hosted at the CSC–IT Center for Science, Finland, and funded by the Academy of Finland [grants 271642 and 263164], the Ministry of Education and Culture, Finland. V.S. was supported by the Finnish Academy [grant number 139635] and the Finnish Foundation for Cardiovascular Research. J.-P.M. was funded by The Finnish Cancer Foundation and The Jane and Aatos Erkko Foundation. Sample collection and genotyping in the Finnish Twin Cohort has been supported by the Wellcome Trust Sanger Institute, ENGAGE—European Network for Genetic and Genomic Epidemiology, FP7-HEALTH-F4–2007; [grant agreement number 201413], the National Institute of Alcohol Abuse and Alcoholism [grants AA-12502 and AA-00145; to R.J.R. and K02AA018755 to D.M.D.] and the Academy of Finland [grants 100499, 205585, 265240 and 263278 to J.K.]. The work of the Colon Cancer Family Registry (CCFR) was supported by the National Cancer Institute (NCI) of the National Institutes of Health (NIH) under Award number U01 CA167551. The CCFR Illumina GWAS was supported by the NCI/NIH under Award Numbers U01 CA122839 and R01 CA143237 to G.C. The content of this manuscript does not necessarily reflect the views or policies of the NCI or any of the collaborating centres in the CCFR, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government or the CCFR. The CORSA study was funded by FFG BRIDGE (grant 829675, to A.G.), the “Herzfelder’sche Familienstiftung” (grant to A.G.) and was supported by COST Action BM1206. We kindly thank all individuals who agreed to participate in the CORSA study. Furthermore, we thank all cooperating physicians and students and the Biobank Graz of the Medical University of Graz. The DACHS study was supported by grants from the German Research Council (Deutsche Forschungsgemeinschaft, BR 1704/6–1, BR 1704/6–3, BR 1704/6–4, BR 1704/6–6 and CH 117/1–1), and the German Federal Ministry of Education and Research (01KH0404, 01ER0814, 01ER0815 and 01ER1505A, 01ER1505B). We thank all participants and cooperating clinicians, and Ute Handte-Daub, Ansgar Brandhorst, Muhabbet Celik and Ursula Eilber for excellent technical assistance. The Croatian study was supported through the 10,001 Dalmatians Project, and institutional support of University Hospital for Tumours, Sestre milosrdnice University Hospital Center. James East and Simon Leedham were funded by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC). The views expressed not necessarily those of the NHS, the NIHR or the Department of Health. We acknowledge use of genotype data from the British 1958 Birth Cohort DNA collection, which was funded by the Medical Research Council Grant G0000934 and the Wellcome Trust Grant 068545/Z/02. A full list of the investigators who contributed to the generation of the data is available from http://www.wtccc.org.uk. The BCAC study would not have been possible without the contributions of the following: Manjeet K. Bolla, Qin Wang, Kyriaki Michailidou and Joe Dennis. BCAC is funded by Cancer Research UK (C1287/A10118, C1287/A16563). For the BBCS study, we thank Eileen Williams, Elaine Ryder-Mills, Kara Sargus. The BBCS is funded by Cancer Research UK and Breast Cancer Now and acknowledges NHS funding to the National Institute of Health Research (NIHR) Biomedical Research Centre (BRC) and the National Cancer Research Network (NCRN). We thank the participants and the investigators of EPIC (European Prospective Investigation into Cancer and Nutrition). The coordination of EPIC is financially supported by the European Commission (DG-SANCO) and the International Agency for Research on Cancer. The national cohorts are supported by: Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Générale de l’Education Nationale, Institut National de la Santé et de la Recherche Médicale (INSERM) (France); German Cancer Aid, German Cancer Research Center (DKFZ), Federal Ministry of Education and Research (BMBF) (Germany); the Hellenic Health Foundation, the Stavros Niarchos Foundation (Greece); Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy and National Research Council (Italy); Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands); Health Research Fund (FIS), PI13/00061 to Granada, PI13/01162 to EPIC-Murcia, Regional Governments of Andalucía, Asturias, Basque Country, Murcia and Navarra, ISCIII RETIC (RD06/0020) (Spain); Cancer Research UK (14136 to EPIC-Norfolk; C570/A16491 and C8221/A19170 to EPIC-Oxford), Medical Research Council (1000143 to EPIC-Norfolk, MR/M012190/1 to EPIC-Oxford) (United Kingdom). We thank the SEARCH and EPIC teams, which were funded by a programme grant from Cancer Research UK (C490/A10124) and supported by the UK NIHR BRC at the University of Cambridge. We thank Breast Cancer Now and the Institute of Cancer Research (ICR) for support and funding of the UKBGS, and the study participants, study staff, and the doctors, nurses and other health-care providers and health information sources who have contributed to the study. Genotyping of the PRACTICAL consortium OncoArray was funded by the US National Institutes of Health (NIH) [U19 CA 148537 for ELucidating Loci Involved in Prostate cancer SuscEptibility (ELLIPSE) project and X01HG007492 to the Center for Inherited Disease Research (CIDR) under contract number HHSN268201200008I]. Additional analytic support was provided by NIH NCI U01 CA188392 (PI: Schumacher). The PRACTICAL consortium was supported by Cancer Research UK Grants C5047/A7357, C1287/A10118, C1287/A16563, C5047/A3354, C5047/A10692, C16913/A6135, European Commission’s Seventh Framework Programme grant agreement n° 223175 (HEALTH-F2–2009–223175), and The National Institute of Health (NIH) Cancer Post-Cancer GWAS initiative grant: No. 1 U19 CA 148537–01 (the GAME-ON initiative). We would also like to thank the following for funding support: The Institute of Cancer Research and The Everyman Campaign, The Prostate Cancer Research Foundation, Prostate Research Campaign UK (now Prostate Action), The Orchid Cancer Appeal, The National Cancer Research Network UK, The National Cancer Research Institute (NCRI) UK. We are grateful for support of NIHR funding to the NIHR Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, the Spanish Instituto de Salud Carlos III (ISCIII) an initiative of the Spanish Ministry of Economy and Innovation (Spain), and the Xunta de Galicia (Spain).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170

  • Pujana Genestar, M. Ángel
  • EMBRACE Collaborators
  • GEMO Study Collaborators
  • Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON)
We analyzed 3,872 common genetic variants across the ESR1 locus (encoding estrogen receptor a) in 118,816 subjects from three international consortia. We found evidence for at least five independent causal variants, each associated with different phenotype sets, including estrogen receptor (ER+ or ER-) and human ERBB2 (HER2(+) or HER2(-)) tumor subtypes, mammographic density and tumor grade. The best candidate causal variants for ER-tumors lie in four separate enhancer elements, and their risk alleles reduce expression of ESR1, RMND1 and CCDC170, whereas the risk alleles of the strongest candidates for the remaining independent causal variant disrupt a silencer element and putatively increase ESR1 and RMND1 expression.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Shared heritability and functional enrichment across six solid cancers

  • Jiang, Xia
  • Finucane, Hilary K.
  • Schumacher, Fredrick R.
  • Schmit, Stephanie L.
  • Tyrer, Jonathan P.
  • Han, Younghun
  • Michailidou, Kyriaki
  • Lesseur, Corina
  • Kuchenbaecker, Karoline B.
  • Dennis, Joe
  • Conti, David V.
  • Cunningham, Julie M.
  • John, Esther M.
  • Couch, Fergus J.
  • Bolla, Manjeet K.
  • Casey, Graham
  • Margolin, Sara
  • Goodman, Gary
  • Evans, D. Gareth
  • Riggan, Marjorie J.
  • Gago-Dominguez, Manuela
  • Jenkins, Mattias
  • Fostira, Florentia
  • Kaneva, Radka
  • Arnold, Susanne M.
  • Offit, Kenneth
  • Ruyck, Kim De
  • Olsson, Håkan
  • Arun, Banu K.
  • Schleutker, Johanna
  • Aronson, Kristan J.
  • Caligo, Maria A.
  • Tardón, Adonina
  • Edlund, Christopher K.
  • Ingles, Sue Ann
  • Hsu, Li
  • Rosenstein, Barry S.
  • Chenevix-Trench, Georgia
  • McKay, James D.
  • Claes, Kathleen B. M.
  • Chanock, Stephen J.
  • Nordestgaard, Børge G.
  • Park, Jong Y.
  • Kupryjanczyk, Jolanta
  • Cadoni, Gabriella
  • Neal, David E.
  • Diez, Orland
  • Ferris, Robert L.
  • Stefansson, Kari
  • Cannon-Albright, Lisa A.
  • Weinberg, Clarice R.
  • McGuffog, Lesley
  • Raskin, Leon
  • Mannermaa, Arto
  • Kibel, Adam S.
  • Neuhausen, Susan L.
  • Hulick, Peter J.
  • Shen, Hongbing
  • Wichmann, H-Erich
  • Goldberg, Mark S.
  • Greene, Mark H.
  • Maehle, Lovise
  • Yannoukakos, Drakoulis
  • Garber, Judy
  • Webb, Penelope M.
  • Weissler, Mark C.
  • Pejovic, Tanja
  • Bojesen, Stig E.
  • Toland, Amanda E.
  • Blomqvist, Carl
  • Knight, Julia A.
  • Huntsman, David G.
  • Dörk, Thilo
  • Gaudet, Mia M.
  • Hong, Yun-Chul
  • Whittemore, Alice S.
  • Torres, Diana
  • Hung, Rayjean J.
  • García-Closas, Montserrat
  • Li, Li
  • Friedman, Eitan
  • Hillemanns, Peter
  • Haugen, Aage
  • Cruz Correa, Marcia
  • Wolk, Alicja
  • Olopade, Olufunmilayo I.
  • Risch, Harvey A.
  • Terry, Kathryn L.
  • Hamdy, Freddie C.
  • Burwinkel, Barbara
  • Brauch, Hiltrud
  • Parsons, Michael T.
  • Tangen, Catherine M.
  • Travis, Ruth C.
  • Middha, Pooja
  • Terry, Mary Beth
  • Newcomb, Lisa F.
  • Nielsen, Finn C.
  • Ness, Andrew R.
  • Stanford, Janet L.
  • Kraft, Peter
  • Montagna, Marco
  • Brenton, James D.
  • Roobol, Monique J.
  • Thibodeau, Stephen N.
  • Sundfeldt, Karin
  • Hampe, Jochen
  • Lubiński, Jan
  • Tung, Nadine
  • Nevanlinna, Heli
  • Chang-Claude, Jenny
  • Stone, Jennifer
  • Swerdlow, Anthony J.
  • Brenner, Hermann
  • Wiklund, Fredrik
  • Bandera, Elisa V.
  • Siegel, Erin M.
  • Lester, Jenny
  • Le, Nhu D.
  • Taylor, Jack A.
  • Chan, Andrew T.
  • Donovan, Jenny L.
  • Landi, Maria Teresa
  • Aldrich, Melinda C.
  • White, Emily
  • Stevens, Victoria L.
  • Velez Edwards, Digna R.
  • Goodman, Marc T.
  • Easton, Douglas F.
  • Dwek, Miriam
  • Berchuck, Andrew
  • deFazio, Anna
  • Devilee, Peter
  • Heitz, Florian
  • Hopper, John L.
  • Hunter, David J.
  • Peters, Ulrike
  • Albanes, Jeroen R.
  • Singer, Christian F.
  • Woll, Penella
  • Tajara, Eloiza H.
  • Brunet, Joan
  • Christiani, David C.
  • Weitzel, Jeffrey N.
  • García-Sáenz, José A.
  • Liloglou, Triantafillos
  • Phipps, Amanda I.
  • Cybulski, Cezary
  • Li, Christopher I.
  • Lazarus, Philip
  • Sawyer, Elinor J.
  • Lane, Jacqueline M.
  • Meindl, Alfons
  • Liu, Geoffrey
  • Grankvist, Kjell
  • Peters, Wilbert H. M.
  • Goode, Ellen L.
  • Godwin, Andrew K.
  • Butzow, Ralf
  • Barkardottir, Rosa B.
  • Bien, Stephanie A.
  • Ulrich, Cornelia M.
  • Brunnström, Hans
  • Goldgar, David E.
  • Lee, Eunjung
  • Koutros, Stella
  • Setiawan, V. Wendy
  • Fletcher, Olivia
  • Moysich, Kirsten B.
  • Høgdall, Estrid
  • Gallinger, Steven
  • Lacko, Martin
  • Chen, Chu
  • Beckmann, Matthias W.
  • Elías Aguado-Barrera, Miguel
  • Barnes, Daniel R.
  • Imyanitov, Evgeny N.
  • Clements, Judith
  • Pandha, Hardev
  • Lenz, Heinz-Josef
  • MacInnis, Robert J.
  • Idos, Gregory
  • Daly, Mary B.
  • Anton-Culver, Hoda
  • Winqvist, Robert
  • Khusnutdinova, Elza
  • Muir, Kenneth
  • Diergaarde, Brenda
  • Collée, J. Margriet
  • Rossing, Mary Anne
  • Radice, Paolo
  • Bjørge, Line
  • Phelan, Catherine M.
  • Usmani, Nawaid
  • Brook, Mark N.
  • Rennert, Hedy S.
  • Lindo, Noralane M.
  • West, Catharine M. L.
  • Lam, Stephan
  • Teare, M. Dawn
  • Sandler, Dale P.
  • van Rensburg, Elizabeth J.
  • Levine, Douglas A.
  • Milne, Roger L.
  • Sorensen, Karina Dalsgaard
  • Sutphen, Rebecca
  • Miller, Austin
  • Isaacs, Claudine
  • Lesse, Davor
  • Zheng, Wei
  • Campbell, Peter T.
  • Olshan, Andrew F.
  • Modugno, Francesmary
  • Ramus, Susan J.
  • James, Paul
  • Cox, Angela
  • Caldés, Trinidad
  • Wang, Qin
  • Simard, Jacques
  • Schabath, Matthew B.
  • Pasaniuc, Bogdan
  • Carvalho, André L.
  • Lambrechts, Diether
  • Antonenkova, Natalia N.
  • Andrew, Angeline S.
  • Johansson, Mikael
  • Johansson, Mattias
  • Herrero, Rolando
  • Boccia, Stefania
  • Håkansson, Niclas
  • Kjaer, Susanne K.
  • Berndt, Sonja I.
  • Lejbkowicz, Flavio
  • Pharoah, Paul D. P.
  • Hamilton, Robert J.
  • Moreno Aguado, Víctor
  • Gruber, Stephen B.
  • Gronberg, Henrik
  • Kristensen, Vessela N.
  • Sieh, Weiva
  • Saxena, Richa
  • Bickeböller, Heike
  • Joshi, Amit D.
  • Olah, Edith
  • Zienolddiny, Shanbeh
  • Vega, Ana
  • Gayther, Simon A.
  • Campbell, Ian
  • Kühl, Tabea
  • Hall, Per
  • Rennert, Gad
  • Dunning, Alison M.
  • Czene, Kamila
  • Stintzing, Sebastian
  • Osorio, Ana
  • Hoffmeister, Michael
  • Spurdle, Amanda B.
  • Marchand, Loïc Le
  • Buchanan, Daniel D.
  • Slattery, Martha L.
  • Hamann, Ute
  • Caporaso, Neil E.
  • Kelemen, Linda E.
  • Mulligan, Anna Marie
  • Fortner, Renée T.
  • Weinstein, Stephanie
  • Penney, Kathryn L.
  • Mucci, Lorelei
  • Jakubowska, Anna
  • Nikitina-Zake, Liene
  • Loupakis, Fotios
  • Van Nieuwenhuysen, Els
  • Wu, Anna H.
  • Pashayan, Nora
  • Risch, Angela
  • Andrulis, Irene L.
  • Ganz, Patricia A.
  • Maier, Christiane
  • Wu, Xifeng
  • Khaw, Kay-Tee
  • Southey, Melissa C.
  • Townsend, Paul A.
  • Thomas, Duncan C.
  • Vachon, Celine M.
  • Eccles, Diana
  • Schmidt, Marjanka K.
  • Kote-Jarai, Zsofia
  • Campa, Daniele
  • Huyghe, Jeroen R.
  • Duell, Eric J.
  • Claessens, Frank
  • May, Taymaa
  • Houlston, Richard
  • Fasching, Peter A.
  • Kim, Jeri
  • Prokofyeva, Darya
  • Giles, Graham G.
  • Karlan, Beth Y.
  • Lindström, Sara
  • Antoniou, Antonis C.
  • Figueiredo, Jane C.
  • Kiemeney, Lambertus A. L. M.
  • Eeles, Rosalind A.
  • Kogevinas, Manolis
  • Bogdanova, Natalia V.
  • Guénel, Pascal
  • Gronwald, Jacek
  • Brennan, Paul
  • Batra, Jyotsna
  • Franceschi, Silvia
  • Lindblom, Annika
  • Amos, Christopher I.
  • Leslie, Goska
  • Thomassen, Mads
  • Haiman, Christopher A.
  • Nussbaum, Robert L.
  • Benlloch, Sara
  • Al Olama, Ali Amin
  • Pring, Miranda
  • Benitez, Javier
  • Ziogas, Argyrios
  • Cancel-Tassin, Géraldine
  • Price, Alkes L.
  • Woods, Michael
  • Tworoger, Shelley S.
  • Nathanson, Katherine L.
  • Ellberg, Carolina
  • Teixeira, Manuel R.
  • Saloustros, Emmanouil
  • Tischkowitz, Marc
  • Zorn, Kristin K.
  • Plaseska-Karanfilska, Dijana
  • Newcomb, Polly A.
Quantifying the genetic correlation between cancers can provide important insights into the mechanisms driving cancer etiology. Using genome-wide association study summary statistics across six cancer types based on a total of 296,215 cases and 301,319 controls of European ancestry, here we estimate the pair-wise genetic correlations between breast, colorectal, head/neck, lung, ovary and prostate cancer, and between cancers and 38 other diseases. We observed statistically significant genetic correlations between lung and head/neck cancer (rg = 0.57, p = 4.6 × 10-8), breast and ovarian cancer (rg = 0.24, p = 7 × 10-5), breast and lung cancer (rg = 0.18, p =1.5 × 10-6) and breast and colorectal cancer (rg = 0.15, p = 1.1 × 10-4). We also found that multiple cancers are genetically correlated with non-cancer traits including smoking, psychiatric diseases and metabolic characteristics. Functional enrichment analysis revealed a significant excess contribution of conserved and regulatory regions to cancer heritability. Our comprehensive analysis of cross-cancer heritability suggests that solid tumors arising across tissues share in part a common germline genetic basis.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification

  • Parsons, Michael T.
  • Tudini, Emma
  • Li, Hongyan
  • Hahnen, Eric
  • Wappenschmidt, Barbara
  • Feliubadaló i Elorza, Maria Lídia
  • Aalfs, Cora M.
  • Agata, Simona
  • Aittomäki, Kristiina
  • Alducci, Elisa
  • Alonso Cerezo, María Concepción
  • Hauke, Jan
  • Heinrich, Tilman
  • Törngren, Therese
  • Hellebrand, Heide
  • Arnold, Norbert
  • Seggewiß, Jochen
  • Caldés, Trinidad
  • Herold, Karen N.
  • Honisch, Ellen
  • Naldi, Nadia
  • Witzel, Isabell
  • Walters, Rhiannon J.
  • Rump, Andreas
  • Horvath, Judit
  • Poplawski, Nicola K.
  • Velasco, Àngela
  • Houdayer, Claude
  • Brunet, Joan
  • Cini, Giulia
  • Hübbel, Verena
  • Iglesias, Silvia
  • Wöckel, Achim
  • Steinemann, Doris
  • Izquierdo, Angel
  • Barbieri, Elena
  • Wang Gohrke, Shan
  • James, Paul A.
  • Carnevali, Ileana
  • Torres Esquius, Sara
  • Janssen, Linda A.M.
  • Jeschke, Udo
  • Kruse, Torben A.
  • Kölbl, Alexandra
  • Ledig, Susanne
  • Cops, Elisa J.
  • Vesper, Anne Sophie
  • Kaulfuß, Silke
  • Porfirio, Berardino
  • Auber, Bernd
  • Weber, Bernhard H. F.
  • Leinert, Elena
  • Rofes, Paula
  • Bruzzone, Carla
  • Woodward, Emma R.
  • Matricardi, Laura
  • Solanes, Ares
  • Carrasco, Estela
  • Mackelenbergh, Marion T.
  • Waha, Anke
  • Nathanson, Katherine L.
  • Tucker, Katherine M.
  • Bucksch, Karolin
  • Navarro, Matilde
  • Faust, Ulrike
  • Bonanni, Bernardo
  • González, Sara
  • Nevanlinna, Heli
  • Nichols, Cassandra B.
  • Cortesi, Laura
  • Wiesmüller, Lisa
  • Niederacher, Dieter
  • Vreeswijk, Maaike P. G.
  • Caux Moncoutier, Virginie
  • Nielsen, Henriette R.
  • Giesecke, Jutta
  • Hackmann, Karl
  • Azzollini, Jacopo
  • Ong, Kai Ren
  • Pachter, Nicholas
  • Galvao, Henrique C.R.
  • Couch, Fergus J.
  • Palmero, Edenir I.
  • Guerrieri Gonzaga, Aliana
  • Cagnoli, Giulia
  • Papi, Laura
  • Asperen, Christi J.
  • Pohl Rescigno, Esther
  • Ramser, Juliane
  • Cavalli, Pietro
  • Pedersen, Inge Søkilde
  • Wagner, Sebastian A.
  • Felbor, Ute
  • Darder, Esther
  • Reis, Rui M.
  • Wieland, Kerstin
  • Gismondi, Viviana
  • Blümcke, Britta
  • Zachariae, Silke
  • Calvello, Mariarosaria
  • Stiller, Mathias
  • Bartram, Claus R.
  • Feroce, Irene
  • Stoppa-Lyonnet, Dominique
  • Keupp, Katharina
  • Hoya, Miguel
  • Lucci Cordisco, Emanuela
  • Sullivan, Kelly J.
  • Susman, Rachel
  • Zampiga, Valentina
  • Guillaud Bataille, Marine
  • Concolino, Paola
  • Sutter, Christian
  • Caliebe, Almuth
  • Gómez, Carolina
  • Tavtigian, Sean V.
  • Lewis, Alexandra L.
  • Montagna, Marco
  • Teo, Soo H.
  • Teulé, Alex
  • Debatin, Irmgard
  • Thomassen, Mads
  • Kvist, Anders
  • Gutiérrez Enríquez, Sara
  • Tibiletti, Maria Grazia
  • Meindl, Alfons
  • Fine, Miriam
  • Tischkowitz, Marc
  • Blanco, Ana
  • Toss, Angela
  • Varesco, Liliana
  • Montes, Eva
  • Garcia, Encarna B.
  • Tognazzo, Silvia
  • Caligo, Maria A.
  • Kiechle, Marion
  • Haaf, Thomas
  • Vargas Parra, Gardenía María
  • Clarke, Edward M.
  • Lim, Joanna
  • Bonache, Sandra
  • Dean, Michael
  • Michelli, Rodrigo D.
  • Gensini, Francesca
  • Gross, Eva
  • Zeder Göß, Christine
  • Gambino, Gaetana
  • Loeffler, Markus
  • Investigators, Kconfab
  • Peissel, Bernard
  • Rivera, Daniela
  • Lázaro García, Conxi
  • Nicolo, Arcangela
  • Mori, Luigi
  • Harris, Marion
  • Radice, Paolo
  • Grau Garcés, Èlia
  • Moghadasi, Setareh
  • Engel, Christoph
  • Revillion, Françoise
  • Krieger, Sophie
  • Schmutzler, Rita Katharina
  • Goldgar, David E.
  • Balmaña, Judith
  • Austin, Rachel
  • Borg, Åke
  • Salinas, Monica
  • López Fernández, Adrià
  • Spurdle, Amanda B.
  • Gehrig, Andrea
  • Capone, Gabriele L.
  • Moles Fernández, Alejandro
  • Bortesi, Beatrice
  • Grill, Sabine
  • Pérez Segura, Pedro
  • Moserle, Lidia
  • Caputo, Sandrine M.
  • Hansen, Thomas V.O.
  • Rhiem, Kerstin
  • Lattimore, Vanessa L.
  • Marabelli, Monica
  • Del Valle, Jesús
  • Lalloo, Fiona
  • Pfeifer, Katharina
  • Delnatte, Capucine
  • Toland, Amanda E.
  • Müller, Clemens R.
  • Viel, Alessandra
  • Derive, Nicolas
  • Diez, Orland
  • Sánchez de Abajo, Ana María
  • Monteiro, Alvaro N.
  • Ditsch, Nina
  • Maass, Nicolai
  • Riboli, Barbara
  • Domchek, Susan M.
  • Varon-Mateeva, Raymonda
  • Weichert, Wilko
  • Dutrannoy, Véronique
  • Eccles, Diana
  • Ehrencrona, Hans
  • Trainer, Alison H.
  • Schmidt, Gunnar
  • Enders, Ute
  • Walker, Logan C.
  • Pineda Riu, Marta
  • Evans, D. Gareth
  • Larsen, Mirjam
  • Foulkes, William D.
  • Gerdes, Anne Marie
  • Ritter, Julia
  • Farra, Chantal
  • Manoukian, Siranoush
  • Tornero, Eva
  • Schoenwiese, Ulrike
  • Germani, Aldo
  • Montalban, Gemma
  • Vega, Ana
  • Lautrup, Charlotte
  • Mundhenke, Christoph
  • Quante, Anne S.
The multifactorial likelihood analysis method has demonstrated utility for quantitative assessment of variant pathogenicity for multiple cancer syndrome genes. Independent data types currently incorporated in the model for assessing BRCA1 and BRCA2 variants include clinically calibrated prior probability of pathogenicity based on variant location and bioinformatic prediction of variant effect, co-segregation, family cancer history profile, co-occurrence with a pathogenic variant in the same gene, breast tumor pathology, and case-control information. Research and clinical data for multifactorial likelihood analysis were collated for 1,395 BRCA1/2 predominantly intronic and missense variants, enabling classification based on posterior probability of pathogenicity for 734 variants: 447 variants were classified as (likely) benign, and 94 as (likely) pathogenic; and 248 classifications were new or considerably altered relative to ClinVar submissions. Classifications were compared with information not yet included in the likelihood model, and evidence strengths aligned to those recommended for ACMG/AMP classification codes. Altered mRNA splicing or function relative to known nonpathogenic variant controls were moderately to strongly predictive of variant pathogenicity. Variant absence in population datasets provided supporting evidence for variant pathogenicity. These findings have direct relevance for BRCA1 and BRCA2 variant evaluation, and justify the need for gene-specific calibration of evidence types used for variant classification.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Interplay between BRCA1 and RHAMM Regulates Epithelial Apicobasal Polarization and May Influence Risk of Breast Cancer.

  • Maxwell, Christopher A.
  • Gomez-Baldó, Laia
  • Bonifaci Cano, Núria
  • Guinó, Elisabet
  • Català, Isabel
  • Petit, Anna
  • Aguilar, Helena
  • Villanueva Garatachea, Alberto
  • Aytés Meneses, Álvaro
  • Serra-Musach, Jordi
  • Aiza, Gemma
  • Brunet, Joan
  • Castellsagué, Joan
  • Martrat Sànchez, Griselda
  • Urruticoechea Ribate, Ander
  • Blanco Guillermo, Ignacio
  • Lázaro García, Conxi
  • Capellá, G. (Gabriel)
  • Genestar, Miquel Àngel
  • Moreno Aguado, Víctor
Differentiated mammary epithelium shows apicobasal polarity, and loss of tissue organization is an early hallmark of breast carcinogenesis. In BRCA1 mutation carriers, accumulation of stem and progenitor cells in normal breast tissue and increased risk of developing tumors of basal-like type suggest that BRCA1 regulates stem/progenitor cell proliferation and differentiation. However, the function of BRCA1 in this process and its link to carcinogenesis remain unknown. Here we depict a molecular mechanism involving BRCA1 and RHAMM that regulates apicobasal polarity and, when perturbed, may increase risk of breast cancer. Starting from complementary genetic analyses across families and populations, we identified common genetic variation at the low-penetrance susceptibility HMMR locus (encoding for RHAMM) that modifies breast cancer risk among BRCA1, but probably not BRCA2, mutation carriers: n = 7,584, weighted hazard ratio (wHR) = 1.09 (95% CI 1.02-1.16), ptrend = 0.017; and n = 3,965, wHR = 1.04 (95% CI 0.94-1.16), ptrend = 0.43; respectively. Subsequently, studies of MCF10A apicobasal polarization revealed a central role for BRCA1 and RHAMM, together with AURKA and TPX2, in essential reorganization of microtubules. Mechanistically, reorganization is facilitated by BRCA1 and impaired by AURKA, which is regulated by negative feedback involving RHAMM and TPX2. Taken together, our data provide fundamental insight into apicobasal polarization through BRCA1 function, which may explain the expanded cell subsets and characteristic tumor type accompanying BRCA1 mutation, while also linking this process to sporadic breast cancer through perturbation of HMMR/RHAMM.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers

  • Lázaro García, Conxi
  • Blanco Guillermo, Ignacio
  • Tornero, Eva
  • Navarro, Matilde
  • CIMBA Consortium
Germline mutations in BRCA1 and BRCA2 are associated with increased risks of breast and ovarian cancer. A genome-wide association study (GWAS) identified six alleles associated with risk of ovarian cancer for women in the general population. We evaluated four of these loci as potential modifiers of ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. Four single-nucleotide polymorphisms (SNPs), rs10088218 (at 8q24), rs2665390 (at 3q25), rs717852 (at 2q31), and rs9303542 (at 17q21), were genotyped in 12,599 BRCA1 and 7,132 BRCA2 carriers, including 2,678 ovarian cancer cases. Associations were evaluated within a retrospective cohort approach. All four loci were associated with ovarian cancer risk in BRCA2 carriers; rs10088218 per-allele hazard ratio (HR) = 0.81 (95% CI: 0.67-0.98) P-trend = 0.033, rs2665390 HR = 1.48 (95% CI: 1.21-1.83) P-trend = 1.8 x 10(-4), rs717852 HR = 1.25 (95% CI: 1.10-1.42) P-trend = 6.6 x 10(-4), rs9303542 HR = 1.16 (95% CI: 1.02-1.33) P-trend = 0.026. Two loci were associated with ovarian cancer risk in BRCA1 carriers; rs10088218 per-allele HR = 0.89 (95% CI: 0.81-0.99) P-trend = 0.029, rs2665390 HR = 1.25 (95% CI: 1.10-1.42) P-trend = 6.1 x 10(-4). The HR estimates for the remaining loci were consistent with odds ratio estimates for the general population. The identification of multiple loci modifying ovarian cancer risk may be useful for counseling women with BRCA1 and BRCA2 mutations regarding their risk of ovarian cancer.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer

  • Couch, Fergus J.
  • Kuchenbaecker, Karoline B.
  • Michailidou, Kyriaki
  • Mendoza-Fandino, Gustavo A.
  • Nord, Silje
  • Lilyquist, Jenna
  • Olswold, Curtis
  • Hallberg, Emily
  • Agata, Simona
  • Ahsan, Habibul
  • Aittomäki, Kristiina
  • Flesch-Janys, Dieter
  • Carpenter, Jane
  • Tomlinson, Ian P.
  • James, Paul
  • Tollenaar, Raem
  • Swerdlow, Anthony J.
  • Bojesen, Stig E.
  • McGuffog, Lesley
  • Miron, Penelope
  • Truong, Thérèse
  • Toland, Amanda E.
  • Henderson, Brian E.
  • Hollestelle, Antoinette
  • Knight, Julia A.
  • Cox, Angela
  • Burwinkel, Barbara
  • Yang, Xiaohong R
  • Yannoukakos, Drakoulis
  • Varon-Mateeva, Raymonda
  • Lázaro García, Conxi
  • Hooning, Maartje J.
  • Rutgers, Emiel J.
  • Domchek, Susan M.
  • Wang-Gohrke, Shan
  • Lambrechts, Diether
  • Wang, Zhaoming
  • Tsimiklis, Helen
  • Daly, Mary B.
  • Arver, Brita
  • Olah, Edith
  • Sawyer, Elinor J.
  • Khaw, Kay-Tee
  • Long, Jirong
  • Eccles, Diana
  • Díez Gibert, Orland
  • Chenevix-Trench, Georgia
  • Pharoah, Paul D. P.
  • Yao, Song
  • Margolin, Sara
  • Kibriya, Muhammad G.
  • Zheng, Wei
  • Manoukian, Siranoush
  • Zamora, M. Pilar
  • Blank, Stephanie V.
  • Ambrosone, Christine
  • Chang-Claude, Jenny
  • Phelan, Catherine M.
  • Szabo, Csilla I.
  • Barrowdale, Daniel
  • Frost, Debra
  • Bolla, Manjeet K.
  • Bonanni, Bernardo
  • Hunter, David J.
  • Nathanson, Katherine L.
  • Liu, Jianjun
  • García Closas, Montserrat
  • Muranen, Taru A.
  • Monteiro, Alvaro N.
  • Buys, Saundra S.
  • Dorfling, Cecilia M.
  • Teulé-Vega, Àlex
  • Claes, Kathleen B. M.
  • Glendon, Gord
  • Damiola, Francesca
  • Darabi, Hatef
  • Kosma, Veli-Matti
  • Park, Sue K.
  • Brenner, Hermann
  • Osorio, Ana
  • Brauch, Hiltrud
  • Rudolph, Anja
  • Weitzel, Jeffrey N.
  • Dunning, Alison M.
  • Haeberle, Lothar
  • Eliassen, Heather
  • Ellis, Steve
  • Pylkäs, Katri
  • Devilee, Peter
  • Poppe, Bruce
  • Hoya, Miguel de la
  • Blomqvist, Carl
  • Jakubowska, Anna
  • Herzog, Josef
  • Ganz, Patricia A.
  • Gapstur, Susan M.
  • Figueroa, Jonine D.
  • Scott, Rodney J.
  • Fasching, Peter A.
  • Cunningham, Julie M.
  • Arun, Banu K.
  • Ko, Yon-Dschun
  • Fostira, Florentia
  • Schmutzler, Rita Katharina
  • Försti, Asta
  • Santos-Silva, Isabel dos
  • John, Esther M.
  • van Rensburg, Elizabeth J.
  • Weiderpass, Elisabete
  • Foulkes, William D.
  • Barkardottir, Rosa B.
  • Robson, Mark
  • Steinemann, Doris
  • Laitman, Yael
  • Khan, Sofia
  • Goldgar, David E.
  • González Neira, Anna
  • Gaudet, Mia M.
  • Teo, Soo-Hwang
  • Romieu, Isabelle
  • Lubinski, Jan
  • Gerdes, Anne-Marie
  • Teixeira, Manuel R.
  • Gayther, Simon A.
  • Friebel, Tara M.
  • Lee, Eunjung
  • Humphreys, Keith
  • Hall, Peter
  • Chung, Wendy K.
  • Beckmann, Matthias W.
  • Mannermaa, Arto
  • Lindström, Sara
  • Hansen, Thomas V. O.
  • Hart, Steven
  • Greene, Mark H.
  • Turnbull, Clare
  • Southey, Melissa C.
  • Guénel, Pascal
  • Tung, Nadine
  • Gronwald, Jacek
  • Hogervorst, Frans B. L.
  • Konstantopoulou, Irene
  • Easton, Douglas F.
  • Dumont, Martine
  • Imyanitov, Evgeny N.
  • Mulligan, Anna Marie
  • Jones, Michael
  • Kabisch, Maria
  • Santella, Regina M.
  • Winqvist, Robert
  • Heikkinen, Tuomas
  • Wildiers, Hans
  • Healey, Sue
  • Andrulis, Irene L.
  • Arndt, Volker
  • Friedman, Eitan
  • Kwong, Ava
  • Olson, Janet E.
  • Marchand, Loïc Le
  • Lester, Jenny
  • Slager, Susan L.
  • Karlan, Beth Y.
  • Vachon, Celine M.
  • Kar, Siddhartha P.
  • Canzian, Federico
  • Giles, Graham G.
  • Malone, Kathleen E.
  • Pilarski, Robert
  • Marmé, Frederik
  • Martens, John W. M.
  • Lindor, Noralane
  • Bogdanova, Natalia V.
  • Lindblom, Annika
  • Janavicius, Ramunas
  • Schmidt, Marjanka K.
  • Rennert, Gad
  • Neuhausen, Susan L.
  • Nevanlinna, Heli
  • Meindl, Alfons
  • Czene, Kamila
  • Anton-Culver, Hoda
  • Hopper, John L.
  • Stenmark-Askmalm, Marie
  • Milne, Roger L.
  • Cross, Simon S.
  • Miller, Austin
  • Mai, Phuong L.
  • Senter, Leigha
  • Garber, Judy
  • Ghoussaini, Maya
  • Huzarski, Tomasz
  • Caldes, Trinidad
  • Dolcetti, Riccardo
  • Tapper, William
  • Soucy, Penny
  • Peeters, Petra H. M.
  • Peissel, Bernard
  • Nordestgaard, Børge G.
  • Ekici, Arif B.
  • Caligo, Maria A.
  • Offit, Kenneth
  • Ehrencrona, Hans
  • Nussbaum, Robert L.
  • Montagna, Marco
  • Beckmann, Lars
  • Sánchez, María José
  • Gunter, Marc J.
  • Kristensen, Vessela N.
  • Isaacs, Claudine
  • Tumino, Rosario
  • Radice, Paolo
  • Rahman, Nazneen
  • Barile, Monica
  • Gammon, Marilie D.
  • Ding, Yuan C.
  • Peto, Julian
  • Gabrielson, Marike
  • Peterlongo, Paolo
  • Richardson, Andrea
  • Stoppa-Lyonnet, Dominique
  • Makalic, Enes
  • Schmidt, Daniel F.
  • Whittemore, Alice
  • Sharma, Priyanka
  • Simard, Jacques
  • Chanock, Stephen J.
  • Goldberg, Mark S.
  • Rappaport-Fuerhauser, Christine
  • Godwin, Andrew K.
  • Rantala, Johanna
  • Hoover, Robert N.
  • Mazoyer, Sylvie
  • Tamimi, Rulla
  • Kraft, Peter
  • Terry, Mary Beth
  • Thomassen, Mads
  • Hamann, Ute
  • Sinilnikova, Olga M.
  • Haiman, Christopher A.
  • Singer, Christian F.
  • Olopade, Olufunmilayo I.
  • Benitez, Javier
  • Antoniou, Antonis C.
  • Ursin, Giski
  • Van Deurzen, Carolien H. M.
  • Tihomirova, Laima
  • Jensen, Uffe Birk
  • Thompson, Deborah J.
  • Schumacher, Fredrick
Common variants in 94 loci have been associated with breast cancer including 15 loci with genome-wide significant associations (P<5 x 10(-8)) with oestrogen receptor (ER)-negative breast cancer and BRCA1-associated breast cancer risk. In this study, to identify new ER-negative susceptibility loci, we performed a meta-analysis of 11 genome-wide association studies (GWAS) consisting of 4,939 ER-negative cases and 14,352 controls, combined with 7,333 ER-negative cases and 42,468 controls and 15,252 BRCA1 mutation carriers genotyped on the iCOGS array. We identify four previously unidentified loci including two loci at 13q22 near KLF5, a 2p23.2 locus near WDR43 and a 2q33 locus near PPIL3 that display genome-wide significant associations with ER-negative breast cancer. In addition, 19 known breast cancer risk loci have genome-wide significant associations and 40 had moderate associations (P<0.05) with ER-negative disease. Using functional and eQTL studies we implicate TRMT61B and WDR43 at 2p23.2 and PPIL3 at 2q33 in ER-negative breast cancer aetiology. All ER-negative loci combined account for similar to 11% of familial relative risk for ER-negative disease and may contribute to improved ER-negative and BRCA1 breast cancer risk prediction.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Germline variation at 8q24 and prostate cancer risk in men of European ancestry

  • Matejcic, Marco
  • Kogevinas, Manolis
  • Haiman, Christopher A.
Chromosome 8q24 is a susceptibility locus for multiple cancers, including prostate cancer. Here we combine genetic data across the 8q24 susceptibility region from 71,535 prostate cancer cases and 52,935 controls of European ancestry to define the overall contribution of germline variation at 8q24 to prostate cancer risk. We identify 12 independent risk signals for prostate cancer (p < 4.28 × 10-15), including three risk variants that have yet to be reported. From a polygenic risk score (PRS) model, derived to assess the cumulative effect of risk variants at 8q24, men in the top 1% of the PRS have a 4-fold (95%CI = 3.62-4.40) greater risk compared to the population average. These 12 variants account for ~25% of what can be currently explained of the familial risk of prostate cancer by known genetic risk factors. These findings highlight the overwhelming contribution of germline variation at 8q24 on prostate cancer risk which has implications for population risk stratification., Genotyping of the OncoArray was funded by the US National Institutes of Health (NIH) [U19 CA 148537 for ELucidating Loci Involved in Prostate Cancer SuscEptibility (ELLIPSE) project and X01HG007492 to the Center for Inherited Disease Research (CIDR) under contract number HHSN268201200008I]. Additional analytic support was provided by NIH NCI U01 CA188392 (PI: Schumacher). The PRACTICAL consortium (http://practical.icr.ac.uk/) was supported by Cancer Research UK Grants C5047/A7357, C1287/A10118, C1287/A16563, C5047/A3354, C5047/A10692, C16913/A6135, European Commission's Seventh Framework Programme grant agreement n° 223175 (HEALTH-F2-2009-223175), and The National Institute of Health (NIH) Cancer Post-Cancer GWAS initiative grant: No. 1 U19 CA 148537-01 (the GAME-ON initiative). We wish to thank all GWAS study groups contributing to the data set from which this study was conducted: OncoArray; iCOGS; The PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium; and The GAME-ON/ELLIPSE Consortium. Detailed acknowledgements and funding information for all GWAS study groups and from all the individual studies involved in the PRACTICAL Consortium are included in Supplementary Note 1. We would also like to thank the following for funding support: The Institute of Cancer Research and The Everyman Campaign, The Prostate Cancer Research Foundation, Prostate Research Campaign UK (now Prostate Action), The Orchid Cancer Appeal, The National Cancer Research Network UK, The National Cancer Research Institute (NCRI) UK. We are grateful for support of NIHR funding to the NIHR Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Germline variation at 8q24 and prostate cancer risk in men of European ancestry

  • Matejcic, Marco
  • Sanders, Edward J.
  • Mengual Brichs, Lourdes
  • PRACTICAL Consortium
Chromosome 8q24 is a susceptibility locus for multiple cancers, including prostate cancer. Here we combine genetic data across the 8q24 susceptibility region from 71,535 prostate cancer cases and 52,935 controls of European ancestry to define the overall contribution of germline variation at 8q24 to prostate cancer risk. We identify 12 independent risk signals for prostate cancer (p < 4.28 × 10-15), including three risk variants that have yet to be reported. From a polygenic risk score (PRS) model, derived to assess the cumulative effect of risk variants at 8q24, men in the top 1% of the PRS have a 4-fold (95%CI = 3.62-4.40) greater risk compared to the population average. These 12 variants account for ~25% of what can be currently explained of the familial risk of prostate cancer by known genetic risk factors. These findings highlight the overwhelming contribution of germline variation at 8q24 on prostate cancer risk which has implications for population risk stratification.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2

  • Pujana Genestar, M. Ángel
  • KConFab Investigators
  • Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON)
  • Epidemiological study of BRCA1 & BRCA2 Mutation Carriers (EMBRACE)
Background: BRCA1 and, more commonly, BRCA2 mutations are associated with increased risk of male breast cancer (MBC). However, only a paucity of data exists on the pathology of breast cancers (BCs) in men with BRCA1/2 mutations. Using the largest available dataset, we determined whether MBCs arising in BRCA1/2 mutation carriers display specific pathologic features and whether these features differ from those of BRCA1/2 female BCs (FBCs). Methods: We characterised the pathologic features of 419 BRCA1/2 MBCs and, using logistic regression analysis, contrasted those with data from 9675 BRCA1/2 FBCs and with population-based data from 6351 MBCs in the Surveillance, Epidemiology, and End Results (SEER) database. Results: Among BRCA2 MBCs, grade significantly decreased with increasing age at diagnosis (P = 0.005). Compared with BRCA2 FBCs, BRCA2 MBCs were of significantly higher stage (P for trend = 2 x 10(-5)) and higher grade (P for trend = 0.005) and were more likely to be oestrogen receptor-positive [odds ratio (OR) 10.59; 95 % confidence interval (CI) 5.15-21.80] and progesterone receptor-positive (OR 5.04; 95 % CI 3.17-8.04). With the exception of grade, similar patterns of associations emerged when we compared BRCA1 MBCs and FBCs. BRCA2 MBCs also presented with higher grade than MBCs from the SEER database (P for trend = 4 x 10(-12)). Conclusions: On the basis of the largest series analysed to date, our results show that BRCA1/2 MBCs display distinct pathologic characteristics compared with BRCA1/2 FBCs, and we identified a specific BRCA2-associated MBC phenotype characterised by a variable suggesting greater biological aggressiveness (i.e., high histologic grade). These findings could lead to the development of gender-specific risk prediction models and guide clinical strategies appropriate for MBC management.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers

  • Menéndez Vilà, Mireia
  • Lázaro García, Conxi
  • Blanco Guillermo, Ignacio
Single Nucleotide Polymorphisms (SNPs) in genes involved in the DNA Base Excision Repair (BER) pathway could be associated with cancer risk in carriers of mutations in the high-penetrance susceptibility genes BRCA1 and BRCA2, given the relation of synthetic lethality that exists between one of the components of the BER pathway, PARP1 (poly ADP ribose polymerase), and both BRCA1 and BRCA2. In the present study, we have performed a comprehensive analysis of 18 genes involved in BER using a tagging SNP approach in a large series of BRCA1 and BRCA2 mutation carriers. 144 SNPs were analyzed in a two stage study involving 23,463 carriers from the CIMBA consortium (the Consortium of Investigators of Modifiers of BRCA1 and BRCA2). Eleven SNPs showed evidence of association with breast and/or ovarian cancer at p<0.05 in the combined analysis. Four of the five genes for which strongest evidence of association was observed were DNA glycosylases. The strongest evidence was for rs1466785 in the NEIL2 (endonuclease VIII-like 2) gene (HR: 1.09, 95% CI (1.03-1.16), p = 2.7x10(-3)) for association with breast cancer risk in BRCA2 mutation carriers, and rs2304277 in the OGG1 (8-guanine DNA glycosylase) gene, with ovarian cancer risk in BRCA1 mutation carriers (HR: 1.12 95% CI: 1.03-1.21, p = 4.8x10(-3)). DNA glycosylases involved in the first steps of the BER pathway may be associated with cancer risk in BRCA1/2 mutation carriers and should be more comprehensively studied.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast–ovarian cancer susceptibility locus

  • Feliubadaló i Elorza, Maria Lídia
  • Genetic Modifiers of Cancer Risk in BRCA1/2 Mutation Carriers (GEMO)
  • Epidemiological study of BRCA1 & BRCA2 Mutation Carriers (EMBRACE)
  • Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON)
  • KConFab Investigators
  • Australian Ovarian Cancer Study Group
A locus at 19p13 is associated with breast cancer (BC) and ovarian cancer (OC) risk. Here we analyse 438 SNPs in this region in 46,451 BC and 15,438 OC cases, 15,252 BRCA1 mutation carriers and 73,444 controls and identify 13 candidate causal SNPs associated with serous OC (P = 9.2 x 10(-20)), ER-negative BC (P = 1.1 x 10(-13)), BRCA1-associated BC (P = 7.7 x 10(-16)) and triple negative BC (P-diff = 2 x 10(-5)). Genotype-gene expression associations are identified for candidate target genes ANKLE1 (P = 2 x 10(-3)) and ABHD8 (P<2 x 10(-3)). Chromosome conformation capture identifies interactions between four candidate SNPs and ABHD8, and luciferase assays indicate six risk alleles increased transactivation of the ADHD8 promoter. Targeted deletion of a region containing risk SNP rs56069439 in a putative enhancer induces ANKLE1 downregulation; and mRNA stability assays indicate functional effects for an ANKLE1 30-UTR SNP. Altogether, these data suggest that multiple SNPs at 19p13 regulate ABHD8 and perhaps ANKLE1 expression, and indicate common mechanisms underlying breast and ovarian cancer risk.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer

  • Blanco Guillermo, Ignacio
  • Australian Cancer Study
  • Australian Ovarian Cancer Study Group
  • GENICA (Gene Environment Interaction and Breast Cancer)
  • SWE-BRCA Group
  • HEBON Investigators
  • EMBRACE Collaborators
  • GEMO Study Collaborators
TERT-locus SNPs and leukocyte telomere measures are reportedly associated with risks of multiple cancers. Using the Illumina custom genotyping array iCOGs, we analyzed ~480 SNPs at the TERT locus in breast (n = 103,991), ovarian (n = 39,774) and BRCA1 mutation carrier (n = 11,705) cancer cases and controls. Leukocyte telomere measurements were also available for 53,724 participants. Most associations cluster into three independent peaks. The minor allele at the peak 1 SNP rs2736108 associates with longer telomeres (P = 5.8 × 10−7), lower risks for estrogen receptor (ER)-negative (P = 1.0 × 10−8) and BRCA1 mutation carrier (P = 1.1 × 10−5) breast cancers and altered promoter assay signal. The minor allele at the peak 2 SNP rs7705526 associates with longer telomeres (P = 2.3 × 10−14), higher risk of low-malignant-potential ovarian cancer (P = 1.3 × 10−15) and greater promoter activity. The minor alleles at the peak 3 SNPs rs10069690 and rs2242652 increase ER-negative (P = 1.2 × 10−12) and BRCA1 mutation carrier (P = 1.6 × 10−14) breast and invasive ovarian (P = 1.3 × 10−11) cancer risks but not via altered telomere length. The cancer risk alleles of rs2242652 and rs10069690, respectively, increase silencing and generate a truncated TERT splice variant.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations

  • Feliubadaló i Elorza, Maria Lídia
  • Teulé-Vega, Àlex
  • CIMBA Consortium
The prevalence and spectrum of germline mutations in BRCA1 and BRCA2 have been reported in single populations, with the majority of reports focused on White in Europe and North America. The Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) has assembled data on 18,435 families with BRCA1 mutations and 11,351 families with BRCA2 mutations ascertained from 69 centers in 49 countries on six continents. This study comprehensively describes the characteristics of the 1,650 unique BRCA1 and 1,731 unique BRCA2 deleterious (disease-associated) mutations identified in the CIMBA database. We observed substantial variation in mutation type and frequency by geographical region and race/ethnicity. In addition to known founder mutations, mutations of relatively high frequency were identified in specific racial/ethnic or geographic groups that may reflect founder mutations and which could be used in targeted (panel) first pass genotyping for specific populations. Knowledge of the population-specific mutational spectrum in BRCA1 and BRCA2 could inform efficient strategies for genetic testing and may justify a more broad-based oncogenetic testing in some populations.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers

  • Coignard, Juliette
  • Beesley, Jonathan
  • O'Mara, Tracy A.
  • Diez Gibert, Orland
  • Lopez-Fernandez, Adrià
  • Dennis, Joe
  • Tyrer, Jonathan
  • Lush, Michael
Càncer de mama; Genètica del càncer; Factors de risc, Cáncer de mama; Genética del cáncer; Factores de riesgo, Breast cancer; Cancer genetics; Risk factors, Breast cancer (BC) risk for BRCA1 and BRCA2 mutation carriers varies by genetic and familial factors. About 50 common variants have been shown to modify BC risk for mutation carriers. All but three, were identified in general population studies. Other mutation carrier-specific susceptibility variants may exist but studies of mutation carriers have so far been underpowered. We conduct a novel case-only genome-wide association study comparing genotype frequencies between 60,212 general population BC cases and 13,007 cases with BRCA1 or BRCA2 mutations. We identify robust novel associations for 2 variants with BC for BRCA1 and 3 for BRCA2 mutation carriers, P < 10−8, at 5 loci, which are not associated with risk in the general population. They include rs60882887 at 11p11.2 where MADD, SP11 and EIF1, genes previously implicated in BC biology, are predicted as potential targets. These findings will contribute towards customising BC polygenic risk scores for BRCA1 and BRCA2 mutation carriers.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Telomere length shows no association with BRCA1 and BRCA2 mutation status

  • Killick, Emma
  • Tymrakiewicz, Malgorzata
  • Cieza-Borrella, Clara
  • Smith, Paula
  • Thompson, Deborah J.
  • Pooley, Karen A.
  • Easton, Douglas F.
  • Bancroft, Elizabeth K.
  • Page, Elizabeth
  • Leongamornlert, Daniel
  • IMPACT Study Collaborators
  • Kote-Jarai, Zsofia
  • Eeles, Rosalind A.
  • Blanco Guillermo, Ignacio
  • Salinas Masdeu, Mònica
This study aimed to determine whether telomere length (TL) is a marker of cancer risk or genetic status amongst two cohorts of BRCA1 and BRCA2 mutation carriers and controls. The first group was a prospective set of 665 male BRCA1/2 mutation carriers and controls (mean age 53 years), all healthy at time of enrolment and blood donation, 21 of whom have developed prostate cancer whilst on study. The second group consisted of 283 female BRCA1/2 mutation carriers and controls (mean age 48 years), half of whom had been diagnosed with breast cancer prior to enrolment. TL was quantified by qPCR from DNA extracted from peripheral blood lymphocytes. Weighted and unweighted Cox regressions and linear regression analyses were used to assess whether TL was associated with BRCA1/2 mutation status or cancer risk. We found no evidence for association between developing cancer or being a BRCA1 or BRCA2 mutation carrier and telomere length. It is the first study investigating TL in a cohort of genetically predisposed males and although TL and BRCA status was previously studied in females our results don't support the previous finding of association between hereditary breast cancer and shorter TL.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus

  • Lázaro García, Conxi
  • Teulé-Vega, Àlex
  • Epidemiological study of BRCA1 & BRCA2 Mutation Carriers (EMBRACE)
  • Genetic Modifiers of Cancer Risk in BRCA1/2 Mutation Carriers (GEMO)
  • Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON)
  • KConFab Investigators
  • AOCS Investigators
Background: Multiple recent genome-wide association studies (GWAS) have identified a single nucleotide polymorphism (SNP), rs10771399, at 12p11 that is associated with breast cancer risk. Method: We performed a fine-scale mapping study of a 700 kb region including 441 genotyped and more than 1300 imputed genetic variants in 48,155 cases and 43,612 controls of European descent, 6269 cases and 6624 controls of East Asian descent and 1116 cases and 932 controls of African descent in the Breast Cancer Association Consortium (BCAC; http://bcac.ccge.medschl.cam.ac.uk/), and in 15,252 BRCA1 mutation carriers in the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Stepwise regression analyses were performed to identify independent association signals. Data from the Encyclopedia of DNA Elements project (ENCODE) and the Cancer Genome Atlas (TCGA) were used for functional annotation. Results: Analysis of data from European descendants found evidence for four independent association signals at 12p11, represented by rs7297051 (odds ratio (OR) = 1.09, 95 % confidence interval (CI) = 1.06-1.12; P = 3 x 10(-9)), rs805510 (OR = 1.08, 95 % CI = 1.04-1.12, P = 2 x 10(-5)), and rs1871152 (OR = 1.04, 95 % CI = 1.02-1.06; P = 2 x 10(-4)) identified in the general populations, and rs113824616 (P = 7 x 10(-5)) identified in the meta-analysis of BCAC ER-negative cases and BRCA1 mutation carriers. SNPs rs7297051, rs805510 and rs113824616 were also associated with breast cancer risk at P < 0.05 in East Asians, but none of the associations were statistically significant in African descendants. Multiple candidate functional variants are located in putative enhancer sequences. Chromatin interaction data suggested that PTHLH was the likely target gene of these enhancers. Of the six variants with the strongest evidence of potential functionality, rs11049453 was statistically significantly associated with the expression of PTHLH and its nearby gene CCDC91 at P < 0.05. Conclusion: This study identified four independent association signals at 12p11 and revealed potentially functional variants, providing additional insights into the underlying biological mechanism(s) for the association observed between variants at 12p11 and breast cancer risk.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers

  • Pujana Genestar, M. Ángel
  • Teulé-Vega, Àlex
  • GEMO Study Collaborators
  • EMBRACE Collaborators
  • KConFab Investigators
  • HEBON Investigators
  • ABCTB Investigators
Breast cancer (BC) risk for BRCA1 and BRCA2 mutation carriers varies by genetic and familial factors. About 50 common variants have been shown to modify BC risk for mutation carriers. All but three, were identified in general population studies. Other mutation carrier-specific susceptibility variants may exist but studies of mutation carriers have so far been underpowered. We conduct a novel case-only genome-wide association study comparing genotype frequencies between 60,212 general population BC cases and 13,007 cases with BRCA1 or BRCA2 mutations. We identify robust novel associations for 2 variants with BC for BRCA1 and 3 for BRCA2 mutation carriers, P < 10-8, at 5 loci, which are not associated with risk in the general population. They include rs60882887 at 11p11.2 where MADD, SP11 and EIF1, genes previously implicated in BC biology, are predicted as potential targets. These findings will contribute towards customising BC polygenic risk scores for BRCA1 and BRCA2 mutation carriers.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Identification of six new susceptibility loci for invasive epithelial ovarian cancer

  • Kuchenbaecker, Karoline B.
  • Ramus, Susan J.
  • Tyrer, Jonathan P.
  • Lee, Andrew
  • Shen, Howard C.
  • Beesley, Jonathan
  • Lawrenson, Kate
  • McGuffog, Lesley
  • Healey, Sue
  • Lee, Janet M.
  • Spindler, Tassja J.
  • Lin, Yvonne G.
  • Pejovic, Tanja
  • Bean, Yukie
  • Li, Qiyuan
  • Coetzee, Simon
  • Hazelett, Dennis
  • Miron, Alexander
  • Southey, Melissa C.
  • Terry, Mary Beth
  • Goldgar, David E.
  • Buys, Saundra S.
  • Janavicius, Ramunas
  • Dorfling, Cecilia M.
  • van Rensburg, Elizabeth J.
  • Neuhausen, Susan L.
  • Ding, Yuan Chun
  • Hansen, Thomas V. O.
  • Jønson, Lars
  • Gerdes, Anne Marie
  • Ejlertsen, Bent
  • Barrowdale, Daniel
  • Dennis, Joe
  • Benitez, Javier
  • Osorio, Ana
  • Garcia, Maria Jose
  • Komenaka, Ian
  • Blanco Guillermo, Ignacio
  • Lázaro García, Conxi
  • Pujana Genestar, M. Ángel
Genome-wide association studies (GWAS) have identified 12 epithelial ovarian cancer (EOC) susceptibility alleles. The pattern of association at these loci is consistent in BRCA1 and BRCA2 mutation carriers who are at high risk of EOC. After imputation to 1000 Genomes Project data, we assessed associations of 11 million genetic variants with EOC risk from 15,437 cases unselected for family history and 30,845 controls and from 15,252 BRCA1 mutation carriers and 8,211 BRCA2 mutation carriers (3,096 with ovarian cancer), and we combined the results in a meta-analysis. This new study design yielded increased statistical power, leading to the discovery of six new EOC susceptibility loci. Variants at 1p36 (nearest gene, WNT4), 4q26 (SYNPO2), 9q34.2 (ABO) and 17q11.2 (ATAD5) were associated with EOC risk, and at 1p34.3 (RSPO1) and 6p22.1 (GPX6) variants were specifically associated with the serous EOC subtype, all with P < 5 × 10(-8). Incorporating these variants into risk assessment tools will improve clinical risk predictions for BRCA1 and BRCA2 mutation carriers.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk

  • Couch, Fergus J.
  • Wang, Xianshu
  • McGuffog, Lesley
  • Lee, Andrew
  • Olswold, Curtis
  • Kuchenbaecker, Karoline B.
  • Soucy, Penny
  • Fredericksen, Zachary
  • Barrowdale, Daniel
  • Dennis, Joe
  • Gaudet, Mia M.
  • Dicks, Ed
  • Kosel, Matthew
  • Healey, Sue
  • Sinilnikova, Olga M.
  • Bacot, François
  • Vincent, Daniel
  • Hogervorst, Frans B. L.
  • Peock, Susan
  • Stoppa-Lyonnet, Dominique
  • Jakubowska, Anna
  • Radice, Paolo
  • Schmutzler, Rita Katharina
  • Domchek, Susan M.
  • Piedmonte, Marion
  • Singer, Christian F.
  • Friedman, Eitan
  • Thomassen, Mads
  • Hansen, Thomas V. O.
  • Neuhausen, Susan L.
  • Szabo, Csilla I.
  • Blanco Guillermo, Ignacio
  • Greene, Mark H.
  • Karlan, Beth Y.
  • Garber, Judy
  • Phelan, Catherine M.
  • Weitzel, Jeffrey N.
  • Montagna, Marco
  • Olah, Edith
BRCA1-associated breast and ovarian cancer risks can be modified by common genetic variants. To identify further cancer risk-modifying loci, we performed a multi-stage GWAS of 11,705 BRCA1 carriers (of whom 5,920 were diagnosed with breast and 1,839 were diagnosed with ovarian cancer), with a further replication in an additional sample of 2,646 BRCA1 carriers. We identified a novel breast cancer risk modifier locus at 1q32 for BRCA1 carriers (rs2290854, P = 2.7×10−8, HR = 1.14, 95% CI: 1.09-1.20). In addition, we identified two novel ovarian cancer risk modifier loci: 17q21.31 (rs17631303, P = 1.4×10−8, HR = 1.27, 95% CI: 1.17-1.38) and 4q32.3 (rs4691139, P = 3.4×10−8, HR = 1.20, 95% CI: 1.17-1.38). The 4q32.3 locus was not associated with ovarian cancer risk in the general population or BRCA2 carriers, suggesting a BRCA1-specific association. The 17q21.31 locus was also associated with ovarian cancer risk in 8,211 BRCA2 carriers (P = 2×10−4). These loci may lead to an improved understanding of the etiology of breast and ovarian tumors in BRCA1 carriers. Based on the joint distribution of the known BRCA1 breast cancer risk-modifying loci, we estimated that the breast cancer lifetime risks for the 5% of BRCA1 carriers at lowest risk are 28%-50% compared to 81%-100% for the 5% at highest risk. Similarly, based on the known ovarian cancer risk-modifying loci, the 5% of BRCA1 carriers at lowest risk have an estimated lifetime risk of developing ovarian cancer of 28% or lower, whereas the 5% at highest risk will have a risk of 63% or higher. Such differences in risk may have important implications for risk prediction and clinical management for BRCA1 carriers.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Identification of a BRCA2-Specific modifier locus at 6p24 related to breast cancer risk

  • Gaudet, Mia M.
  • Kuchenbaecker, Karoline B.
  • Vijai, Joseph
  • Klein, Robert J.
  • Kirchhoff, Tomas
  • McGuffog, Lesley
  • Barrowdale, Daniel
  • Dunning, Alison M.
  • Lee, Andrew
  • Dennis, Joe
  • Healey, Sue
  • Dicks, Ed
  • Soucy, Penny
  • Sinilnikova, Olga M.
  • Pankratz, Vernon S.
  • Wang, Xianshu
  • Eldridge, Ronald C.
  • Tessier, Daniel C.
  • Vincent, Daniel
  • Bacot, François
  • Hogervorst, Frans B. L.
  • Peock, Susan
  • Stoppa-Lyonnet, Dominique
  • Peterlongo, Paolo
  • Schmutzler, Rita Katharina
  • Nathanson, Katherine L.
  • Piedmonte, Marion
  • Singer, Christian F.
  • Thomassen, Mads
  • Hansen, Thomas V. O.
  • Neuhausen, Susan L.
  • Blanco Guillermo, Ignacio
  • Lázaro García, Conxi
Common genetic variants contribute to the observed variation in breast cancer risk for BRCA2 mutation carriers; those known to date have all been found through population-based genome-wide association studies (GWAS). To comprehensively identify breast cancer risk modifying loci for BRCA2 mutation carriers, we conducted a deep replication of an ongoing GWAS discovery study. Using the ranked P-values of the breast cancer associations with the imputed genotype of 1.4 M SNPs, 19,029 SNPs were selected and designed for inclusion on a custom Illumina array that included a total of 211,155 SNPs as part of a multi-consortial project. DNA samples from 3,881 breast cancer affected and 4,330 unaffected BRCA2 mutation carriers from 47 studies belonging to the Consortium of Investigators of Modifiers of BRCA1/2 were genotyped and available for analysis. We replicated previously reported breast cancer susceptibility alleles in these BRCA2 mutation carriers and for several regions (including FGFR2, MAP3K1, CDKN2A/B, and PTHLH) identified SNPs that have stronger evidence of association than those previously published. We also identified a novel susceptibility allele at 6p24 that was inversely associated with risk in BRCA2 mutation carriers (rs9348512; per allele HR = 0.85, 95% CI 0.80-0.90, P = 3.9×10−8). This SNP was not associated with breast cancer risk either in the general population or in BRCA1 mutation carriers. The locus lies within a region containing TFAP2A, which encodes a transcriptional activation protein that interacts with several tumor suppressor genes. This report identifies the first breast cancer risk locus specific to a BRCA2 mutation background. This comprehensive update of novel and previously reported breast cancer susceptibility loci contributes to the establishment of a panel of SNPs that modify breast cancer risk in BRCA2 mutation carriers. This panel may have clinical utility for women with BRCA2 mutations weighing options for medical prevention of breast cancer.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers

  • Teulé-Vega, Àlex
  • Lázaro García, Conxi
  • Blanco Guillermo, Ignacio
  • Valle Domínguez, Jesús del
  • COGS (Collaborative Oncological Gene-environment Study)
  • CIMBA Consortium
  • EMBRACE Collaborators
  • HEBON Investigators
  • GEMO Study Collaborators
  • CONSIT Team (CONsorzio Studi ITaliani sui Tumori Ereditari Alla Mammella, Italy)
Introduction: Individuals carrying pathogenic mutations in the BRCA1 and BRCA2 genes have a high lifetime risk of breast cancer. BRCA1 and BRCA2 are involved in DNA double-strand break repair, DNA alterations that can be caused by exposure to reactive oxygen species, a main source of which are mitochondria. Mitochondrial genome variations affect electron transport chain efficiency and reactive oxygen species production. Individuals with different mitochondrial haplogroups differ in their metabolism and sensitivity to oxidative stress. Variability in mitochondrial genetic background can alter reactive oxygen species production, leading to cancer risk. In the present study, we tested the hypothesis that mitochondrial haplogroups modify breast cancer risk in BRCA1/2 mutation carriers. Methods: We genotyped 22,214 (11,421 affected, 10,793 unaffected) mutation carriers belonging to the Consortium of Investigators of Modifiers of BRCA1/2 for 129 mitochondrial polymorphisms using the iCOGS array. Haplogroup inference and association detection were performed using a phylogenetic approach. ALTree was applied to explore the reference mitochondrial evolutionary tree and detect subclades enriched in affected or unaffected individuals. Results: We discovered that subclade T1a1 was depleted in affected BRCA2 mutation carriers compared with the rest of clade T (hazard ratio (HR) = 0.55; 95% confidence interval (CI), 0.34 to 0.88; P = 0.01). Compared with the most frequent haplogroup in the general population (that is, H and T clades), the T1a1 haplogroup has a HR of 0.62 (95% CI, 0.40 to 0.95; P = 0.03). We also identified three potential susceptibility loci, including G13708A/rs28359178, which has demonstrated an inverse association with familial breast cancer risk. Conclusions: This study illustrates how original approaches such as the phylogeny-based method we used can empower classical molecular epidemiological studies aimed at identifying association or risk modification effects.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women

  • Rebbeck, Timothy R.
  • Friebel, Tara M.
  • Mitra, Nandita
  • Wan, Fei
  • Chen, Stephanie
  • Andrulis, Irene L.
  • Apostolou, Paraskevi
  • Arnold, Norbert
  • Arun, Banu K.
  • Barrowdale, Daniel
  • Benitez, Javier
  • Ramus, Susan J.
  • Berger, Raanan
  • Berthet, Pascaline
  • Borg, Åke
  • Buys, Saundra S.
  • Caldes, Trinidad
  • Carter, Jonathan
  • Chiquette, Jocelyne
  • Claes, Kathleen B. M.
  • Couch, Fergus J.
  • Cybulski, Cezary
  • Daly, Mary B.
  • Hoya, Miguel de la
  • Díez Gibert, Orland
  • Domchek, Susan M.
  • Nathanson, Katherine L.
  • Durda, Katarzyna
  • Ellis, Steve
  • Evans, D. Gareth
  • EMBRACE Collaborators
  • Foretova, Lenka
  • Friedman, Eitan
  • Frost, Debra
  • Ganz, Patricia A.
  • HEBON Investigators
  • Garber, Judy
  • Glendon, Gord
  • Godwin, Andrew K.
  • Greene, Mark H.
  • KConFab Investigators
  • Gronwald, Jacek
  • Hahnen, Eric
  • Hallberg, Emily
  • Hamann, Ute
  • Hansen, Thomas V. O.
  • Imyanitov, Evgeny N.
  • Isaacs, Claudine
  • Jakubowska, Anna
  • Janavicius, Ramunas
  • Jaworska-Bieniek, Katarzyna
  • John, Esther M.
  • Karlan, Beth Y.
  • Kaufman, Bella
  • Kwong, Ava
  • Laitman, Yael
  • Lasset, Christine
  • Lázaro García, Conxi
  • Lester, Jenny
  • Loman, Niklas
  • Lubinski, Jan
  • Manoukian, Siranoush
  • Mitchell, Gillian
  • Montagna, Marco
  • Neuhausen, Susan L.
  • Nevanlinna, Heli
  • Niederacher, Dieter
  • Nussbaum, Robert L.
  • Offit, Kenneth
  • Olah, Edith
  • Olopade, Olufunmilayo I.
  • Kyung Park, Sue
  • Piedmonte, Marion
  • Radice, Paolo
  • Rappaport-Fuerhauser, Christine
  • Rookus, Matti A.
  • Seynaeve, Caroline
  • Simard, Jacques
  • Singer, Christian F.
  • Soucy, Penny
  • Southey, Melissa C.
  • Stoppa-Lyonnet, Dominique
  • Sukiennicki, Grzegorz
  • Szabo, Csilla I.
  • Tancredi, Mariella
  • Teixeira, Manuel R.
  • Teo, Soo-Hwang
  • Terry, Mary Beth
  • Thomassen, Mads
  • Tihomirova, Laima
  • Tischkowitz, Marc
  • Ewart Toland, Amanda
  • Toloczko-Grabarek, Aleksandra
  • Tung, Nadine
  • Rensburg, Elizabeth J. van
  • Villano, Danylo J.
  • Wang-Gohrke, Shan
  • Wappenschmidt, Barbara
  • Weitzel, Jeffrey N.
  • Zidan, Jamal
  • Zorn, Kristin K.
  • McGuffog, Lesley
  • Easton, Douglas F.
  • Chenevix-Trench, Georgia
  • Antoniou, Antonis C.
Background: Most BRCA1 or BRCA2 mutation carriers have inherited a single (heterozygous) mutation. Transheterozygotes (TH) who have inherited deleterious mutations in both BRCA1 and BRCA2 are rare, and the consequences of transheterozygosity are poorly understood. Methods: From 32,295 female BRCA1/2 mutation carriers, we identified 93 TH (0.3 %). "Cases" were defined as TH, and "controls" were single mutations at BRCA1 (SH1) or BRCA2 (SH2). Matched SH1 "controls" carried a BRCA1 mutation found in the TH "case". Matched SH2 "controls" carried a BRCA2 mutation found in the TH "case". After matching the TH carriers with SH1 or SH2, 91 TH were matched to 9316 SH1, and 89 TH were matched to 3370 SH2. Results: The majority of TH (45.2 %) involved the three common Jewish mutations. TH were more likely than SH1 and SH2 women to have been ever diagnosed with breast cancer (BC; p = 0.002). TH were more likely to be diagnosed with ovarian cancer (OC) than SH2 (p = 0.017), but not SH1. Age at BC diagnosis was the same in TH vs. SH1 (p = 0.231), but was on average 4.5 years younger in TH than in SH2 (p < 0.001). BC in TH was more likely to be estrogen receptor (ER) positive (p = 0.010) or progesterone receptor (PR) positive (p = 0.013) than in SH1, but less likely to be ER positive (p < 0.001) or PR positive (p = 0.012) than SH2. Among 15 tumors from TH patients, there was no clear pattern of loss of heterozygosity (LOH) for BRCA1 or BRCA2 in either BC or OC. Conclusions: Our observations suggest that clinical TH phenotypes resemble SH1. However, TH breast tumor marker characteristics are phenotypically intermediate to SH1 and SH2.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer

  • Couch, Fergus J.
  • Kuchenbaecker, Karoline B.
  • Michailidou, Kyriaki
  • Mendoza-Fandino, Gustavo A.
  • Nord, Silje
  • Lilyquist, Janna
  • Olswold, Curtis
  • Hallberg, Emily
  • Agata, Simona
  • Ahsan, Habibul
  • Aittomäki, Kristiina
  • Ambrosone, Christine B.
  • Andrulis, Irene L.|||0000-0002-4226-6435
  • Anton-Culver, Hoda
  • Arndt, Volker|||0000-0001-9320-8684
  • Arun, Banu K.
  • Arver, Brita
  • Barile, Monica
  • Barkardottir, Rosa B.
  • Barrowdale, Daniel|||0000-0003-1661-3939
  • Beckmann, Lars
  • Beckmann, Matthias W.
  • Benitez, Javier|||0000-0002-0923-7202
  • Blank, Stephanie V.
  • Blomqvist, Carl
  • Bogdanova, Natalia V.
  • Bojesen, Stig E.
  • Bolla, Manjeet K.|||0000-0002-4351-9326
  • Bonanni, Bernardo|||0000-0003-3589-2128
  • Brauch, Hiltrud|||0000-0001-7531-2736
  • Brenner, Hermann
  • Burwinkel, Barbara
  • Buys, Saundra|||0000-0003-4120-5697
  • Caldes, Trinidad
  • Caligo, Maria|||0000-0003-0589-1829
  • Canzian, Federico|||0000-0002-4261-4583
  • Carpenter, Jane
  • Chang-Claude, Jenny
  • Chanock, Stephen|||0000-0002-2324-3393
  • Chung, Wendy
  • Claes, Kathleen|||0000-0003-0841-7372
  • Cox, Angela
  • Cross, Simon S.
  • Cunningham, Julie M.
  • Czene, Kamila
  • Daly, Mary B.
  • Damiola, Francesca
  • Darabi, Hatef
  • Hoya, Miguel de la|||0000-0002-8113-1410
  • Devilee, Peter|||0000-0002-8023-2009
  • Diez, Orland|||0000-0001-7339-0570
  • Ding, Yuan C.
  • Dolcetti, Riccardo
  • Domchek, Susan M.|||0000-0002-5914-7272
  • Dorfling, Cecilia M.
  • dos-Santos-Silva, Isabel
  • Dumont, Martine
  • Dunning, Alison M.
  • Eccles, Diana M.|||0000-0002-9935-3169
  • Ehrencrona, Hans|||0000-0002-5589-3622
  • Ekici, Arif B.
  • Eliassen, Heather
  • Ellis, Steve
  • Fasching, Peter A.
  • Figueroa, Jonine
  • Flesch-Janys, Dieter
  • Försti, Asta|||0000-0002-9857-4728
  • Fostira, Florentia
  • Foulkes, William|||0000-0001-7427-4651
  • Friebel, Tara
  • Friedman, Eitan|||0000-0002-6745-1733
  • Frost, Debra
  • Gabrielson, Marike
  • Gammon, Marilie D.
  • Ganz, Patricia A.
  • Gapstur, Susan M.
  • Garber, Judy
  • Gaudet, Mia M.
  • Gayther, Simon A.|||0000-0001-7937-5443
  • Gerdes, Anne-Marie
  • Ghoussaini, Maya
  • Giles, Graham G.
  • Glendon, Gord
  • Godwin, Andrew K.|||0000-0002-3987-9580
  • Goldberg, Mark S.
  • Goldgar, David E.
  • González-Neira, Anna
  • Greene, Mark H.|||0000-0003-1852-9239
  • Gronwald, Jacek
  • Guénel, Pascal
  • Gunter, Marc
  • Haeberle, Lothar
  • Haiman, Christopher A.
  • Hamann, Ute|||0000-0001-6705-7624
  • Hansen, Thomas V. O.
  • Hart, Steven
  • Healey, Sue
  • Heikkinen, Tuomas|||0000-0003-1154-6204
  • Henderson, Brian E.
  • Herzog, Josef
  • Hogervorst, Frans B. L.
  • Hollestelle, Antoinette
  • Hooning, Maartje J.
  • Hoover, Robert
  • Hopper, John L.
  • Humphreys, Keith
  • Hunter, David J.
  • Huzarski, Tomasz
  • Imyanitov, Evgeny N.
  • Isaacs, Claudine|||0000-0002-9646-1260
  • Jakubowska, Anna|||0000-0002-5650-0501
  • James, Paul|||0000-0002-4361-4657
  • Janavicius, Ramunas
  • Jensen, Uffe Birk
  • John, Esther M.
  • Jones, Michael
  • Kabisch, Maria
  • Kar, Siddhartha
  • Karlan, Beth Y.|||0000-0002-9451-2933
  • Khan, Sofia
  • Khaw, Kay-Tee
  • Kibriya, Muhammad G.
  • Knight, Julia A.
  • Ko, Yon-Dschun
  • Konstantopoulou, Irene|||0000-0002-0470-0309
  • Kosma, Veli-Matti
  • Kristensen, Vessela
  • Kwong, Ava
  • Laitman, Yael
  • Lambrechts, Diether
  • Lázaro García, Conxi|||0000-0002-7198-5906
  • Lee, Eunjung
  • Le Marchand, Loic
  • Lester, Jenny
  • Lindblom, Annika
  • Lindor, Noralane M.
  • Lindstrom, Sara
  • Liu, Jianjun|||0000-0002-3255-3019
  • Long, Jirong
  • Lubinski, Jan|||0000-0003-2931-3003
  • Mai, Phuong L.
  • Makalic, Enes
  • Malone, Kathleen E.
  • Mannermaa, Arto
  • Manoukian, Siranoush
  • Margolin, Sara
  • Marme, Frederik
  • Martens, John W. M.
  • McGuffog, Lesley|||0000-0003-1237-0546
  • Meindl, Alfons
  • Miller, Austin|||0000-0001-9739-8462
  • Milne, Roger L.|||0000-0001-5764-7268
  • Miron, Penelope
  • Montagna, Marco
  • Mazoyer, Sylvie
  • Mulligan, Anna M.
  • Muranen, Taru A.|||0000-0002-5895-1808
  • Nathanson, Katherine L.|||0000-0002-6740-0901
  • Neuhausen, Susan L.|||0000-0001-5053-0390
  • Nevanlinna, Heli|||0000-0002-0916-2976
  • Nordestgaard, Børge G.|||0000-0002-1954-7220
  • Nussbaum, Robert L.|||0000-0003-3445-8880
  • Offit, Kenneth
  • Olah, Edith
  • Olopade, Olufunmilayo I.|||0000-0002-9936-1599
  • Olson, Janet E.
  • Osorio, Ana|||0000-0001-8124-3984
  • Park, Sue K.
  • Peeters, Petra H.
  • Peissel, Bernard|||0000-0001-9233-3571
  • Peterlongo, Paolo|||0000-0001-6951-6855
  • Peto, Julian|||0000-0002-1685-8912
  • Phelan, Catherine M.
  • Pilarski, Robert
  • Poppe, Bruce
  • Pylkäs, Katri
  • Radice, Paolo|||0000-0001-6298-4111
  • Rahman, Nazneen
  • Rantala, Johanna
  • Rappaport, Christine
  • Rennert, Gad|||0000-0002-8512-068X
  • Richardson, Andrea
  • Robson, Mark
  • Romieu, Isabelle
  • Rudolph, Anja
  • Rutgers, Emiel J.
  • Sánchez Pérez, María José|||0000-0003-4817-0757
  • Santella, Regina M.
  • Sawyer, Elinor J.
  • Schmidt, Daniel F.
  • Schmidt, Marjanka K.|||0000-0002-2228-429X
  • Schmutzler, Rita K.
  • Schumacher, Fredrick
  • Scott, Rodney
  • Senter, Leigha
  • Sharma, Priyanka
  • Simard, Jacques|||0000-0001-6906-3390
  • Singer, Christian F.
  • Sinilnikova, Olga M.
  • Soucy, Penny
  • Southey, Melissa C.|||0000-0002-6313-9005
  • Steinemann, Doris|||0000-0001-8797-0816
  • Stenmark-Askmalm, Marie
  • Stoppa-Lyonnet, Dominique
  • Swerdlow, Anthony
  • Szabo, Csilla I.
  • Tamimi, Rulla
  • Tapper, William
  • Teixeira, Manuel R.|||0000-0002-4896-5982
  • Teo, Soo|||0000-0002-0444-590X
  • Terry, Mary Beth
  • Thomassen, Mads
  • Thompson, Deborah
  • Tihomirova, Laima
  • Toland, Amanda Ewart|||0000-0002-0271-1792
  • Tollenaar, Robert A. E. M.
  • Tomlinson, Ian
  • Truong, Thérèse
  • Tsimiklis, Helen
  • Teule, Alex|||0000-0003-0028-7200
  • Tumino, Rosario
  • Tung, Nadine
  • Turnbull, Clare
  • Ursin, Giski
  • van Deurzen, Carolien H. M.
  • van Rensburg, Elizabeth J.|||0000-0003-2077-230X
  • Varon-Mateeva, Raymonda
  • Wang, Zhaoming
  • Wang-Gohrke, Shan
  • Weiderpass, Elisabete
  • Weitzel, Jeffrey N.
  • Whittemore, Alice S.
  • Wildiers, Hans
  • Winqvist, Robert
  • Yang, Xiaohong R.
  • Yannoukakos, Drakoulis
  • Yao, Song
  • Zamora Auñon, Maria del Pilar|||0000-0003-2631-9653
  • Zheng, Wei|||0000-0003-1226-070X
  • Hall, Per
  • Kraft, Peter
  • Vachon, Celine
  • Slager, Susan|||0000-0002-5173-4712
  • Chenevix-Trench, Georgia
  • Pharoah, Paul D.P.|||0000-0001-8494-732X
  • Monteiro, Alvaro A. N.
  • García-Closas, Montserrat
  • Easton, Douglas F.|||0000-0003-2444-3247
  • Antoniou, Antonis C.
Common variants in 94 loci have been associated with breast cancer including 15 loci with genome-wide significant associations (P <5 × 10 -8) with oestrogen receptor (ER)-negative breast cancer and BRCA1 -associated breast cancer risk. In this study, to identify new ER-negative susceptibility loci, we performed a meta-analysis of 11 genome-wide association studies (GWAS) consisting of 4,939 ER-negative cases and 14,352 controls, combined with 7,333 ER-negative cases and 42,468 controls and 15,252 BRCA1 mutation carriers genotyped on the iCOGS array. We identify four previously unidentified loci including two loci at 13q22 near KLF5, a 2p23.2 locus near WDR43 and a 2q33 locus near PPIL3 that display genome-wide significant associations with ER-negative breast cancer. In addition, 19 known breast cancer risk loci have genome-wide significant associations and 40 had moderate associations (P <0.05) with ER-negative disease. Using functional and eQTL studies we implicate TRMT61B and WDR43 at 2p23.2 and PPIL3 at 2q33 in ER-negative breast cancer aetiology. All ER-negative loci combined account for ∼11% of familial relative risk for ER-negative disease and may contribute to improved ER-negative and BRCA1 breast cancer risk prediction. Oestrogen negative breast cancer is associated with a poor prognosis. In this study, the authors perform a meta-analysis of 11 breast cancer genome-wide association studies and identify four new loci associated with oestrogen negative breast cancer risk. These findings may aid in stratifying patients in the clinic.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus

  • Zeng, Chenjie
  • Guo, Xingyi
  • Long, Jirong
  • Kuchenbaecker, Karoline B.
  • Droit, Arnaud
  • Michailidou, Kyriaki
  • Ghoussaini, Maya
  • Kar, Siddhartha
  • Freeman, Adam
  • Hopper, John L.
  • Milne, Roger L.|||0000-0001-5764-7268
  • Bolla, Manjeet K.|||0000-0002-4351-9326
  • Wang, Qin
  • Dennis, Joe|||0000-0003-4591-1214
  • Agata, Simona
  • Ahmed, Shahana
  • Aittomäki, Kristiina
  • Andrulis, Irene L.|||0000-0002-4226-6435
  • Anton-Culver, Hoda
  • Antonenkova, Natalia N.
  • Arason, Adalgeir|||0000-0003-0480-886X
  • Arndt, Volker|||0000-0001-9320-8684
  • Arun, Banu K.
  • Arver, Brita
  • Bacot, Francois
  • Barrowdale, Daniel|||0000-0003-1661-3939
  • Baynes, Caroline
  • Beeghly-Fadiel, Alicia|||0000-0001-9913-732X
  • Benitez, Javier|||0000-0002-0923-7202
  • Bermisheva, Marina
  • Blomqvist, Carl
  • Blot, William
  • Bogdanova, Natalia V.
  • Bojesen, Stig E.
  • Bonanni, Bernardo|||0000-0003-3589-2128
  • Borresen-Dale, Anne-Lise
  • Brand, Judith S.
  • Brauch, Hiltrud|||0000-0001-7531-2736
  • Brennan, Paul
  • Brenner, Hermann
  • Broeks, Annegien
  • Brüning, Thomas
  • Burwinkel, Barbara
  • Buys, Saundra|||0000-0003-4120-5697
  • Cai, Qiuyin
  • Caldes, Trinidad
  • Campbell, Ian|||0000-0002-7773-4155
  • Carpenter, Jane
  • Chang-Claude, Jenny
  • Choi, Ji-Yeob
  • Claes, Kathleen|||0000-0003-0841-7372
  • Clarke, Christine L.
  • Cox, Angela
  • Cross, Simon S.
  • Czene, Kamila
  • Daly, Mary B.
  • Hoya, Miguel de la|||0000-0002-8113-1410
  • De Leeneer, Kim
  • Devilee, Peter|||0000-0002-8023-2009
  • Diez, Orland|||0000-0001-7339-0570
  • Domchek, Susan M.|||0000-0002-5914-7272
  • Doody, Michele
  • Dorfling, Cecilia M.
  • Dörk, Thilo|||0000-0002-9458-0282
  • dos-Santos-Silva, Isabel
  • Dumont, Martine
  • Dwek, Miriam
  • Dworniczak, Bernd
  • Egan, Kathleen
  • Eilber, Ursula
  • Einbeigi, Zakaria
  • Ejlertsen, Bent
  • Ellis, Steve
  • Frost, Debra
  • Lalloo, Fiona
  • Fasching, Peter A.
  • Figueroa, Jonine
  • Flyger, Henrik
  • Friedlander, Michael|||0000-0003-3090-795X
  • Friedman, Eitan|||0000-0002-6745-1733
  • Gambino, Gaetana
  • Gao, Yu-Tang
  • Garber, Judy
  • García-Closas, Montserrat
  • Gehrig, Andrea
  • Damiola, Francesca
  • Lesueur, Fabienne|||0000-0001-7404-4549
  • Mazoyer, Sylvie
  • Stoppa-Lyonnet, Dominique
  • Giles, Graham G.
  • Godwin, Andrew K.|||0000-0002-3987-9580
  • Goldgar, David E.
  • González-Neira, Anna
  • Greene, Mark H.|||0000-0003-1852-9239
  • Guénel, Pascal
  • Haeberle, Lothar
  • Haiman, Christopher A.
  • Hallberg, Emily
  • Hamann, Ute|||0000-0001-6705-7624
  • Hansen, Thomas V. O.
  • Hart, Steven
  • Hartikainen, Jaana M.
  • Hartman, Mikael
  • Hassan, Norhashimah
  • Healey, Sue
  • Hogervorst, Frans B. L.
  • Verhoef, Senno
  • Hendricks, Carolyn B.
  • Hillemanns, Peter
  • Hollestelle, Antoinette
  • Hulick, Peter J.
  • Hunter, David J.
  • Imyanitov, Evgeny N.
  • Isaacs, Claudine|||0000-0002-9646-1260
  • Ito, Hidemi
  • Jakubowska, Anna|||0000-0002-5650-0501
  • Janavicius, Ramunas
  • Jaworska-Bieniek, Katarzyna
  • Jensen, Uffe Birk
  • John, Esther M.
  • Joly Beauparlant, Charles
  • Jones, Michael
  • Kabisch, Maria
  • Kang, Daehee
  • Karlan, Beth Y.|||0000-0002-9451-2933
  • Kauppila, Saila
  • Kerin, Michael J.
  • Khan, Sofia
  • Khusnutdinova, Elza
  • Knight, Julia A.
  • Konstantopoulou, Irene|||0000-0002-0470-0309
  • Kraft, Peter
  • Kwong, Ava
  • Laitman, Yael
  • Lambrechts, Diether
  • Lázaro García, Conxi|||0000-0002-7198-5906
  • Le Marchand, Loic
  • Lee, Chuen Neng
  • Lee, Min Hyuk
  • Lester, Jenny
  • Li, Jingmei
  • Liljegren, Annelie
  • Lindblom, Annika
  • Lophatananon, Artitaya
  • Lubinski, Jan|||0000-0003-2931-3003
  • Mai, Phuong L.
  • Mannermaa, Arto
  • Manoukian, Siranoush
  • Margolin, Sara
  • Marme, Frederik
  • Matsuo, Keitaro
  • McGuffog, Lesley|||0000-0003-1237-0546
  • Meindl, Alfons
  • Menegaux, Florence
  • Montagna, Marco
  • Muir, Kenneth
  • Mulligan, Anna Marie
  • Nathanson, Katherine L.|||0000-0002-6740-0901
  • Neuhausen, Susan L.|||0000-0001-5053-0390
  • Nevanlinna, Heli|||0000-0002-0916-2976
  • Newcomb, Polly A.
  • Nord, Silje
  • Nussbaum, Robert L.|||0000-0003-3445-8880
  • Offit, Kenneth
  • Olah, Edith
  • Olopade, Olufunmilayo I.|||0000-0002-9936-1599
  • Olswold, Curtis
  • Osorio, Ana|||0000-0001-8124-3984
  • Papi, Laura
  • Park-Simon, Tjoung-Won
  • Paulsson-Karlsson, Ylva
  • Peeters, Stephanie
  • Peissel, Bernard|||0000-0001-9233-3571
  • Peterlongo, Paolo|||0000-0001-6951-6855
  • Peto, Julian|||0000-0002-1685-8912
  • Pfeiler, Georg
  • Phelan, Catherine M.
  • Presneau, Nadege
  • Radice, Paolo|||0000-0001-6298-4111
  • Rahman, Nazneen
  • Ramus, Susan J.|||0000-0003-0005-7798
  • Rashid, Muhammad Usman
  • Rennert, Gad|||0000-0002-8512-068X
  • Rhiem, Kerstin
  • Rudolph, Anja
  • Salani, Ritu
  • Sangrajrang, Suleeporn
  • Sawyer, Elinor J.
  • Schmidt, Marjanka K.|||0000-0002-2228-429X
  • Schmutzler, Rita K.
  • Schoemaker, Minouk J.
  • Schürmann, Peter
  • Seynaeve, Caroline
  • Shen, Chen-Yang
  • Shrubsole, Martha J.
  • Shu, Xiao-Ou
  • Sigurdson, Alice
  • Singer, Christian F.
  • Slager, Susan|||0000-0002-5173-4712
  • Soucy, Penny
  • Southey, Melissa C.|||0000-0002-6313-9005
  • Steinemann, Doris|||0000-0001-8797-0816
  • Swerdlow, Anthony
  • Szabo, Csilla I.
  • Tchatchou, Sandrine
  • Teixeira, Manuel R.|||0000-0002-4896-5982
  • Teo, Soo|||0000-0002-0444-590X
  • Terry, Mary Beth
  • Tessier, Daniel C.
  • Teule, Alex|||0000-0003-0028-7200
  • Thomassen, Mads
  • Tihomirova, Laima
  • Tischkowitz, Marc
  • Toland, Amanda Ewart|||0000-0002-0271-1792
  • Tung, Nadine
  • Turnbull, Clare
  • van den Ouweland, Ans M. W.
  • van Rensburg, Elizabeth J.|||0000-0003-2077-230X
  • ven den Berg, David
  • Vijai, Joseph
  • Wang-Gohrke, Shan
  • Weitzel, Jeffrey N.
  • Whittemore, Alice S.
  • Winqvist, Robert
  • Wong, Tien Y.
  • Wu, Anna H.
  • Yannoukakos, Drakoulis
  • Yu, Jyh-Cherng
  • Pharoah, Paul D.P.|||0000-0001-8494-732X
  • Hall, Per
  • Chenevix-Trench, Georgia
  • Dunning, Alison M.
  • Simard, Jacques|||0000-0001-6906-3390
  • Couch, Fergus J.
  • Antoniou, Antonis C.
  • Easton, Douglas F.|||0000-0003-2444-3247
  • Zheng, Wei|||0000-0003-1226-070X
Multiple recent genome-wide association studies (GWAS) have identified a single nucleotide polymorphism (SNP), rs10771399, at 12p11 that is associated with breast cancer risk. We performed a fine-scale mapping study of a 700 kb region including 441 genotyped and more than 1300 imputed genetic variants in 48,155 cases and 43,612 controls of European descent, 6269 cases and 6624 controls of East Asian descent and 1116 cases and 932 controls of African descent in the Breast Cancer Association Consortium (BCAC; ), and in 15,252 BRCA1 mutation carriers in the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Stepwise regression analyses were performed to identify independent association signals. Data from the Encyclopedia of DNA Elements project (ENCODE) and the Cancer Genome Atlas (TCGA) were used for functional annotation. Analysis of data from European descendants found evidence for four independent association signals at 12p11, represented by rs7297051 (odds ratio (OR) = 1.09, 95 % confidence interval (CI) = 1.06-1.12; P = 3 × 10 -9), rs805510 (OR = 1.08, 95 % CI = 1.04-1.12, P = 2 × 10 -5), and rs1871152 (OR = 1.04, 95 % CI = 1.02-1.06; P = 2 × 10 -4) identified in the general populations, and rs113824616 (P = 7 × 10 -5) identified in the meta-analysis of BCAC ER-negative cases and BRCA1 mutation carriers. SNPs rs7297051, rs805510 and rs113824616 were also associated with breast cancer risk at P < 0.05 in East Asians, but none of the associations were statistically significant in African descendants. Multiple candidate functional variants are located in putative enhancer sequences. Chromatin interaction data suggested that PTHLH was the likely target gene of these enhancers. Of the six variants with the strongest evidence of potential functionality, rs11049453 was statistically significantly associated with the expression of PTHLH and its nearby gene CCDC91 at P < 0.05. This study identified four independent association signals at 12p11 and revealed potentially functional variants, providing additional insights into the underlying biological mechanism(s) for the association observed between variants at 12p11 and breast cancer risk. The online version of this article (doi:10.1186/s13058-016-0718-0) contains supplementary material, which is available to authorized users.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

CDK5RAP3, a New BRCA2 Partner That Regulates DNA Repair, Is Associated with Breast Cancer Survival

  • Minguillón Pedreño, Jordi|||0000-0003-2124-8294
  • Ramírez de Haro, Ma. José|||0000-0003-1417-7731
  • Rovirosa Mulet, Llorenç|||0000-0003-2986-9001
  • Bustamante-Madrid, Pilar|||0000-0003-4540-9742
  • Camps-Fajol, Cristina
  • Ruiz de Garibay, Gorka|||0000-0001-9936-8419
  • Shimelis, Hermela
  • Montanuy Escribano, Helena
  • Pujol Calvet, Maria Roser|||0000-0003-1840-5455
  • Hernández Viedma, Gonzalo|||0000-0002-3048-9607
  • Bogliolo, Massimo|||0000-0001-8240-7784
  • Castillo, Pau
  • Soucy, Penny
  • Martrat, Griselda
  • Gómez Moruno, Antonio|||0000-0001-5308-981X
  • Cuadras, Daniel|||0000-0001-8780-1764
  • García, María J.
  • Gayarre, Javier|||0000-0003-0377-6712
  • Lázaro García, Conxi|||0000-0002-7198-5906
  • Benitez, Javier|||0000-0002-0923-7202
  • Couch, Fergus J.
  • Pujana, Miguel Angel|||0000-0003-3222-4044
  • Surralles, Jordi|||0000-0002-4041-7519
BRCA2 is essential for homologous recombination DNA repair. BRCA2 mutations lead to genome instability and increased risk of breast and ovarian cancer. Similarly, mutations in BRCA2-interacting proteins are also known to modulate sensitivity to DNA damage agents and are established cancer risk factors. Here we identify the tumor suppressor CDK5RAP3 as a novel BRCA2 helical domain-interacting protein. CDK5RAP3 depletion induced DNA damage resistance, homologous recombination and single-strand annealing upregulation, and reduced spontaneous and DNA damage-induced genomic instability, suggesting that CDK5RAP3 negatively regulates double-strand break repair in the S-phase. Consistent with this cellular phenotype, analysis of transcriptomic data revealed an association between low CDK5RAP3 tumor expression and poor survival of breast cancer patients. Finally, we identified common genetic variations in the CDK5RAP3 locus as potentially associated with breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Our results uncover CDK5RAP3 as a critical player in DNA repair and breast cancer outcomes.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers

  • Coignard, Juliette
  • Beesley, Jonathan
  • O'Mara, Tracy A.
  • Diez Gibert, Orland
  • Lopez Fernandez, Adrià
  • Dennis, Joe
  • Tyrer, Jonathan
  • Lush, Michael
Càncer de mama; Genètica del càncer; Factors de risc, Cáncer de mama; Genética del cáncer; Factores de riesgo, Breast cancer; Cancer genetics; Risk factors, Breast cancer (BC) risk for BRCA1 and BRCA2 mutation carriers varies by genetic and familial factors. About 50 common variants have been shown to modify BC risk for mutation carriers. All but three, were identified in general population studies. Other mutation carrier-specific susceptibility variants may exist but studies of mutation carriers have so far been underpowered. We conduct a novel case-only genome-wide association study comparing genotype frequencies between 60,212 general population BC cases and 13,007 cases with BRCA1 or BRCA2 mutations. We identify robust novel associations for 2 variants with BC for BRCA1 and 3 for BRCA2 mutation carriers, P < 10−8, at 5 loci, which are not associated with risk in the general population. They include rs60882887 at 11p11.2 where MADD, SP11 and EIF1, genes previously implicated in BC biology, are predicted as potential targets. These findings will contribute towards customising BC polygenic risk scores for BRCA1 and BRCA2 mutation carriers.